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The diminished incretin effect is a pathological characteristic of type 2 diabetes 
mellitus (T2DM), caused by reduced secretion of glucagon-like-peptide-1 (GLP-1) 
and blunted biological actions of glucose-dependent insulinotropic polypeptide (GIP). 
Presently, clinically approved GLP-1 analogues, targeting the GLP-1 arm of the 
incretin axis, help to overcome the diminished GLP-1 secretion. However, currently 
there is no clinically approved therapeutic agent to potentiate the biological actions of 
GIP. Furthermore, established pharmacological agents currently fail to replicate the 
benefits of bariatric surgery, which along with increasing prevalence increases both 
health and socio-economic burdens. Likewise, due to the multifactorial characteristics, 
current monotherapies fail to elicit persistent effective management. Therefore, novel, 
more-effective treatment paradigms are required to address these unmet needs. The 
gut hormone xenin has been reported to potentiate biological actions of GIP, with 
truncated analogues of xenin displaying more potent antidiabetic effects. This thesis 
characterised the GIP-potentiating effects of xenin-based therapies, along with their 
therapeutic applicability for diabetes and/or obesity. This included xenin-8-Gln, as 
part of a hybrid agent- (DAla2)GIP/xenin-8-Gln, multiple novel xenin hexapeptides, 
as well as TNP-470, an angiogenesis inhibitor shown to increase xenin concentrations. 
Importantly, in all therapies assessed, there was clear augmentation of GIP action, 
resulting in enhanced metabolic effects. (DAla2)GIP/xenin-8-Gln administered in 
combination with exendin-4 demonstrated metabolic benefits that were persistent in 
nature, which is highly favourable in such a progressive disease. Further 
characterisation of truncated xenin peptides showed that ψ-xenin-6 was the most 
potent truncated hexapeptide assessed, with GIP-potentiating and satiety effects 





administration of ψ-xenin-6 in combination with sitagliptin further augmented the 
efficacy of sitagliptin, with effects more prominent and rapid with combined 
modulation. Additionally, beneficial efficacy of sitagliptin was augmented through 
combined administration with TNP-470, displaying improvements in glucose 
tolerance, insulin sensitivity and significant anti-obesity effects. Together, these 
findings provide reinforcing evidence for development of novel xenin-based therapies, 
which act to potentiate biological actions of GIP, and the need for combinational 
therapeutic approaches to target multiple pathways to help alleviate hyperglycaemia 
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1.1 DIABETES MELLITUS  
Diabetes mellitus is a complex progressive metabolic disease that occurs due to 
pancreatic beta cell dysfunction and/or insulin resistance, and manifests itself through 
chronically elevated glucose concentrations. Consequently, patients with diabetes 
require continuous monitoring and control of their blood glucose levels mainly 
through exogenous drug therapy. According to recent statistics compiled by the 
International Diabetes Federation (2019), 463 million adults have diabetes, which is 
expected to rise to 700 million by 2045, with 4.2 million deaths attributed to diabetes 
and its associated complications each year [IDF, 2019]. It is estimated that by 2030 
diabetes will be the seventh leading cause of mortality worldwide [WHO, 2011]. This 
metabolic disorder has become a global epidemic with major contributing factors 
including obesity, physical inactivity and an excessive calorie consumption. Diabetes 
has become a global economic burden, due to its ever-increasing healthcare 
expenditures, along with its escalating rates of mortality and morbidity and has 
become one of the biggest health care challenges of the 21st century [Lu et al. 2014]. 
Diabetes accounts for nearly 12% of global health expenditure and globally cost more 
than 760 billion dollars in 2019 [IDF, 2019], accounting for over 10% of the NHS 
budget in the UK. Therefore, these staggering statistics clearly highlight the challenge 
that diabetes presents, and the vital need to develop new and more efficacious 
treatments. 
 
1.1.1 TYPES OF DIABETES  
The two main forms of diabetes are; type 1 diabetes mellitus (T1DM), which accounts 
for 10% of all diagnosed cases, and type 2 diabetes mellitus (T2DM), which is the 





share some similarities, including presenting indications such as polydipsia or 
polyuria. However, due to their variances in aetiology, they are considered to be at 
opposite ends of a spectrum in relation to insulin production and function.  
 
In T1DM, patients are dependent on insulin due to the irreversible, cell-mediated 
destruction of the pancreatic beta cells, resulting in complete insulin deficiency. 
Therefore, the disturbance of insulin production in T1DM is the main feature of this 
type. T1DM usually has a juvenile onset and is associated with genetic susceptibility 
inherited via the major histocompatibility complex (MHC) (HLA class II region on 
chromosome 6p21) genes encoding DQ and DR [Nobel and Valdes, 2011]. The 
autoimmune response in susceptible type 1 individuals can be triggered by 
environmental factors [Knip and Simell, 2012], such as toxins or foods, resulting in 
the abnormal stimulation of B-cell and T-cell mediated immune response. This 
initiates the production of autoantibodies, including islet cell autoantibodies (ICA), 
insulin autoantibodies (IAA), autoantibodies to glutamic acid decarboxylase (GADA) 
and autoantibodies to tyrosine phosphatases (IA-2a and IA-2b) [Sørgjerd, 2019] 
against beta cell antigens and triggers insulitis, with subsequent destruction of the 
pancreatic insulin producing beta cells, creating absolute insulin deficiency.  
 
However, unlike T1DM, patients with T2DM have preserved ability to produce insulin 
from their beta cells, but due to insulin resistance, peripheral cells fail to respond to 
insulin. Therefore, it is the disturbance of insulin action from the diminished response 
of peripheral tissues to insulin in T2DM that is the main feature [Ta, 2014]. Albeit, 
T2DM patients also present with decreased beta cell mass. This means that the 





of the beta cells, resulting in subsequent loss of insulin secretion. There are various 
factors that contribute to development of T2DM, and these include poor lifestyle 
choices and obesity, as well as genetic factors linked to beta cell dysfunction [Colberg, 
2010]. The diminishing effects of insulin secretion and action in T2DM are related to 
increased levels of ectopic fat storage, increased secretion of adipokines and elevated 
non-esterified fatty acids in circulation. T2DM was previously more commonly 
diagnosed in adulthood, with predisposition linked with ethnicity and family history 
[Oldroyd et al. 2005]. However, age onset for this disorder has decreased, with 
incidence of T2DM increasing in children. This reflects the rise in childhood obesity 
[Rosenbloom, 2002], along with other factors, including lack of physical activity and 
diets high in saturated fats.  
 
Other types of diabetes include gestational diabetes, which affects approximately 3-
5% of all pregnancies and develops between the 24th and 28th week of pregnancy. The 
babies born from mothers with gestational diabetes and the women themselves have 
an increased risk of developing T2DM later in life. Maturity-onset diabetes of the 
young (MODY) is another type of diabetes, which usually develops before the age of 
25 affecting around 1-2% of people with diabetes. There are now at least 14 known 
MODY-causing mutations, which vary dependent on age onset and treatment response 
[Hoffman and Jialal, 2019]. The four most common mutations are HNF1B, GCK, 
HNF1A and HNF4A, however other mutations include INS, NEURO1, PDX1, PAX4, 








1.1.2 ISLETS OF LANGERHANS  
Islets of Langerhans were first identified as clusters of endocrine cells scattered 
throughout the pancreas by Paul Langerhans in 1869. The normal human pancreas 
contains about 1,000,000 islets, which play critical roles in energy homeostasis, 
nutrient metabolism and controlling blood glucose levels through the secretion of 
insulin. These islets consist of five different cell types including alpha cells, beta cells, 
delta cells, pancreatic polypeptide-producing (PP) cells and epsilon cells [Scharfmann 
et al. 2008]. The alpha and beta cells are responsible for secretion of glucagon and 
insulin respectively, and are the most abundant, playing vital roles in the maintenance 
of glucose homeostasis [Bosco, 2010]. Somatostatin secreted by pancreatic delta cells, 
inhibits secretion of insulin and glucagon [Briant et al. 2016]. The PP cells, which 
express pancreatic polypeptide, have an inhibitory response on pancreatic exocrine 
secretion [Kojima et al. 2007]. The epsilon cells, which secrete ghrelin, comprise less 
than 1% of pancreatic cells. It has been suggested that ghrelin has roles in suppressing 
insulin secretion and it possesses hyperglycaemic effects [Broglio et al. 2001]. The 
structure of islets are highly species specific. In rodent islets, beta cells encompass 70-
80% of the pancreatic cells and are localised at the core. In contrast, alpha-, delta- and 
PP cells are located at the periphery of the islet, known classically as the islet mantle 
[Cabrera et al. 2006; Steiner et al. 2010]. Unlike the defined beta cell core and alpha 
cell periphery of rodent islets, human islets maintain a more scattered endocrine cell 
organisation [Steiner et al. 2010; Cabrera et al. 2006]. Islets have a rich blood and 
nervous supply, with vascularisation and innervation playing key roles in islet function 
[Diez et al. 2017]. In the various aetiologies of diabetes aforementioned, the unique 





disturbed, therefore resulting in dysfunction of the islet cells [Rahier et al. 1983; 
Brereton et al. 2015]. 
 
1.1.3. INSULIN  
Insulin, a 51-amino acid peptide with a molecular weight of 5805 Da [Mangesh et al. 
2014], is synthesised within the ribosomes of the endoplasmic reticulum (ER) [Vargas 
and Sepulveda, 2018]. Insulin is initially synthesised as a single-chain 110-amino acid 
precursor polypeptide, preproinsulin, which is cleaved forming proinsulin [Patzelt et 
al. 1978], and transported to the Golgi apparatus where it is further cleaved by multiple 
specific endopeptidases, generating the mature form of insulin and C-peptide. Insulin 
is subsequently packed into secretory vesicles within beta cells, prior to the stimulation 
of insulin release by exocytosis [Shpakov, 2015]. 
 
The secretion of insulin is dependent on the ability of beta cells to respond 
appropriately to physiological stimuli, predominately changes in plasma glucose 
concentrations, by turning increased glycolytic metabolism into exocytotic release of 
insulin [Squires et al. 2005]. The occurrence of insulin secretion is biphasic, involving 
triggering (first phase) and amplification (second phase) pathways. These insulin 
granules comprised in beta cells can either be readily available for release; first phase 
of insulin release or present as reserve pools; second phase of insulin release, which 
involves transformation from reserve to readily releasable before exocytosis 
[Bratanova-Tochkova et al. 2002]. Pancreatic beta cells express a high volume of 
GLUT2 transporters, but human beta cells express predominantly GLUT1 
transporters, which ensure that any changes in intracellular glucose concentrations 





response to increased glucose levels, beta cells depolarise and generate action 
potentials to secrete insulin, therefore acting as glucose sensors [Rorsman and Braun, 
2012]. The triggering pathway is well characterised, and the cascade leading to 
exocytosis of insulin during this first phase of insulin release is primarily driven by 
circulating glucose levels. 
 
Glucose enters beta cells by facilitated diffusion, through glucose transporters. 
GLUT2 is critical for glucose-stimulated insulin secretion [Thorens, 2015], which is 
coupled by glycolysis [Guo et al. 2012]. On entering the beta cell, glucose is 
phosphorylated by a highly specific and low affinity glucokinase [Squires et al. 2005], 
a hexokinase enzyme, to glucose-6-phosphate and undergoes glycolysis resulting in 
production of pyruvate and yield of adenosine triphosphate (ATP). The rise in ATP: 
ADP ratio causes closure of ATP-sensitive potassium (KATP) channels, resulting in 
membrane depolarisation. In response, L-type voltage-dependent Ca2+ channels open, 
causing a rapid influx of extracellular Ca2+ ions. These changes in extracellular Ca2+ 
concentrations are monitored by a calcium-sensing receptor found within pancreatic 
islets [Squires et al. 2000], which plays key roles in cell-to-cell communication 
enabling a co-ordinated insulin secretory response [Jones et al. 2007]. This rapid 
influx increases intracellular Ca2+ concentrations and triggers the exocytotic 
machinery, resulting in an increased rate of insulin secretion from the beta cell 
[Komatsu et al. 2013]. Therefore, pancreatic beta cells can be described as secretory 
cells, which have evolved mechanisms to link increased metabolic activity with 






In second phase insulin release, metabolism of glucose produces signals that augment 
Ca2+ induced insulin exocytosis [Grespan et al. 2018]. This phase is a sustained, slow 
release of the newly formed vesicles [Grespan et al. 2018]. Under these conditions, 
glucose still increases insulin secretion in a concentration-dependent manner, as well 
as through a non-glucose mediated response [Henquin, 2000]. This pathway remains 
functionally silent as long as glucose has not reached its threshold and initiated an 
influx of Ca2+ ions during the first triggering pathway [Henquin, 2000].  
 
Once released, insulin initiates its actions through binding to the alpha subunit on a 
glycoprotein cell surface receptor, stimulating the tyrosine-specific protein kinase of 
the beta subunit [Gammeltoft and Van Obberghen, 1986]. Activation of intrinsic 
tyrosine kinase activity initiates both the PI-3-kinase-dependent pathway, which is 
essential for GLUT4 translocation, as well as the CAP/Cbl complex pathway, and 
plays a vital role in insulin-stimulated glucose utilisation through a PI-3-kinase–
independent pathway [Baumann et al. 2000]. In muscle, glucose uptake is 
fundamentally insulin-dependent through GLUT4 and promotes glycogen synthesis 
by activating glycogen synthase [Bouskila et al. 2008]. This enables the release, 
anaerobically, of energy by glycolysis. Insulin acts on the adipose tissue to promote 
glucose uptake, stimulates lipogenesis, but supresses lipolysis [Cignarelli et al. 2019]. 
In liver, insulin modulates lipoprotein metabolism and protein synthesis, as well as 
glucose storage and inhibits gluconeogenesis [Claus and Pilkis, 1976]. It has also been 
suggested that in the brain, insulin acts as a neuropeptide, playing roles in regulation 






However, characteristics of T2DM include the loss of first-phase and reduced second-
phase secretion. A reduction in glucose-stimulated-insulin-secretion as well as 
impaired glucose tolerance are indicators of early T2DM. Therefore, this necessitates 
the development of novel therapeutics that help restore adequate secretion of insulin 
in T2DM [Henquin, 2000]. 
 
1.1.4 OBESITY AND TYPE 2 DIABETES MELLITUS 
The WHO defines obesity as an “abnormal or excessive fat accumulation that presents 
a risk to health”. Body mass index (BMI), calculated by dividing a person’s weight 
(kg) by the square of body height (m2), is a crude method in diagnosing obesity, with 
percentage body fat a more accurate method [Romero-Corral et al. 2008]. In 
comparison to a normal BMI range of 18.5 – 24.9 kg/m2, a BMI of ≥ 30 kg/m2 is 
generally considered as obese, with a BMI equal to ≥ 25 kg/m2 classed as overweight 
[WHO, 2019]. Overweight and obesity was once considered a problem in only 
wealthier countries, however there have been dramatic increases in lower and middle-
income countries. In 1995, the global obese population was estimated to be 
approximately 200 million adults [Golay and Ybarra, 2005]. However, in 2016, over 
650 million adults were reported as obese, with over 340 million children, aged 5-19, 
classed as obese [WHO, 2018]. There are also strikingly similar observations with the 
prevalence of T2DM. 
 
Various factors contribute to this global epidemic, for example environmental, food 
availability, geographic influences, genetic obesity-related traits [Frayling et al. 2007; 
Loos and Bouchard, 2008; Meyre et al. 2009; Speliotes et al. 2010], as well as 





to the escalating rates of obesity, other chronic disease risks are further exacerbated, 
as obesity is a major risk factor for osteoarthritis, hypertension, cancer, respiratory 
diseases, cardiovascular diseases and diabetes. It is estimated by the McKinsey 
Institute that overweight and obesity related problems cost US$2 trillion annually 
[Dobbs et al. 2014]. In the UK, it was estimated to cost the NHS £6.1 billion in 2014 
-2015, with this projected to reach £9.7 billion by 2050 [Foresight, 2007], if we fail to 
address this epidemic. This increasing escalation in the global epidemic of obesity has 
triggered a parallel vertiginous rise in incidence and prevalence in T2DM diagnosis. 
Obesity and T2DM are closely linked, with obese individuals having a seven times 
greater risk of developing this disorder [Abdullah et al. 2010]. However, precise 
mechanisms on how the two conditions link still remain unclear. Recent studies have 
identified various links between obesity and T2DM, including pro-inflammatory 
cytokines (tumour necrosis factor and interleukin-6), insulin resistance, deranged fatty 
acid metabolism, and cellular processes such as mitochondrial dysfunction and 
endoplasmic reticulum stress [Kern et al. 2001; Blaak, 2003; Højlund et al. 2008; 
Cnop et al. 2012]. 
 
Studies have proposed various links between insulin resistance and obesity, which 
predispose to T2DM. This includes excessive fat deposition, particularly in the 
visceral area [Kahn, 2003], which reduce the ability of peripheral tissues to respond 
adequately to insulin. Also an increased production of adipokines and pro-
inflammatory cytokines, including tumour necrosis factor-α, resistin, and retinol-
binding protein 4, which worsen insulin resistance and reduce adiponectin levels 
[Deng and Scherer, 2010]. Furthermore, mitochondrial dysfunction, which decreases 





2010]. Moreover, changes in the glucose-fatty acid balance contribute to insulin 
resistance and hyperglycaemia. In obesity, the increase in lipid oxidation due to 
elevated plasma free fatty acids results in insulin resistance, with escalation of this 
associated with development of diabetes. Due to insulin resistance, there is a 
compensatory mechanism in obese individuals, which aims to elevate secretion of 
insulin [Cavaghan et al. 2000] through increased beta cell mass and function [Chen et 
al. 2017]. Nevertheless, despite compensatory mechanisms of increased glycaemia 
and insulinaemia, the persistent insensitivity to insulin and resistance to glucose 
uptake in obese individuals gradually leads to T2DM and its associated complications. 
 
Current therapeutics for T2DM, other than metformin, tend to be weight-neutral or 
associated with weight gain, which is highly unfavourable due to the major links 
aforementioned between obesity and T2DM. Therefore, there is pressing issue for 
novel therapeutics, as studies have demonstrated that even modest weight reductions 
can improve glycaemic control and reduce the risk of T2DM [Resnick et al. 2000; 
Wilding, 2014; Avery et al. 2019]. 
 
1.1.5 BETA-CELL DYSFUNCTION AND INSULIN RESISTANCE IN TYPE 2 
DIABETES MELLITUS 
The pathogenesis of T2DM is characterised by hyperglycaemia that is worsened by 
both beta cell dysfunction and insulin resistance, both inherently complex. Chronic 
exposure to hyperglycaemia leads to oxidative stress and inflammation, which induces 
changes in gene expression regulation and an increase in apoptosis [Gilbert and 
Liu, 2012]. Beta cell dysfunction, a critical determinant of T2DM [Ashcroft and 





resistance, insulin can still be secreted but insulin insensitivity is established in target 
tissues [Cerf, 2013]. As these worsen, hyperglycaemia is augmented resulting in the 
progression of T2DM, associated with cytokine-induced inflammation, obesity, 
insulin resistance, overconsumption of free fatty acids and saturated fats [Cerf, 2013], 
with progressive beta cell decline leading to cell exhaustion and beta cell failure 
[Ferrannini, 2010; Talchai et al. 2012; Cerf, 2013]. This loss of beta cell mass and 
function is fundamental to the development of T2DM [Ferrannini, 2010]. 
 
An early physiologic indicator of beta cell dysfunction is a delay in the acute insulin 
response to glucose [LeRoith, 2002]. In T2DM, the first-phase response to elevated 
glucose concentrations is lost, resulting in excessive elevation of postprandial glucose. 
This ultimately leads to a hyperinsulinaemic second-phase insulin response to help 
dispose of this excess glucose [Porte and Kahn, 1995]. This compensatory mechanism 
occurs when integrity of the beta cells is weakened. If successful, normal physiology 
of the beta cells is maintained. However, if exhausted, beta cell dysfunction follows, 
with insulin resistance further impairing normal physiology and compensation thus 
exacerbating beta cell function [Cerf, 2013]. Others have suggested that the 
pathogenesis of this dysfunction may mimic hepatic steatosis: intra-tissue fat depots 
that induce inflammation thus triggering cell demise and dysfunction [Cerf, 2013]. 
Glucose toxicity and lipotoxicity also contribute to beta cell dysfunction, therefore if 
metabolic control is restored, this dysfunction could potentially be reversed [LeRoith, 
2002]. 
 
Beta cell dysfunction is mediated by cytokine pro-inflammatory response, 





primary source of cytokines is through the infiltration of macrophages [Stienstra et 
al. 2007], with obesity also being a determinant of insulin resistance. However, the 
clear pathogenic mechanisms between obesity and insulin resistance still remains 
unclear, nevertheless numerous studies have suggested potential links between 
obesity, insulin resistance and T2DM. Obesity is a state of low-grade inflammation, 
and obesity-linked inflammation is found in adipose tissue and liver, coupled with 
elevated macrophage infiltration and pro-inflammatory cytokines [Ye, 2013]. This 
inflammation is associated with inhibition of insulin signalling pathways through 
various mechanisms, such as inhibition of IRS-1 and insulin receptors, inhibition of 
PPARγ function and accumulation of free fatty acids through triggering lipolysis [Ye, 
2007; 2013]. In muscle, insulin resistance leads to impaired insulin stimulated glucose 
utilisation and decreased glycogen synthesis [Wilcox, 2005; Abdul-Ghani and 
DeFronzo 2010], whereas, as a result of accumulation of lipids in hepatocytes, liver 
inflammation is associated with hepatic steatosis, linked with insulin resistance. In 
obesity, insulin resistance is further exacerbated through intracellular fat deposition in 
muscle, liver and pancreas, resulting in fatty acids and glucose competing for uptake 
and metabolism in tissues [Cerf, 2013]. This elevation in FFA levels, which induce a 
glucolipotoxic state, coupled with persistent hyperglycaemia, is detrimental to 
pancreatic beta cell function and structure. 
 
Elevated plasma insulin levels are a surrogate marker for insulin resistance [Greenberg 
and McDaniel, 2002]. In adipose tissue, increased expression of TNF-α has been 
shown to closely correlate with elevated fasting insulin levels. Hotamisligil and 
colleagues also demonstrated a direct link between expression of TNF-α and obesity‐





when TNF-α was neutralised [Hotamisligil et al. 1993]. Cytokines, such as TNF-α and 
IL-6, have also been shown to increase adipocyte lipolysis which in turn leads to 
elevated release of free fatty acids [Päth et al. 2001] which ultimately leads to the loss 
of insulin-secreting abilities [Boden, 1997].  
 
1.2 CURRENT TREATMENT OPTIONS FOR T2DM 
Non-pharmacological treatment for T2DM includes lifestyle and diet changes, to 
achieve normoglycaemia. However, lifestyle interventions are often not enough to 
achieve effective glycaemic control, and therefore pharmacological intervention is 
required. Table 1.1 summarises traditional treatment classes for T2DM, with 
metformin being the first-line therapy. Metformin, belonging to the class of 
antidiabetic agents known as biguanides, acts to improve insulin sensitivity and lower 
glucose production to enable more effective insulin utilisation, which can be used in 
combination with other drug classes that focus on stimulating insulin secretion. 
However, many of these conventional agents exhibit reduced efficacy over time, 
resulting in poor glycaemic control. There has also been a disappointing effect of these 
drug classes on weight loss, with older anti-diabetic therapies such as sulfonylureas 
and thiazolidinediones exacerbating weight gain. However, newer glucose-lowering 
agents including incretin mimetics and SGLT2 inhibitors have demonstrated weight-
lowering effects [Pereira and Eriksson, 2019]. Therefore, various newer classes of 









Table 1.1: Classes of T2DM therapeutics 
INSULIN SENSITIZERS 
Class Mechanism of Action Advantages Limitations 
 Biguanides – 
Example: 
Metformin 
Stimulates AMP activated 
protein kinase [Klip and 
Leiter 1990] and inhibits 
adenylate cyclase 
[Bridges, 2014], to 
increase insulin 
sensitivity, suppress 
hepatic glucose output 
and to increase glucose 
uptake in the muscle 
[Zhou et al. 2001]. 
 Prevents 
weight gain 
 Reduces risk of 
hypoglycaemia 
 Decreased risk 
of associated 
complications 





 In patients with 
renal 
impairment, it 






TZD’s directly bind on 
the nuclear receptor 
peroxisome proliferator-
activated receptor gamma 
(PPARγ), to regulate the 
transcription of various 
factors including 


















effects such as 
fluid retention, 
edema, weight 








Class Mechanism of Action Advantages Limitations 
 Sulfonylureas - 
Example: 
Tolbutamide 
Binds to the sulfonylurea 
receptor (SUR1) on the 
beta cells, leading to the 
closure of ATP-dependant 
potassium (KATP) 
channels initiating cell 
depolarisation [de Wet 
and Proks, 2015], 
resulting in an influx of 
intracellular Ca2+ which 















 Weight gain 
 Increased risk 
of 
cardiovascular 
disorders [Li et 
al. 2014].  
 Meglitinides - 
Example: 
Repaglinide 
Binds to the benzamido 
site within the SUR1 








 Improve insulin 
resistance 
 Expensive 








1.2.1 SODIUM GLUCOSE CO-TRANSPORTER 2 (SGLT2) INHIBITORS 
SGLT-2, present in proximal tubule of the nephron, assists in re-absorption of glucose 
in the kidneys. SGLT-2 inhibitors, such as canagliflozin and dapagliflozin, represent 
the most recently approved oral class of T2DM drugs. SGLT-2 inhibitors increase 
urinary excretion of glucose and reduce serum glucose levels [Vallianou et al. 2016]. 
Key advantages of SGLT-2 inhibitors include enhanced insulin secretion due to 
indirect effects on improved beta cell function, improved glycaemic control, weight 
loss and reduced blood pressure. SGLT-2 inhibitors promote urinary glucose excretion 
through inhibition of glucose reabsorption, resulting in related caloric reduction and 
projected weight loss. However, the expected weight loss is often not translated to the 
clinic, which suggests a compensatory increase in caloric intake during treatment with 
SGLT-2 inhibitors [Tentolouris et al. 2019]. Inhibition of SGLT-2 receptors have been 
shown to enhance glucagon secretion, through lowering intracellular glucose levels. 
This results in an increase in glucagon to insulin ratio, thus promoting lipolysis and 
ketogenesis [Tentolouris et al. 2019]. SGLT-2 inhibitors have also been shown to have 
a positive effect on the brain and cognitive activity [Lin et al. 2014]. SGLT-2 
inhibitors are quickly becoming a favourable treatment option, but increase risks of 
contracting urinary tract infections [Bouchie, 2013]. 
 
1.2.2 INCRETIN MIMETICS 
The incretin effect in patients with T2DM is severely reduced with this 
pathophysiological trait likely playing a vital role in the insufficient secretion of 
insulin to prevent hyperglycaemia after an oral glucose load in these individuals 
(Figure 1.1). The diminished incretin effect includes reduced GLP-1 secretion and 





hormones, GLP-1 and GIP. Unlike GIP, the insulinotropic effect of GLP-1 is 
preserved in individuals with T2DM, therefore therapeutics have been modulated 
based around exploiting the beneficial actions of GLP-1. These agents mimic the anti-
hyperglycaemic properties of GLP-1 by stimulating insulin secretion, reducing 
glucose uptake and inhibiting glucagon secretion [Nielsen, 2005; Gupta et al. 2016]. 
GLP-1 incretins approved for clinical use can be classed as either short acting (e.g. 
exendin-4), or long acting (e.g. liraglutide) [Uccellatore et al. 2015]. Exendin-4, the 
first incretin mimetic to be approved in 2005, is isolated from the saliva of the 
venomous lizard Heloderma suspectum [Eng et al. 1992]. This mimetic requires twice 
daily administration, and stimulates both first and second phase insulin secretion and 
has favourable effects on body weight [Szayna et al. 2000; Kolterman et al. 2003; 
Uccellatore et al. 2015]. Liraglutide, exhibits a similar beneficial effect to exendin-4, 
but only requires once daily injection. Weekly formulations of these GLP-1 mimetics 
have also been approved. These combine the GLP-1 agonists with either human 
albumin (Albiglutide) or with an IgG fragment (Dulaglutide) [Jimenez-Solem et al. 
2010; Trujillo and Nuffer, 2014]. More recently, an oral GLP-1 mimetic has been FDA 
approved; Semaglutide [Dhillon, 2018].   
 
Incretin mimetics are DPP-4 resistant. The use of these therapeutics have favourable 
advantages over aforementioned treatment options including better glycaemic control 
with reduced risk of hypoglycaemia, robust effects on weight loss, enhancements in 
beta cell function and improvements in patients’ cardiovascular risk profile [Nauck, 
2013]. Although incretin mimetics have been considered extensively for their 
beneficial effects for diabetes management, studies have also revealed beneficial 





data has suggested favourable anabolic effects [Mabilleau et al. 2014; 2015; Sun et al. 
2015], however others contradict this and suggest that use of these mimetics could 
potentially increase fracture risk [Su et al. 2015]. Other studies have demonstrated 
improvements in cognitive function, and both cerebral and systemic microvascular 
architecture [Kelly et al. 2015] leading to improvements in learning and memory 
[Gault and Hölscher, 2008; Porter et al. 2011; Gupta, 2012], as well as promoting 
neuroneogenesis [Hamilton et al. 2011]. Like all therapeutics, some side effects have 
been reported including moderate nausea, vomiting and diarrhoea [Lund et al. 2014].  
 
 
Figure 1.1 The incretin effect. Following an oral glucose load there is a stimulation 
of insulin secretion in healthy patients. However, in T2DM following an oral glucose 
load, this stimulation of insulin secretion is greatly impaired. [Taken from Nauck et al. 
1986]. 
 
1.2.3 DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS  
Dipeptidyl peptidase-4 (DPP-4) is an enzyme responsible for the degradation and 
subsequent short half-life of incretin hormones GIP and GLP-1 (Figure 1.2). DPP-4 





impaired incretin effect, blockade of DPP-4 has been utilised as a mechanism to 
restore normal glycaemia in T2DM.  
 
Clinically approved DPP-4 inhibitors, are a rationally designed drug class based on 
known endocrinology of GLP-1 and understanding of DPP-4 in metabolism, and 
include sitagliptin, saxagliptin, vildagliptin, alogliptin and linagliptin. By slowing the 
degradation of incretin hormones, these therapeutics result in higher circulating levels 
of active GLP-1 and GIP, which enhance their insulinotropic effects in T2DM patients 
[Green et al. 2004], as well as slowing gastric emptying, reducing food intake and 
reducing postprandial glucagon [Makrilakis, 2019]. 
 
Sitagliptin was the first clinically approved oral DPP-4 inhibitor and necessitates once-
daily treatment. It is used in combination with other anti-hyperglycaemic therapeutics 
for the management of T2DM. The efficacy of sitagliptin has been firmly established 
in both animal models and in a broad spectrum of individuals with T2DM [Mu et al. 
2006; Aschner et al. 2006; Williams-Herman et al. 2010; Katzeff et al. 2015]. DPP-4 
inhibitors are not associated with an increased risk of hypoglycaemia or weight gain 
[Scheen, 2012] and are usually well tolerated, but are more expensive than some other 
available anti-diabetic therapeutics. Long term treatment with DPP-4 inhibitors in 
mouse models of obesity/diabetes, facilitates improved glycaemic control [Ahrén et 
al. 2004], beta-cell survival [Pospisilik et al. 2003], cognition [Gault et al. 2015b], as 
well as improving both cardiac and vascular endothelial stiffness [Aroor et al. 2014]. 
The benefits of DPP-4 inhibitors are mediated through the preservation of both incretin 
and non-incretin substrates, [Andersen et al. 2018], and not because of direct inhibitor 





been raised regarding potential increased risks of pancreatitis [Sue et al. 2013] and 
pancreatic cancer [Tseng, 2016]. However, with its convenient oral, once-daily 
routine, high efficacy and tolerability, as well as low risk of pharmacokinetic drug-




Figure 1.2 Metabolic Pathway of DPP-4. Following oral glucose, the incretin 
hormones GLP-1, secreted from intestinal L-cells, and GIP, secreted from intestinal 
K-cells are released. Upon binding to their respective receptors (GLP-1R and GIPR) 
in pancreatic beta cells, a cascade is triggered, resulting in increased cyclic adenosine 
monophosphate (cAMP) concentrations and subsequent activation of protein kinase 
A, potentiating glucose-stimulated insulin secretion. GIP and GLP-1 have relatively 
short half-lives due to their rapid degradation by the proteolytic enzyme DPP-4. 
However, treatment with DPP-4 inhibitors can hinder this process, thus augmenting 
the incretin effect and subsequent glucose-dependent insulin secretion, increasing 
glucose uptake in the muscle, decreasing glucose production in the liver, leading to 
reductions in blood glucose levels. [Taken from Proença et al. 2019]. 
 
1.2.4 BARIATRIC SURGERY 
The gastrointestinal tract plays a key role in metabolic regulation and control, thus 
many treatment paradigms act to target the gastrointestinal tract to manage T2DM. 





key target in the management of T2DM. Bariatric surgery not only results in 
significant weight loss and beneficial effects on glucose homeostasis, insulin secretion 
and sensitivity, but has been shown to result in T2DM remission [Cefalu et al. 2016]. 
Primarily, bariatric surgery improves beta-cell function through enhanced insulin 
sensitivity, and increases circulating levels of GLP-1 and GIP, which sequentially 
promote insulin secretion. The surgery also promotes the secretion of other gut 
hormones, such as PYY and the enteroglucagon family of peptides [Vincent and Le 
Roux, 2008], thus affecting metabolism, food consumption and satiety effects [Holst 
et al. 2018]. However, bariatric surgery is not an available option to all patients, and 
therefore novel therapies, which can replicate the success of this surgery is required.  
 
1.2.5 INSULIN THERAPIES  
When diet, lifestyle changes and other anti-diabetic agents have been optimally used, 
insulin therapy is often required. Previously, insulin therapy was used as a last resort 
therapy in T2DM, however it is now often prescribed earlier, and can be used as an 
initial ‘rescue therapy’ to help stabilise glycaemia. The preferred methods of insulin 
initiation in patients with T2DM include long-acting basal insulin, once-daily 
formulations or in combination with GLP-1 receptor agonists or other orally available 
antidiabetic drugs [Silver et al. 2018]. 
 
1.2.6 NEED FOR NOVEL ANTIDIABETIC DRUG DEVELOPMENT 
Current therapies used to manage T2DM are primarily synthetic pharmacological 
drugs, which aim to improve insulin secretion, sensitivity to insulin and for glucose 
control. They are generally well tolerated in patients and can be effective in managing 





number of patients, with a high failure rate of current therapies and resultant side 
effects [Nyenwe et al. 2011]. Moreover, due to the increasing prevalence of this 
disorder [IDF, 2019], cost and drug availability are becoming an increasing concern. 
Therefore, there is a continuous and rapid need to develop novel therapeutics that are 
effective, affordable and globally available to manage T2DM. 
 
1.3 PEPTIDES THERAPEUTICS 
Peptides, with a relatively low molecular weight, can be used as unique 
pharmaceutical compounds, which have evolved as highly effective signal 
transduction molecules capable of exerting significant physiological effects [Fosgerau 
and Hoffmann, 2015]. Peptides as therapeutics are generally well tolerated and are 
regarded as safe, in addition to being highly selective and efficacious [Fosgerau and 
Hoffmann, 2015]. Thus, there is an increased interest into the research and 
development of peptides as potential therapeutics. Currently over 60 peptide drugs 
have been approved for use, 260 peptide drugs have been tested in human clinical 
trials, with a further 150 currently in active clinical development [Lau and Dunn, 
2018]. The global market for peptide therapeutics is continually expanding, with $30 
billion spent in 2018, however this is estimated to surpass $50 billion by 2024. This 
significant increase into novel peptide therapeutics has been triggered by the high 
prevalence of lifestyle disorders like obesity and T2DM and their associated side 
effects. 
 
1.3.1 PEPTIDES AS DRUGS 
The use of peptides as drugs has long been recognised as a significant opportunity, 





targets. Peptides used as therapeutic agents are normally derived from natural sources 
and termed bioactive peptides; however, peptides can also be isolated from chemical 
or genetic libraries. As peptides are naturally occurring, they have many advantages 
over small molecules including cheaper to synthesise, diverse, safer, with minimal risk 
of drug-drug interactions [Marqus et al. 2017], high binding affinity towards a broad 
range of therapeutic targets, and very potent resulting in enhanced efficacy, selectivity 
and specificity, even at lower doses [Fosgerau and Hoffmann, 2015]. Therefore, 
peptides are of high interest for many drug developers. However, peptides as drugs 
only represent ~2% of the drug market, whereas small molecules compile ~80%, with 
enhanced stability, oral bioavailability and permeability over unmodified peptides, but 
they may increase the risk of toxicity. 
 
Unfortunately, despite their numerous advantages, clinical use of these peptides is 
hampered due to certain drawbacks limiting their therapeutic practice. These 
limitations comprise increased proteolytic instability, reduced oral bioavailability, 
limited permeation across biological barriers due to high hydrogen bonding capacity 
and lipophilicity [Rezai et al. 2006], susceptibility to enzymatic degradation as well 
as rapid renal clearance [Di, 2015]. Unmodified peptides are also usually limited to 
extracellular targets due to poor cell membrane penetration [Di, 2015]. Peptides have 
poor oral bioavailability and are normally administered either by subcutaneous, 
intramuscular or intravenous injections.  
 
Importantly, these limitations can be overcome as various peptides have shown 
effectiveness for numerous disease states such as peptide-derived vaccine for prostate 





Marqus et al. 2017], management of irritable bowel disease with the peptide 
compound linaclotide [Bassotti et al. 2018], and the clinically approved GLP-1 
receptor agonist exendin-4, isolated from the salvia of the Gila monster Heloderma 
suspectum [Eng et al. 2002] for management of T2DM. 
 
1.3.2 APPROACHES TO IMPROVE PEPTIDE PHARMACOKINETICS AND 
PHARMACODYNAMICS  
The pharmaceutical industry has taken considerable interest in development of 
peptides as novel drug candidates, due to their impressive physiological and 
biochemical effects, as well as subjugating the afore-mentioned limitations. This has 
included various approaches to improve both the pharmacokinetic and 
pharmacodynamic profile of peptide-based therapeutics with modified peptides or 
peptidomimetics. These approaches consist of maintaining or enhancing biological 
activity, whilst altering the peptides physiochemical characteristics [Gentilucci et al. 
2006].  
 
Peptides have a shorter biological half-life due to their susceptibility to enzymatic 
degradation and rapid renal clearance, consequently resulting in reduced peptide 
efficacy due to reduced exposure to target tissues. Therefore, to overcome this 
problem, various approaches are being established to increase peptide half-life. This 
includes structural modification of the N-terminal/C-terminal of peptides such as 
amidation, acetylation or glycosylation to enhance stability, as well as cyclization to 
enhance peptide stability and rigidity [Werle and Bernkop-Schnürch, 2006; Goodwin 
et al. 2012; Di, 2015]. Amino acid substitutions, including the replacement of naturally 





increase peptide stability, as very limited enzymes have been discovered to degrade 
D-amino acids [Feng and Xu, 2016]. Peptide half-life can also be increased through 
the covalent attachment of polyethylene glycol (PEG) chains to peptides. This also 
prevents the recognition and degradation of peptides by proteolytic enzymes. 
Furthermore, due to the now increased peptide size by PEG, renal filtration is reduced 
and peptide bio-distribution altered, as well as decreased immunogenicity and 
antigenicity of the peptides [Veronese, and Pasut, 2005; Veronese and Mero, 2008]. 
Increasing peptide molecular size, through conjugation with gamma immunoglobulin 
(IgG), can also result in increased uptake of the peptide at the biological active site 
[Bruno et al. 2013]. Attachment of fatty acids to peptides has also been shown to 
increase their half-life by reducing glomerular filtration via albumin binding [Madsen 
et al. 2007]. Albumin is the most abundant blood serum protein, with a biological half-
life of 19 days [Peters, 1996], therefore the use of ligands as carrier systems, which 
carry the peptide onto longer-lived serum proteins like albumin, helps to enhance 
peptide half-life [Larsen et al. 2016]. Peptide drugs, which contain albumin-binding 
fatty acids in their structure, include liraglutide, which due to the retardation of renal 
elimination due to albumin binding, gives liraglutide a half-life of 12 hours [Krentz 
and Sinclair, 2012]. Covalent linkage of peptides with the serum protein albumin or 
IgG fragments can reduce renal clearance; extend peptide half-life whilst retaining 
peptide potency. For example, albiglutide, a GLP-1 mimetic, which has an increased 
half-life of 5-days, enabling a once weekly injectable drug [Rosenstock et al. 2009]. 
Peptide half-life can be enhanced through the introduction of reduced peptide bonds, 
resulting in a peptide highly resistant to enzymatic and chemical degradation [Feurle 
et al. 2003]. Bio-stability of peptides can be further improved through the inclusion of 





structural stabilisation of peptides [Chen et al. 2001]. Half-life of peptides can also be 
increased using sustained release techniques, this includes the use of matrix-free 
formulation, such as in taspoglutide [Rosenstock et al. 2013], or through the 
incorporation of polylactide-glycolide microsphere suspension with peptides, for 
example exenatide-LAR [Drucker et al. 2008].  
 
To help further the efficacy of peptide therapeutics, approaches to increase peptide 
bioavailability have been used. Through the addition of modules enabling passive or 
active transport, peptide drug penetration through biological barriers can be improved 
[Fasano, 1998]. This includes the use of positively charged amino acids, especially at 
terminal positions, to improve cell and tissue penetration [Teesalu et al. 2009; Li and 
Cho, 2012], as well as the incorporation of sugars which can improve tissue 
penetration including transport across the blood-brain barrier [Otvos and Wade, 2014]. 
Conjugation of peptides with ligands of various cell surface receptors can also help 
improve penetration of peptides. Intracellular transport of peptide drugs can be further 
enhanced through the fusion with highly cationic low molecular weight penetrating 
peptides [Lindgren and Langel, 2011]. 
 
Increasing peptide solubility can also help improve peptide drug efficacy. Solubility 
can be increased in peptide formulations through the incorporation of salts, sugars or 
other compounds such as heparin [Uhlig et al. 2014]. A successful peptide dosage 
formulation requires sufficient solubility, dependent on the pH of the peptide solution, 
to allow for a dosing volume suitable for the selected route of administration [Bak et 





peptide’s isoelectric point. Tolerable range of intravenous administration is pH 3–10 
[Bak et al. 2015].  
 
The route of administration largely affects the pharmacokinetics of peptide-based 
drugs, with parenteral routes commonly used for peptide drug administration. 
However, more patient friendly routes of administration have been a recent research 
focus, with oral delivery being the most pursued. Many advances to accomplish oral 
delivery includes the use of carriers such as nanoparticles, microspheres and liposomes 
[Muheem et al. 2016; He et al. 2019], as well as the use of absorption enhancers such 
as bile salts, which enhance penetration and improve the bioavailability [Brayden 
and Mrsny, 2011; Sizer, 1997]. Previous studies demonstrated the potential of 
conjugating biotin with GLP-1 for oral drug delivery [Chae et al. 2007]. However, it 
was not until 2019, when the first oral GLP-1 mimetic was clinically approved by the 
FDA, using a stable and soluble carrier, SNAC (Sodium N-[8-(2-
hydroxybenzoyl)Amino]Caprylate), which chaperones the GLP-1 mimetic, 
semaglutide, through the gastrointestinal membrane, thus overcoming issues with 
bioavailability without interrupting the therapeutic agent [Bucheit et al. 2020]. 
Metabolic profile of peptide drugs can also be improved. To better understand the 
pharmacokinetic profile of peptide drugs, absorption, distribution, metabolism and 
excretion have to be evaluated. Assessment of biological activity of peptide-based 
therapeutics can be assessed both in vitro and in vivo. 
 
In addition, and specifically for the gut peptide xenin, given that other related insulin-
releasing peptides, for example neurotensin, xenopsin and caerulein, possess an N-





life [Zahid et al. 2011], this approach may prove favourable for the augmentation of 
bioactivity of xenin and related fragment peptides. These methods outlined above 
result in the improvement of both the pharmacokinetic and pharmacodynamic profile 
of peptide drug candidates, consequently enhancing their therapeutic promise. The 
versatility, effectiveness, safety and tolerability of peptide-based candidates, due to 
the above approaches, is resulting in the increased translation to peptide-based 
therapies by several pharmaceutical industries, predominantly in the management or 
treatment of obesity and diabetes.  
 
1.4 GUT PEPTIDES  
In 1969, the concept of using gut-derived hormones as therapeutics for metabolic 
conditions was first considered [Unger and Eisentraut, 1969]. These early studies 
explained how food consumption stimulates release of various gut hormones that 
regulate the secretion of insulin [Drucker, 2006]. Various bioactive peptides and 
hormones are produced by the gut, such as GIP, GLP-1, xenin, ghrelin, 
oxyntomodulin, PYY, cholecystokinin (CCK) and gastrin [Feurle, 1998; Drucker, 
2006; Wren and Bloom, 2007]. These active peptides and hormones are produced by 
endocrine cells within the gastrointestinal system, and can be released into circulation 
following food intake [Ahrén, 2003].  
 
Previous studies highlighted the ability of interaction of gut peptides to stimulate 
insulin secretion, particularly following food ingestion. CCK, gastrin, GIP and GLP-
1, could play vital roles in regulating insulin secretion and lowering blood glucose 
levels [Dupre et al. 1973; Ahrén et al. 2000; Drucker, 2007; Rehfeld, 2017], whilst 





and Bloom, 2013]. Thus, due to defects in secretion of insulin in T2DM, the 
insulinotropic capabilities of these gut peptides may be promising targets for the 
treatment of this disorder. As such, direct modulation of one or multiple peptide 
pathways may prove useful for treatment of obesity/T2DM. Direct targeting of GLP-
1 has already been established as a therapeutic agent for T2DM [Doyle and Egan, 
2007], as well as research into gut hybrid peptides targeting multiple signalling 
pathways [Fosgerau et al. 2013; Irwin et al. 2013a, 2015; Bhat et al. 2013; Hasib et 
al. 2017, 2018; Craig et al. 2020]. However, further investigations are required to 
establish the role of the other related gut hormones, either alone but particularly in 
combination, as potential therapeutic agents for the treatment and aetiology of T2DM. 
 
1.4.1 IMPAIRED INCRETIN EFFECT IN DIABETES 
The incretin effect is defined as the increased stimulation of glucose-dependent insulin 
secretion elicited by oral as compared with intravenous administration of glucose 
under similar glucose conditions [Holst and Ørskov, 2004]. The incretin effect is 
mediated by gut-derived incretin hormones, GLP-1 and GIP, which are responsible 
for approximately 50-70% of postprandial insulin secretion [Nauck et al. 1986]. GLP-
1 and GIP are confirmed incretin hormones in man [Irwin et al. 2019], and are secreted 
by enteroendocrine cells in the intestinal mucosa. Normally, the circulatory levels of 
these hormones increase following nutrient intake and stimulate glucose-induced 
insulin secretion [Nauck and Meier, 2018]. However, in T2DM this incretin effect is 
severely diminished and patients exhibit an almost complete loss of incretin hormone 







This deficiency of the incretin effect could be due to the decreased secretion of GLP-
1 and loss of second phase stimulation of the insulinotropic actions of GIP [Nauck et 
al. 1993; Holst et al. 2004; Holst et al. 2011], or impaired effects in pancreatic islet 
function. Compared to GLP-1, the reduced insulinotropic actions of GIP may be 
attributed to downregulation of GIP receptors (GIPR) [Holst et al. 1997]. Various 
studies have demonstrated the decreased expression of these receptors in both in vitro 
and in vivo hyperglycaemic states [Lynn et al. 2003, Xu et al. 2007; Pathak et al. 
2015], showing the effects of elevated glucose levels and GIPR expression. 
 
1.4.1.1 GLUCAGON-LIKE-PEPTIDE-1 (GLP-1)  
The peptide hormone, GLP-1, acts as an incretin to stimulate release of insulin from 
beta cells in response to oral glucose. GLP-1, a 30-amino-acid hormone, is secreted 
from enteroendocrine L-cells in the small intestine [Herrmann et al. 1995]. GLP-1 is 
a posttranslational product of proglucagon, the precursor of glucagon [Orskov et al. 
1989]. The 180-amino-acid preproglucagon is cleaved, forming the 160 amino acid 
proglucagon, which is cleaved to GLP-1 by prohormone convertase 1/3 (PC1/3) in 
intestinal L-cells, and by PC2 in pancreatic alpha cells [Whalley et al. 2011]. There 
are two major biologically active forms of GLP-1: GLP-1(7-36) amide and GLP-1(7-
37). Native GLP-1 is rapidly degraded by DPP-4 with only 8% of newly secreted intact 
GLP-1 reaching peripheral circulation [Hjøllund et al. 2011]. This results in inactive 
metabolites and a short biological half-life, less than 2 minutes in rodents [Kieffer et 
al. 1995] and approximately 7 and 5 minutes in healthy subjects and individuals with 
T2DM, respectively [Deacon et al. 2000], therefore rendering the native form 






The actions of GLP-1 are primarily mediated through binding to G-protein coupled 
receptors (GLP-1R) [Thompson and Kanamarlapudi, 2013], which are widely 
expressed in the pancreatic islets, heart, stomach, intestines, lung, kidney, pituitary, 
hypothalamus and brain stem [Holst, 2007; Baggio and Drucker, 2007], as well as 
areas related to appetite regulation [Turton et al. 1996]. The main target for GLP-1 is 
the pancreatic islets, but GLP-1 also has roles in modulating the activity of other 
organs [Holst, 2007]. These pancreatic and extra pancreatic actions are summarised in 
Table 1.2. The main function of GLP-1 is to act as an incretin hormone, with its ability 
to augment postprandial insulin production being the most studied physiological effect 
of GLP-1.  
 Table 1.2: Biological actions of the incretin hormone GLP-1 
Tissue: Effects 
Pancreas 
 Increases insulin and somatostatin secretion 
 Decreases glucagon secretion 
 Increases insulin gene expression 
 Increase beta-cell sensitivity to glucose 
 Increase beta-cell proliferation and neogenesis  
 Decreases beta-cell apoptosis 
Adipose  
 Increases glucose uptake 
 Increases lipolysis 
Stomach 
 Delays gastric emptying 
 Decreases gastric motility 
 Reduces gastric acid secretion 
Brain 
 Increase satiety and energy expenditure 
 Reduces appetite 
 Promotes neuroprotection  
Heart 
 Increases glucose uptake 
 Promotes cardiac function and protection 
Liver  Decreases hepatic glucose production 
Muscle 
 Increases glucose uptake 
 Favourable effects on muscle blood flow 
Bone 
 Promotes bone formation 









1.4.1.2 GLUCOSE-DEPENDENT INSULINOTROPIC POLYPEPTIDE (GIP) 
GIP(1-42) is synthesised from its 153 amino acid precursor; ProGIP, by prohormone 
convertase PC1/3 [Kim and Egan, 2008], and to GIP(1-30) in the intestine and 
pancreatic alpha cells by PC2 [Fujita et al. 2010]. The enzyme DPP-4 rapidly degrades 
GIP, through cleavage at the N-terminal Ala2 position, producing GIP(3-42), a GIP 
receptor antagonist [Gault et al. 2002a], thus GIP has a very short half-life of 2-5 
minutes in circulation [Tatarkiewicz et al. 2014]. The incretin hormone GIP consists 
of three bioactive domains; GIP(1-14) - the N-terminal domain, GIP(19-30) - the mid 
domain, and GIP(31-42) - the C-terminal domain [Hinke et al. 2001]. The N-terminal 
and mid domains are involved with the insulin-releasing incretin effect, whereas the 
C-terminal domain is known for its enterogastrone activity [Hinke et al. 2001].  
 
GIP, a 42-amino acid incretin hormone first isolated in 1969, is secreted from 
enteroendocrine K-cells in the intestinal mucosa in response to oral glucose [Nauck et 
al. 2004]. The established actions of GIP include, but are not limited to, stimulating 
glucose-induced insulin secretion, regulating postprandial glucose homeostasis, 
slowing gastric emptying and promoting pancreatic beta cell proliferation and survival 
[Irwin and Flatt, 2013]. Various studies in both rodents [Gault et al. 2003b] and 
humans [Gasbjerg et al. 2019], have established GIP as the major incretin hormone, 
which accounts for approximately 70% of the full incretin effect [Gault et al. 2003c; 
Holst, 2019]. In the pancreas, various studies have demonstrated the direct effects of 
GIP on beta cells to stimulate the secretion of insulin, protect against apoptosis 
[Taminato et al. 1977; Adrian et al. 1978], and enhance beta cell proliferation through 
the stimulation of PKA, PKB, MAPK and P13K pathways [Trümper et al. 2001]. GIP 





lipolysis in adipose tissue [Gupta and Raja, 2019], favourable cognitive effects 
including increase in proliferation of progenitor cells in the brain and positive effects 
on memory [Faivre et al. 2012], improving glucose utilisation in the liver [Chiang et 
al. 2012], and augmenting bone formation/decreasing resorption [Nissen et al. 2014]. 
 
Nevertheless, clinical exploitation of GIP has been hindered due to its well-
characterised reduced action in T2DM, however, both GIP agonism and antagonism 
have both been associated with T2DM therapies. Numerous GIP-receptor agonists 
have shown insulinotropic potential and favourable anti-hyperglycaemic effects 
[Gault et al. 2003a; O’Harte et al. 2002; Irwin et al. 2005a, 2005b, 2006a, 2006b]. 
However, increasing concentrations of GIP have also been associated with promoting 
obesity [Thondam et al. 2017], due to the ability of GIP to stimulate fat synthesis 
[Fulurija et al. 2008]. Accordingly, more interest has been shown in GIPR antagonists, 
which have been described to reduce body weight and favourable changes in 
triglyceride levels [Kim et al. 2012; McClean et al. 2008]. However, analogues of GIP 
may yet offer a novel class of drugs for the management of diabetes, as in healthy 
individuals GIP seems to be the major incretin contributor [Bastin and Andreelli, 
2019]. Due to the synergistic relationship between GLP-1 and GIP on beta cells, 
simultaneous activation of both pathways may provide additional benefits on beta cell 
functions. Bastin and Andreelli [2019], also suggest that through the enhancement of 
reduced blood glucose levels by GLP-1, this in effect promotes GIP activity to achieve 
improved metabolic control.  
 
In patients with T2DM, the biological activity and glucose-induced insulin secretory 





The primary pathophysiological source of this impairment is thought to be caused by 
the desensitisation and downregulation of the GIP-receptor in the pancreas [Knop et 
al. 2007b], caused by splicing of the mRNA resulting in decreased activity of the GIP-
receptor [Gupta et al. 2017]. This diminished incretin effect is thought to be an early 
defect in T2DM, second to the development of insulin resistance [Muscelli et al. 
2008]. Due to its weak efficacy and biological activity, this native 42-amino acid 
hormone exhibits unfavourable pharmacokinetic properties for the treatment of T2DM 
[Irwin et al. 2006a, 2006b]. However, due to the favourable insulinotropic actions of 
GIP which could be restored, including not only augmentation of the incretin effects, 
but also to protection against further decline in beta-cell mass; an underlying 
pathophysiological problems in diabetes, it would be highly beneficial if the actions 
of GIP were re-sensitised in patients with T2DM.  
 
1.4.2 XENIN 
Xenin, a 25 amino acid peptide, is the human counterpart of the amphibian peptide 
xenopsin [Araki et al. 1975], synthesised from its 35-amino acid precursor pro-xenin 
through the posttranslational enzymatic action of cathepsin-E [Kageyama, 1995; 
Hamscher et al.1996; Feurle, 1998]. Interestingly, this precursor proxenin has been 
described with sequence homology to yeast and mammalian alpha coat protein 
(COPA) [Hamscher et al. 1996], with all 35 amino acid residues of COPA identical to 
that of proxenin, with treatment of proxenin with pepsin releasing the biologically 
active xenin-25 [Chow and Quek, 1997; Craig et al. 2018]. It is a naturally occurring 
peptide hormone originally identified by Feurle and colleagues from isolates of human 
gastric duodenal and jejunal mucosa [Feurle et al. 1992], with subsequent studies 





of various other animal species, including rat, rabbit, dog and pig [Hamscher et al. 
1995; Craig et al. 2018]. In humans, xenin-25 is synthesised and secreted into the 
bloodstream from a subpopulation of chromogranin A-positive enteroendocrine K-
cells [Anlauf et al. 2000], similar to GIP, in response to food intake [Taylor et al. 2010, 
Martin et al. 2016, Craig et al 2018]. A specific receptor for xenin is yet to be 
identified, but it is believed that due to the structural similarities between xenin-25 and 
neurotensin, some biological effects may be mediated through activation of 
neurotensin receptors [Clemens et al. 1997; Craig et al. 2018]. However, there is 
suggestions that some biological effects of xenin-25 may be independent of these 
receptors [Heuser et al. 2002].  
 
The biological actions of xenin-25, summarised in figure 1.3, have been well 
established including effects on appetite suppression [Alexiou et al. 1998; Leckstrom 
et al. 2009; Chowdhury et al. 2014; Martin et al. 2016; Craig et al. 2018] 
gastrointestinal transit rate and gastric emptying [Feurle et al. 1992; Cline et al. 2007; 
Kim and Mizuno, 2010; Craig et al. 2018] as well as pancreatic endocrine and exocrine 
secretions [Feurle et al. 1992; Silvestre et al. 2003; Martin et al. 2016; Craig et al. 
2018]. These actions of xenin are outlined in more detail below. 
 
Appetite Suppression  
Similar to other anorectic gastrointestinal peptides, circulating levels of xenin-25 
increase following food intake, thus in harmony with this xenin-25 acts to control 
energy intake by acting as a satiety factor. [Feurle et al. 2003; Leckstrom et al. 2009; 
Cooke et al. 2009; Craig et al. 2018]. Indeed, Mrózek et al. 2012 demonstrated the 





may be altered by both intestinal inflammation and obesity. The clear anorexigenic 
effects of xenin-25 have been confirmed in both chicks [Cline et al. 2007] and rodents 
[Alexiou et al. 1998; Leckstrom et al. 2009; Cooke et al. 2009; Taylor et al. 2010; 
Craig et al. 2018]. The effects on feeding by xenin-25 may be directly associated with 
the actions on gastrointestinal transit as outlined below [Kim and Mizuno, 2010; 
Chowdhury et al. 2014], as decreased food consumption and a 93% reduction in the 
rate of gastric empting in xenin-25 treated mice was demonstrated by Kim and 
Mizuno, 2010. However, it has also been suggested that the anorexia inducing impact 
of xenin-25 in chicks is centrally mediated through the direct effects on ventromedialis 
hypothalami [Nandar et al. 2008]. Similarly, others have demonstrated these effects 
are also linked with the activation of cells in the nucleus of the solitary tract [Kim and 
Mizuno, 2010].  
 
Xenin-25 may also affect feeding, independent of the actions of both melanocortin and 
leptin, by modulating neurotensin receptor related signalling pathways in the 
hypothalamus [Leckstrom et al. 2009; Kim et al. 2016]. It is believed by others that 
activation of these hypothalamic neurotensin receptors helps to control food intake 
through the stimulation of extracellular signal regulated kinase activity [Morikawa et 
al. 2004]. However, the suppressive effects of xenin-25 on appetite by extracellular 
signal regulated kinase pathways is also deliberated by others [Kim et al. 2016]. IL-1 
signalling has also been identified as another potential central pathway through which 
energy balance is modulated by xenin-25 [Kim et al. 2014]. Indeed, it has also been 
suggested that myenteric neurons may also mediate the effects on feeding by xenin-
25, along with xenin-25 effects on gastric emptying, gall bladder contractions, and gut 





25 have been described on lipid metabolism and adipose tissue, including an increase 
in lipolysis and reduction in lipogenesis [Bhavya et al. 2017], which may also link to 
the notable effects on energy turnover by xenin-25 [Craig et al. 2018].  
 
Gastrointestinal transit 
The delay in gastric emptying is evident in both rodents and humans by xenin-25 [Kim 
and Mizuno, 2010; Chowdhury et al. 2014], with this effect thought to be linked to the 
presence of neurotensin receptors on nerve fibres in longitudinal stomach muscle 
[Chowdhury et al. 2014]. Extensive studies have outlined the actions of xenin-25 in 
both the small and the large intestines of guinea pigs [Feurle et al. 1996]. In the 
jejunum, a biphasic response to xenin-25 is elicited resulting in a small relaxation 
followed by a large contraction. This is assumed to be caused by a neurokinetic 
excitatory effect, along with muscarinic purinergic and tachykinin-related 
mechanisms [Feurle et al. 1996]. In the colon, xenin-25 induces a myokinetic 
relaxation effect, which involves the calcium-dependent potassium channels and the 
P2-purinoceptor [Feurle et al. 1996]. These distinct differences in the action of xenin-
25 in the intestines of guinea pigs, may suggest there are variants in both neurokinetic 
and myokinetic receptors responsible for these effects by xenin-25 [Craig et al. 2018]. 
Additionally, in the rat ileum, Clemens et al. 2007, reported that this effect is mediated 
by an apamin-sensitive neurotensin-type receptor. In dogs, a dose-dependent 
neurotensin-like effect on gall bladder contractions, with a non-dose dependent effect 
on jejunum contractions was elicited by xenin-25 [Kamiyama et al. 2007].  
 
However, others have also proposed that the effects of xenin-25 may not be entirely 





et al. 2002], but suggest the presence of other receptors which can regulate the activity 
of xenin-25 [Mazella et al. 2012]. Following Roux-en-Y gastric bypass, recent studies 
have demonstrated the absence of xenin-25 stimulated gastrointestinal transit [Kaji et 
al. 2017], indicating the importance of the duodenum in this regard [Craig et al. 2018]. 
In humans, interdigestive and postprandial duodenojejunal motility is also modulated 
by xenin-25, demonstrated at relatively low infusion doses of 40 ρmol/kg for 10 min 
[Feurle et al. 2001]. Feurle and co-workers also demonstrated the inhibition of 
pentagastrin-stimulated gastric acid secretions by xenin-25, which could also be a 
factor in the modulation of overall gastric transit [Feurle et al. 1997].  
 
Pancreas 
Initial studies by Feurle et al. 1992, showed that xenin-25 stimulated secretions from 
the exocrine pancreas, with the same research team presenting that, in dogs, xenin-25 
also induces secretion of pancreatic-derived endocrine hormones, including insulin, 
glucagon and pancreatic polypeptide [Feurle et al. 1997], which was later confirmed 
in isolated mouse islets [Silvestre et al. 2003]. These studies would therefore suggest 
that the effects on glucagon and insulin release by xenin-25 is mediated through a 
direct effect on the pancreatic alpha and beta cells, respectively [Craig et al. 2018]. In 
contrast, it has also been suggested that xenin-25 does not act directly on the pancreatic 
beta cells, but instead acts on non-ganglionic cholinergic neurons to stimulate 
acetylcholine release resulting in the activation of beta cell muscarinic receptors [Wice 
et al. 2010]. However, it has been reported that these cholinergic pathways are not 
involved in the stimulatory effects on pancreatic secretions by xenin-25 [Nustede et 
al. 1999]. Furthermore, studies have also suggested that the insulinotropic actions of 





et al. 2010]. More recent studies have also highlighted the potential of xenin-25 as a 
direct independent insulinotropic agent, as well as its ability to potentiate both insulin-
releasing and glucose-lowering actions of GIP, the incretin hormone [Taylor et al. 
2010; Wice et al. 2010, 2012; Martin et al. 2012, 2014; Gault et al. 2015; Parthsarathy 
et al. 2016]. Additionally, xenin-25 has been shown to enhance proliferation in 
pancreatic beta cells in both rodent and human beta cells [Khan et al. 2017a], offering 
further potential as a viable therapeutic option for individuals with T2DM, since this 
disorder is characterised by both beta cell loss [Halban et al. 2014] and reduced 
bioactivity of GIP [Vilsboll et al. 2002]. However, it should be noted that some have 
suggested that xenin-25 may inhibit GLP-1 secretions, which if confirmed true, would 
be detrimental in terms of the antidiabetic actions [Sterl et al. 2016], although further 
research is required to confirm this finding. This initial work, which characterised the 
impact of xenin-25 on gut motility and energy turnover, together with more recent 
findings highlighting the encouraging effects on metabolic control, demonstrates 
favourable and potentially translatable effects. 
 
1.4.2.1 XENIN-25 AS AN ANTIDIABETIC AGENT 
Under both normal and type 2 diabetic conditions, numerous studies have 
demonstrated that xenin-25 can induce the release of insulin and potentiate the 
biological actions of the incretin hormone GIP [Taylor et al. 2010; Wice et al. 2010, 
2012; Martin et al. 2012; Chowdhury et al. 2014; Gault et al. 2015; Craig et al. 2018]. 
However, the short biological half-life of xenin-25, due to enzymatic degradation, 
creates a major barrier to its exploitation as a therapeutic agent [Martin et al. 2014]. 





been developed and characterised, and demonstrated clear therapeutic potential (Table 
1.3). As such, stabilised forms of xenin-25 have been developed, as outlined below.  
 
1.4.2.2 STABILISED FORMS OF XENIN 
Stable, enzyme-resistant forms of xenin-25 have been generated. As such, a fatty acid 
derivative form of xenin-25, namely xenin-25[Lys13PAL], has been synthesised and 
fully characterised, with hypothesised antidiabetic effects [Martin et al 2012]. A 
follow-up study, conducted in high fat fed diabetic mice, employing chronic 
administration of xenin-25[Lys13PAL], confirmed this suggestion, demonstrating 
augmentation of insulin secretion, enhanced glucose homeostasis and tissue insulin 
sensitivity, as well as partial restoration of normal islet architecture [Gault et al. 2015]. 
Since the degradation of xenin-25 is primarily due to serine-like proteases [Martin et 
al. 2014; Craig et al. 2018], this led to the generation of a modified analogue of xenin-
25, where Lysine (Lys) and Arginine (Arg) amino acid residues were substituted for 
Glutamine (Gln), yielding xenin-25-Gln [Parthsarathy et al. 2016]. This novel 
analogue was enzyme resistant and retained similar biological activity to the parent 
peptide, xenin-25. Chronic administration of xenin-25-Gln in high fat fed and ob/ob 
mice, resulted in enhanced sensitivity to GIP, improved metabolic control and an 
improved circulating lipid profile [Parthsarathy et al. 2016]. These observations with 
stabilised, potent and long-acting xenin-25 analogues highlight the antidiabetic 
potential offered by these peptides. However, another approach to help exploitation of 
this favourable gut hormone could be through increasing xenin concentrations, which 
could be possibly achieved through MetAP2 inhibitors, which may inhibit xenin 






1.4.2.3 XENIN-25 FRAGMENT PEPTIDES 
Stable xenin-25 analogues, outlined above, have demonstrated beneficial effects in 
preclinical models of diabetes-obesity. However, therapeutic attractiveness of these 
stabilised forms could be further enhanced with truncated and bioactive peptide 
fragments, which could make peptide synthesis easier and cheaper, as well as 
facilitating possible non-injectable peptide drug delivery [Novakovic et al. 2013; Park 
et al. 2015]. A comprehensive study revealed the degradation profile of xenin-25 in 
mouse plasma, including evidence of the following C-terminally truncated 
metabolites; xenin 9-25, xenin 11-25, xenin 14-25 and xenin 18-25, where xenin 18-
25 represents xenin-8 (Table 1.3) [Martin et al. 2014]. Of these discovered xenin-25 
metabolites, only xenin-8 was shown to possess biological activity [Martin et al. 
2014]. This C-terminal octapeptide of xenin-25 has long been recognised as a naturally 
occurring bioactive form of xenin-25 [Feurle et al. 1997], with studies highlighting the 
clear effects of xenin-8 on pancreatic endocrine cells [Rodrıguez-Gallardo et al. 2001; 
Silvestre et al. 2003], including potent release of insulin [Martin et al. 2014]. However, 
unlike xenin-25 which has effects on satiety, xenin-8 has been shown to have no effect 
on satiety [Martin et al. 2014], which may suggest a change in passage through the 
blood-brain barrier of this fragment peptide compared to the parent molecule [Kim 
and Mizuno, 2010]. Interestingly, the C-terminal octapeptide of xenin-25-Gln, namely 
xenin-8-Gln [Parthsarathy et al. 2016], has been shown to retain full gluco-regulatory 
and antidiabetic actions of the full-length stable analogue [Martin et al. 2016]. 
Additionally, xenin-6 (xenin 20-25) has also underwent characterisation as a 
biologically active fragment peptide of xenin-25 [Feurle et al. 2003], and possesses 
prominent insulinotropic actions. These notable bioactive actions have been shown to 





between the Lys20 and Arg21 amino acid residues in xenin-6 [Feurle et al 2002; Craig 
et al. 2019]. However, full characterisation of this reduced pseudopeptide, as well as 
other xenin-6 fragment peptides, is lacking and thus, analogues of xenin-6 may yet 


































Table 1.3: Amino acid sequences of xenin-25 as well as its related stable analogues 
and naturally occurring fragment peptides [Craig et al. 2018]. 
 











































Figure 1.3 Schematic showing the main biological actions of xenin-25 on adipose, brain, gallbladder, gut and pancreas. [Taken from 





1.5 TNP-470 – A METHIONINE AMINOPEPTIDASE 2 INHIBITOR  
Methionine aminopeptidase 2 (MetAP2) is a bi-functional protein which plays a key 
role in both the regulation of protein synthesis and post-translational processing. This 
agent is currently being investigated for potential treatment of metabolic diseases, 
including obesity and diabetes. MetAP2 is an enzyme responsible for the co-
translational cleavage of the N-terminal methionine from nascent proteins, such as in 
the gut hormone xenin. Therefore, the use of MetAP2 inhibitors may also extend the 
biological half-life of xenin and allow for clinical exploitation of xenin as a novel 
therapeutic. By eluding degradation, the favourable effects of xenin, such as 
inducement of insulin secretion and potentiating the actions of GIP [Craig et al. 2017], 
may be increased within T2DM regimes.  
 
MetAP2 is also known as the molecular target of the angiogenesis inhibitor TNP-470. 
TNP-470, an analogue of fumagillin, originally shown to be an effective anti-
angiogenic agent and an inhibitor of endothelial cell growth [Yeh et al. 2006], with 
efficacy of such inhibitors demonstrated in the treatment of various cancers [Kruger 
and Figg, 2000; Logothetis et al. 2001; Nahari et al. 2006]. Studies have also 
demonstrated their anti-inflammatory, anti-infective and anti-obesity effects 
[Bråkenhielm et al. 2004; Mann-Steinberg and Satchi-Fainaro, 2008]. TNP-470 has 
also been shown to reduce oxidative stress and hyper-permeability [Mauriz et al. 2003; 
Satchi-Fainaro et al. 2005], which are favourable attributes for cancer treatments. The 
angiostatic mechanism, preventing cell proliferation, includes the suppression of 
MetAP2 in endothelial cells. Recent studies have also demonstrated the inhibition of 





cells [Ogata et al. 2003], hepatic stellate cells [Wang et al. 2000] and mesangial cells 
[Haraguchi et al. 1997].  
 
More recent evaluations of this inhibitor have shown and focused on the potential of 
MetAP2 inhibitors to be used as therapeutic options for the prevention or management 
of obesity and T2DM, and are already being investigated as a novel drug class [Kim 
et al. 2007; Hughes et al. 2013]. Recent studies have confirmed the unique anti-obesity 
efficacy in various models of obesity / diabetes, as significant weight reductions 
compared to controls were demonstrated [White et al. 2012; Proietto et al. 2016]. 
Significant reductions in food intake was observed, as well as reductions in 
subcutaneous and omental fat depots. Another study demonstrated that treatment with 
TNP-470 decreased insulin levels and improved insulin sensitivity [Bråkenhielm et al. 
2004]. Therefore, this suggests that MetAP2 inhibitors, such as TNP-470, could prove 
therapeutically favourable as a novel treatment for T2DM due to the relationship 
between obesity and T2DM, or as a preventative measure. It is suggested that the 
favourable improvement by MetAP2 inhibitors on glycaemic control and significant 
weight loss benefits may be through mechanisms involving fat metabolism, storage 
and fatty acid synthesis [Bråkenhielm et al. 2004; Kim et al. 2007; Lijnen et al. 2010; 
Elfers and Roth, 2017; Burkey et al. 2018]. Additional benefits of TNP-470 in T2DM 
may include enhancement of xenin levels, with subsequent potentiation of the incretin 
hormone GIP. 
 
1.6 COMBINATIONAL TREATMENT APPROACHES 
Monotherapy frequently fails to elicit all the ideal properties required to successfully 





been studied to create a novel treatment paradigm that is closer to an idyllic treatment 
regimen. Combinational therapeutic approaches could improve patient tolerability, as 
two different compounds may be employed below their individual side effect dose 
thresholds. Combinational methods may also offer greater efficacy, with reduced risk 
and improved adverse effect profile compared to up-titration monotherapy, as well as 
reduced costs and enhanced drug concordance. Combinational drug approach may 
also reduce the development of drug resistance. 
 
In T2DM, the majority of patients fail to achieve adequate glycaemic control with a 
single therapeutic agent [Dodd et al. 2009; Bailey et al. 2016]. Therefore, the 
administration of multiple therapeutic agents is required to successfully manage this 
disorder, and ideally improve clinical outcomes and quality of life for individuals with 
T2DM [Bell, 2013]. Due to the complex pathogenesis of T2DM, and the multiple 
metabolic defects associated with T2DM, simultaneously targeting multiple metabolic 
pathways can improve diabetic status, as single agents currently do not adequately 
address the complexity of this disease. Metformin is the most common first-line 
therapy for T2DM, therefore initial combinational approaches included metformin. 
Metformin has shown success when given in combination with either sulfonylureas, 
thiazolidinediones, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, or 
with insulin, with triple therapy used when dual combination fails to elicit the set target 
response. Combination drug choice is based on various characteristics such as the 
individual patient and disease progression as well as drug efficacy, hypoglycaemic 
risk, weight loss effects, potential side effects and overall cost. The goal of 
combination therapy in T2DM is to achieve optimum blood glucose levels whilst 





1.7 HYBRID PEPTIDES    
Due to the ever-increasing prevalence of T2DM and obesity, novel treatment options 
are necessary to help achieve efficient glycaemic control and enable weight loss, as 
current treatment options contribute to further deterioration due to their weight neutral 
or gain effects. The alleviation, post bariatric surgery, of diabetes and obesity 
emphasise the therapeutic importance of the gut-brain axis, and involvement of several 
gut hormones, therefore necessitating the development of novel patient friendly 
therapeutic approaches, which can replicate the favourable effects of bariatric 
surgeries. As stated previously, gastric bypass surgery has been shown to significantly 
reduce body weight and improve glycaemic control, with complete eradication of 
T2DM shown because of this surgery [Pournaras et al. 2010]. Thus, hybrid agents, 
entailing gut hormones, could closely mimic the hormonal changes after this surgery, 
since the effects elicited by gut hormones are multifactorial. Therefore, since surgery 
is not a viable option for many patients, development of such treatments could 
potentially provide similar outcomes, but to a larger patient cohort. 
 
Hybrid peptides have the capacity to combine the beneficial effects of multiple 
compounds, and modulate the various biological pathways involved, within a single 
compound. A proof of concept for utilisation of hybrid peptides includes the naturally 
occurring dual agonist oxyntomodulin (OXM), which activates both glucagon-like 
peptide-1 receptor and glucagon receptor pathways [Pocai, 2013]. These hybrid 
therapeutics focus on improving patient convenience and compliance, through 
strategies that allow less-frequent dosing, with possible oral administrations. Chemical 
approaches for the development of such multifunctional compounds can include a 





as chimeras, where the second pharmacological activity is ‘designed in’ to an already 
existing peptide backbone [Fosgerau and Hoffmann, 2015]. Hybrid drugs offer various 
advantages including improved dosage compliance, with reduced toxicity risks, the 
ability to design better drug combinations using the bioactive regions of peptides, as 
well as delaying or avoiding the development of drug resistance.  
 
Recent studies have highlighted the possibility of linking together different bioactive 
peptide fragment domains, to create multi-targeting hybrid peptides [Irwin et al. 2015; 
Mansur et al. 2016; Tschöp and DiMarchi, 2017], which stimulates multiple pathways 
through a single agent. In T1DM, the clinical success of combined modulation through 
a single drug formulation of insulin and GLP-1 (IDegLira), further highlights the 
benefits of stimulating multiple signalling pathways for enhanced therapeutic 
outcomes [Kapitza et al. 2015]. In T2DM, Gault et al. 2011 demonstrated improved 
glucose-lowering and insulinotropic properties from a GLP-1 and GIP combination. 
Furthermore, a CCK/GLP-1 hybrid has been characterised, displaying notable benefits 
on appetite, insulinotropic effects as well as pancreatic beta cell function and 
morphology [Irwin et al. 2015]. Hasib et al. (2017) demonstrated the promising 
antidiabetic properties of a GIP/xenin hybrid, namely (DAla2)GIP/xenin-8-Gln. Other 
hybrid peptides displaying therapeutic efficacy for the treatment of diabetes / obesity 
includes a GIP-oxyntomodulin hybrid, showing weight reducing and favourable anti-
diabetic effects [Bhat et al. 2013] and triple acting hybrid peptides incorporating 
GIP/glucagon/GLP-1, displaying therapeutic potential in high fat fed mice [Gault et 
al. 2013]. Given the initial promise of the above agents, and considering GIP and xenin 
are both secreted from the same intestinal K-cells, it would seem reasonable to assume 





of T2DM. Additionally, given the evidence against augmenting GIP in T2DM 
treatment [Gault et al. 2003b; Irwin et al. 2004, 2019], employing hybrid agents may 
improve efficacy, compared to monotherapy. Dual or triple target pharmacology, such 
as the aforementioned multifunctional hybrid peptides, as opposed to single target 
pharmacology, could present new therapeutic challenges due to the complexity in 
targeting various receptors and signalling pathways, especially in translation from 
animal to human situations. However, it is highly probable that such hybrid agents 
will offer superior efficacy, together with reduced adverse effects and low dose 
administration [Irwin and Flatt, 2015], as well as being more patient friendly. 
 
1.8 AIMS OF THESIS 
The primary aim of this thesis is to capitalise on the previous success of xenin-25 
analogues, as well as related hybrid peptides, to further build on prospects of re-
sensitising the actions of the incretin hormone GIP, and to establish their 
insulinotropic, glucose-lowering and satiety effects in different mouse models of 
obesity and diabetes. 
 
Main aims and objectives: 
1. To assess the chronic and persistent in vivo antidiabetic benefits of 
(DAla2)GIP/xenin-8-Gln, in combination with the clinically approved GLP-1 
mimetic exendin-4, and examine its persistent beneficial metabolic effects in 






2. To investigate the in vitro and acute in vivo biological actions and potential 
antidiabetic properties, including glucose-lowering, insulinotropic and satiety 
effects, of a series of modified novel xenin-6 peptides.  
 
3. To evaluate the antidiabetic therapeutic efficacy of Ψ-xenin-6 and sitagliptin, 
alone or in combination, in STZ treated high fat fed mice. 
 
4. To examine the antidiabetic and anti-obesity properties of 18-day combined 
administration of TNP-470 and sitagliptin on anti-hyperglycaemic, 










































2.1 MATERIALS  
Purified water was obtained from an Elga PURELAB Ultra system (Elga, Celbridge, 
Ireland). Chemicals and reagents were sourced as follows:   
Abcam (Cambridge, UK): mouse monoclonal antibody to insulin, rabbit monoclonal 
antibody to glucagon and rabbit polyclonal antibody to ki-67 
BDH Chemicals Ltd. (Poole, UK): Calcium chloride (CaCl2.6H2O), 
dichloromethane (CH2Cl2), di-sodium hydrogen orthophosphate (Na2HPO4), ethanol, 
D-glucose, hydrochloric acid (HCl), magnesium sulphate (MgSO4.7H2O), 
paraformaldehyde (PFA), potassium dihydrogen orthophosphate (KH2PO4), sodium 
bicarbonate (NaHCO3), sodium chloride (NaCl), sodium dihydrogen orthophosphate 
(NaH2PO4) and tri-sodium citrate (C6H5Na3O7.2H2O). 
Gibco Life Technologies Ltd. (Paisley, UK): RPMI 1640 tissue culture medium, 
antibiotics (100U/ml penicillin and 0.1g/L streptomycin), Dulbecco’s Modified Eagle 
Medium (DMEM) (25 mmol/l glucose) supplemented with 2 mmol/l L-glutamine, 
10% (v/v) FCS and antibiotics (100 U/ml penicillin and 0.1 g/l streptomycin), foetal 
bovine serum (FBS), Hanks buffered saline solution (HBSS 10x stock) and 
trypsin/EDTA (10x stock).  
Invitrogen (Paisley, UK): Alexa Fluor 594 goat anti-mouse IgG (H+L), Alexa Fluor 
488 goat anti-mouse IgG (H+L), Alexa Fluor 594 goat anti-guinea-pig IgG (H+L), 
Alexa Fluor 488 goat anti-guinea-pig IgG (H+L), Alexa Fluor 594 goat ant-rabbit IgG 
(H+L), Alexa Fluor 488 goat anti-rabbit IgG (H+L) and xylene.   
Millipore (Hertfordshire UK): Rat/mouse GIP (total) ELISA, GLP-1 total ELISA 
and Glucagon ELISA Kit 
Novo Industria (Copenhagen, Denmark): Rat insulin standard  
Perkin Elmer (Cambridge, UK): Sodium iodide – Na125I (74Mbq/20µl stock)  
Phoenix Pharmaceuticals (California, USA): Xenin 25 ELISA Kit 
Rathburn (Walkersburn, Scotland, UK): Dichloromethane (DCM)  
Roche Diagnostics (Sussex, UK): LightCycler 480 SYBR Green I Master and 
LightCycler 480 Multi-well Plates 
Sigma-Aldrich Chemical Company Ltd. (Poole, UK): Acetonitrile, α-cyano-4-
hydroxycinnamic acid, bovine insulin (crystalline), bovine serum albumin (essentially 
fatty acid free, endotoxin free), charcoal (activated/untreated), collagenase-V, dextran 





dimethyl sulphoxide (DMSO), C,N-diphenyl-N’-(4,5 dimethylthiazol-2-yl) 
tetrazolium bromide (MTT), ethanol, ethylene diaminetetraacetic acid (EDTA), 
glycerol, hydrogen peroxide (H2O2; 30% w/w), N-2-hydroxyethylpeprazine N’-2-
ethanesulphonic acid (HEPES), isopropanol, 2-mercaptoethanol, palmitic acid sodium 
salt, Phosphate buffered saline (PBS) tablets, potassium chloride (KCl), sodium 
hydroxide (NaOH), streptozotocin, sequencing grade trifluoroacetic acid (TFA), 
1,3,4,6-tetrachloro-3α,6α-diphenylglycouril (iodogen), thimerosal, Triton X-100, 
trizma base, trizma hydrochloride, trypan blue solution (0.4%), TUNEL reaction 
mixture and tween-20.   
VWR International (Lutterworth, UK): Disodium hydrogen orthophosphate 
(Na2HPO4) and sodium dihydrogen orthophosphate (NaH2PO4.2H2O) and Polysine
TM 
coated slides.   
 
2.2 PEPTIDE SYNTHESIS 
Native xenin-25 was synthesised by GL Biochem (Shanghai, China; >95% purity). 
Xenin-6, xenin-6-NH2, xenin-6-Gln and xenin-6-Gln-NH2 (Table 2.1) were 
synthesised by Synpeptide Ltd (Shanghai; China; >95% purity). Ψ-xenin-6 was 
obtained from Saxon Biochemicals (Hannover, Germany). All peptides were procured 
at >95% purity. Sitagliptin phosphate monohydrate, used in chapters 5 and 6, was 
purchased from Apex Bio Technology (Houston, TX, USA; >97% purity; MW 523.3; 
CAS No. 654671-77-9). TNP-470, used in chapter 6, was purchased from Apex Bio 
Technology (>98% purity; MW 401.9; CAS No. 129298-91-5). 
 
2.3 PEPTIDE PURIFICATION AND CHARACTERISATION 
2.3.1 Peptide purification confirmation using reverse phase high performance 
liquid chromatography (RP-HPLC) 
The purity of all peptides, dissolved in distilled water at a concentration of 1 mg/ml, 





system attached to Spectra Series UV100 detector. 40 µl of each peptide solution was 
made up to 100 µl using 0.1% (v/v TFA/water) and injected into HPLC column for 
succeeding spectra analysis, using 70% acetonitrile as eluting solution. This was 
chromatographed using Kinetex C-18 analytical column (150 x 4.60 mm, 
Phenomenex, Chesire, UK) equilibrated with 0.1% (v/v) TFA/water at flow rate of 1.5 
ml/min. Using linear gradients, the concentration of eluting solution was raised from 
0 to 20% acetonitrile over 2 minutes followed by 20 to 80% over 27 minutes, followed 
by 80 to 100% over 3 minutes. Absorbance was measured at 214 nm. Collected peaks 
were analysed using Thermo Electron ChromQuest data collection software (version 
3). Purified fractions were further analysed by mass spectrometry (Section 2.3.2). 
 
2.3.2 Confirmation of molecular mass by matrix-assisted laser desorption 
ionisation time of flight mass spectrometry (MALDI-TOF MS) 
The molecular weight of each peptide was confirmed using a Voyager-DE 
Biospectrometer (PerSeptive Biosystems, Hertfordshire, UK), equipped with a 1 metre 
time-of-flight tube. Matrix solution consisted of 10 mg/ml solution of α-cyano-4-
hydroxycinnamic acid (CHCA), prepared in 80% acetonitrile, 20% water with 0.1% 
TFA. 10 µl of each peptide sample was mixed with 10 µl of matrix solution and 
applied to a predefined well on a 100-well stainless steel plate and allowed to dry at 
room temperature. Each sample measured was collected in linear positive ionisation 
mode using 100 laser shots/spectrum. Mass spectra were recorded as mass-to-charge 
(m/z) ratio against relative abundance. Experimental masses obtained for each peptide 







2.4 METABOLIC STABILITY STUDIES 
2.4.1 Assessment of plasma degradation of peptides 
Murine plasma was collected as described in Section 2.15. Plasma degradation of 
peptides was performed as follows; 40 µl of peptide (1 mg/ml) was incubated at 37 
oC, with 10 µl of murine plasma in 380 µl triethanolamine-HCl (50 mmol/l, pH 7.8) 
for 0, 120, 240 and 360 minutes. Reactions were stopped via addition of 50 µl of 10% 
(v/v) TFA/water. Degradation products were separated using HPLC (Section 2.3.1), 
with MALDI-TOF MS analyses of collected peaks (Section 2.3.2).  
 
2.5 CELL CULTURE 
Derived from electrofusion of New England Deaconess Hospital (NEDH) rat islets 
and immortal rat insulinoma RINm5F cells [McClenaghan et al. 1996], BRIN-BD11 
cells were cultured in 25 ml pre-warmed RPMI-1640 growth media (11.1 mmol/l 
glucose), supplemented with 10% v/v FBS and 1% v/v antibiotics (0.1 mg/ml 
streptomycin and 100 U/ml penicillin) in 75 cm2 vented sterile tissue culture flasks 
(Nunc, Roskilde, Denmark). Cells were maintained at 37 oC and 5% atmospheric CO2, 
in LEEC incubator (Laboratory technical engineering, Nottingham, UK) as described 
previously by McClenaghan et al. [1996]. INS-1 cells have a high insulin content and 
are a glucose responsive cell line. The INS-1 cell line was cultured in RPMI-1640 
(11.1 mol/l glucose), supplemented with 10% FBS, 1% penicillin-streptomycin (5000 
U/l), 200 µM 2-mercatoethanol and 1 mmol/l sodium pyruvate. The hybrid cell line 
1.1B4 is derived from electrofusion of a primary culture of human pancreatic islets 
with PANC-1, a human pancreatic ductal carcinoma cell line [McCluskey et al. 2011]. 
Cells were cultured at 37 oC and 5% CO2 in RPMI-1640 media containing 11.1 mmol/l 





(FCS) and antibiotics (100 U/ml penicillin and 0.1 g/l streptomycin). α-TC1.9 cells 
were cultured in Dulbecco’s Modified Eagle Medium (DMEM) containing 25 mmol/l 
glucose and 2 mmol/l L-glutamine supplemented with 10% (v/v) FCS and antibiotics 
(100 U/ml penicillin and 0.1 g/l streptomycin). 
 
Prior to experimentation, all cells were routinely passaged in the following manner. 
Once 70-80% confluent, culture media was decanted from flasks and cells washed 
with 10 ml pre-warmed HBSS. After washing, cells were incubated at 37 oC for 3-5 
minutes with 3 ml pre-warmed dissociation agent, trypsin/EDTA (0.025%, w/v), to 
allow cell detachment. Action of trypsin was stopped by addition of fresh culture 
media (7 ml), and pipetted, forming a single suspension, which was then transferred 
to a 50 ml Sterilin tube (Sterilin Ltd., Hounslow, UK). This was centrifuged for 5 
minutes at 900 rpm. The supernatant was discarded and the pellet was re-suspended 
in a known volume of fresh tissue culture medium. For maintenance cell cultures, cells 
were re-suspended in fresh tissue culture medium (25 ml) and maintained at 37 oC 
until 70-80% confluent. For experimentation assays, the number of cells were 
determined using a Neubauer haemocytometer (Scientific Supplies Co., UK), after 
staining 100 µl of cell suspension with 100 µl trypan blue. Viable cells were counted 
in all four WBC squares and averaged to obtain the total number of cells in suspension.  
 
2.6 INSULIN SECRETION FROM BRIN-BD11 AND INS-1 CELLS 
2.6.1 Acute in vitro insulin release studies from BRIN-BD11 and INS-1 cells 
BRIN-BD11 and INS-1 cells were used to assess insulin releasing activity of all 
peptides. Cells used for experiments were between passages 16 and 35. Acute tests for 





were harvested and counted as described in Section 2.5, and seeded at density of 
150,000 cells per well in 24-well plates (Flacon Ltd) and supplemented with 1 ml of 
RPM1-1640 media. Cells were allowed to attach overnight at 37oC to form 
monolayers. Following attachment, culture media was decanted and cells pre-
incubated in 1 ml Krebs-Ringer bicarbonate buffer (KRBB- 115 mmol/l NaCl, 4.7 
mmol/l KCl, 1.2 mmol/l MgSO4, 1.28 mmol/l CaCl2, 1.2 mmol/l KH2PO4, 25 mmol/l 
HEPES and 8.4% NaHCO3, containing 0.5% (w/v) BSA, pH 7.4) supplemented with 
1.1 mmol/l glucose for 40 minutes at 37 oC. Following pre-incubation, the solution 
was removed and fresh buffer containing either 1.1, 5.6 or 16.7 mmol/l glucose 
(BRIN-BD11 cells), or 5.6 mmol/l glucose (INS-1 cells) along with a known 
concentration of peptide (10-12 to 10-6 mol/l) was added to each well and incubated for 
20 minutes at 37 oC. Following test incubation, 950 µl assay buffer from each well 
was collected and duplicate aliquots of 200 µl stored at -20oC for measurement of 
insulin by radioimmunoassay (RIA) as outlined in Section 2.11.2. In a separate set of 
experiments, BRIN-BD11 cells were incubated, as above, at 5.6 mmol/l glucose with 
test peptides in the presence of GIP (10-6 mol/l), and insulin measured by RIA as 
described in Section 2.11.2. In another set of experiments, BRIN-BD11 cells were 
incubated, as above, in glucotoxic conditions (22.2 mmol/l glucose) with test peptides 
alone (10-6 mol/l), or in the presence of GIP (10-6 mol/l), and insulin measured by RIA. 
 
2.7 DETERMINATION OF PEPTIDE TOXICTY 
2.7.1 Cytotoxicity assay 
Lactate dehydrogenase (LDH) is released from cells when their membrane integrity 
has been lost. In this study, toxicity of test peptides (10-6 mol/l, 20 minutes) was 





sulfoxide (DMSO, Sigma-Aldrich, UK) used as a positive control. This was performed 
using the cell supernatants obtained from the acute insulin-release experiments. 
Concentrations of LDH were measured using a CytoTox96 non-radioactive 
cytotoxicity assay kit (Promega, Madison, WI) according to manufacturer’s protocol. 
This is a colorimetric method of assessing the number of nonviable cells within a cell 
population. Following insulin release studies, 50 µl aliquots of the previously obtained 
supernatant was mixed with an equal volume of LDH assay buffer in 96-well 
microtiter plates (n=4; Orange Scientific, California, USA). Due to the light sensitive 
nature of the LDH assay buffer, samples were incubated and covered in foil for 30 
minutes at room temperature. To stop the reaction, 50 µl of stop solution was added 
to samples. Samples were then measured using SoftMaxPro software on FlexStation 
fluorimeter (Molecular devices, Sunnyvale, USA), with LDH levels detected at an 
absorbance of 490 nm as described by Allen et al. [1994] and Srinivasan et al. [2014]. 
This assay is highly sensitive and capable of accurately measuring the lower levels of 
LDH known to be present within beta cells [Schuit et al. 2001]. 
 
2.8 GLUCAGON SECRETION IN α-TC1.9 CELLS  
2.8.1 Acute glucagon secretion from α-TC1.9 cells 
α-TC1.9 cells were harvested and counted as described above (Section 2.5). Cells were 
seeded and cultured for 48-72 h at 37 oC in 24-well plates at a cell density of 100,000 
cells per well in 1 ml DMEM containing 25 mmol/l glucose and 2 mmol/l L-glutamine 
supplemented with 10% (v/v) FCS and antibiotics (100 U/ml penicillin and 0.1 g/l 
streptomycin) culture medium to ensure attachment. Before commencement of acute 
studies, cells were pre-incubated with 1 ml KRBB supplemented with 20 mmol/l 





incubated for 2 h at 37 oC with glucose (1.4 mmol/l) and test peptides (10-6 mol/l) alone 
or in combination with GIP (10-6 mol/l). Following test incubation, 900 µl assay 
supernatant from each well was removed and stored at -20 oC until glucagon 
measurement by chemiluminescent enzyme-linked immunosorbent assay (ELISA; 
Millipore, Watford, UK) as outlined in Section 2.12.1. 
 
2.9 PROLIFERATION AND APOPTOSIS 
2.9.1 In vitro beta-cell proliferation and apoptosis 
Rodent BRIN-BD11 and human 1.1B4 beta-cells were used to investigate effects of 
test peptides on beta-cell proliferation and protection against cytokine-induced 
apoptosis. GLP-1 (10-8 and 10-6 mol/l) was employed as a positive control for all 
studies. Ki-67 immunostaining was used to assess effects on proliferation. Cells were 
cultured as previously described above (Section 2.5), and seeded onto coverslips at a 
cell density of 40,000 cells per coverslip and cultured overnight (18 h) at 37 °C, in the 
presence of test peptides (10-8 and 10-6 mol/l). Cells were then washed with PBS, and 
fixed using 4% paraformaldehyde. Following antigen retrieval with citrate buffer at 
90 °C for 20 minutes, cells were blocked using 1.1% BSA for 30 minutes. Cells were 
then incubated with Ki-67 primary antibody (1:200; Abcam ab16667), followed by 
Alexa Fluor 594 goat anti-rabbit IgG (1:400). Coverslips were washed with PBS, 
mounted on slides for viewing using a FITC (488 nm) or TRITC filter (594 nm) 
fluorescent microscope (Olympus System Microscope) and photographed by DP70 
camera adapter system. Proliferation frequency was expressed as percentage of total 
cells analysed as detailed in Section 2.17. 
For analysis of the ability of test peptides to protect against cytokine-induced 





exposed to a cytokine-cocktail (IL-1β 300 U/ml, IFN-γ 300 U/ml, TNF-α 40 U/ml; 
[Vasu et al. 2014a]) in the presence or absence of test peptides (10-8 and 10-6 mol/l) 
for 2 h, with hydrogen peroxide as an additional control. TUNEL assay was performed 
using fluorescein in situ cell death detection kit, according to the manufacturer’s 
protocol (Roche Diagnostics, UK). In brief, following overnight incubation, cells were 
washed with PBS and fixed using 4% paraformaldehyde at room temperature for 30 
minutes. Following another wash, cells were incubated in sodium citrate buffer (94 oC 
for 20 minutes; 10 mmol/l Sodium Citrate, 0.05% Tween 20, pH 6.0), and then allowed 
to cool (20 minutes). Cells were incubated in TUNEL solution for 1 h at 37 oC before 
subsequent rinsing in PBS and mounted onto slides for viewing under a fluorescent 
microscope (Olympus System Microscope) as above. Apoptosis was expressed as 
percentage of total cells analysed. Approximately 150 cells were analysed per group.  
 
2.10 INSULIN AND GLUCAGON SECRETION FROM ISOLATED MOUSE 
ISLETS 
2.10.1 Islet isolation by collagenase digestion 
Described previously by Lacy and Kostinosky [1967], islets from mouse (NIH Swiss 
mice, male, 10-12 weeks) pancreas were isolated using a modified collagenase 
digestion method [Gunawardana et al. 2004]. Stock islet isolation HBSS was prepared 
by dissolving 136.9 mmol/l NaCl, 5.4 mmol/l KCl, 1.3 mmol/l CaCl2, 0.4 mmol/l 
MgSO4.7H2O, 0.5 mmol/l MgCl2.6 H2O, 0.4 mmol/l Na2HPO4.H2O, 0.4 mmol/l 
KH2PO4, 5.6 mmol/l glucose, 0.06 mmol/l phenol red and 4.2 mmol/l NaHCO3 in 
distilled water. Collagenase solution (5 ml per pancreas) was prepared by adding 1.4 
mg/ml collagenase to stock islet isolation HBSS. Wash buffer was prepared by adding 





by cervical dislocation and pancreata removed and placed on ice-cold collagenase 
solution and cut with scissors to aid digestion. Pancreas collagenase mix was placed 
in a shaking water bath for 10 minutes at 37 oC to allow digestion. The tube was 
removed and shaken vigorously for a few seconds to dissociate islets and separate 
exocrine tissues. The tubes were then filled with ice-cold wash buffer and centrifuged 
at 1200 rpm for 2 minutes. After centrifugation, supernatant was poured off. This 
washing procedure was repeated three times and unwanted tissues were removed by 
filtration. Filtrate was centrifuged for 2 minutes at 1200 rpm and supernatant 
discarded. The pellet obtained was re-suspended in pre-warmed RPMI-1640 media 
supplemented with 10% BSA, 1% penicillin/streptomycin and transferred to petri-
dishes. Islets were cultured at 37 °C and 5% CO2, in a LEEC incubator for 2-3 days 
prior to use. 
 
2.10.2 Acute insulin release studies from isolated mouse islets 
Acute insulin release on isolated islets was performed as described previously by 
Pathak et al. (2015). Following 48 h culture, 10 islets were picked under the 
microscope into 1.5 ml Eppendorf tubes. Tubes were centrifuged at 2000 rpm for 1 
minute to remove excess media. Islets were pre-incubated in 1 ml of Krebs–Ringer 
bicarbonate buffer (KRBB- 115 mmol/l NaCl, 4.7 mmol/l KCl, 1.2 mmol/l MgSO4, 
1.28 mmol/l CaCl2, 1.2 mmol/l KH2PO4, 25 mmol/l HEPES and 8.4% NaHCO3, 
containing 0.5% (w/v) BSA, pH 7.4) supplemented with 1.4 mmol/l glucose for 1 h at 
37 oC. The pre-incubation buffer was decanted after centrifugation at 2000 rpm for 1 
minute. Test incubations were then carried out for 1 h at 16.7 mmol/l glucose with a 
range of concentrations of peptides (10-8 to 10-6 mol/l). After incubation, tubes were 





collected. Duplicate aliquots of 200 µl were stored at -20 oC for measurement of 
insulin by dextran-coated charcoal radioimmunoassay (Section 2.11.2). Acid ethanol 
extraction for total islet insulin content was carried out. Briefly, after retrieval of test 
solutions, 500 µl of ice-cold acid ethanol solution (1.5% HCl, 75% ethanol and 23.5% 
H2O) was added to each Eppendorf tube containing islets and incubated overnight at 
4 oC. Supernatant was collected after centrifugation and stored at -20 oC. For 
measurement of total insulin content by RIA (Section 2.11.2), 5 µl of test sample was 
diluted with 195 µl of working RIA buffer (1:40 dilution). 
 
2.10.3 Acute glucagon release studies from isolated mouse islets 
Islets were isolated as above (Section 2.10.1). Following 48 h culture, 10 islets were 
picked under the microscope into 1.5 ml Eppendorf tubes. Tubes were centrifuged at 
2000 rpm for 1 minute to remove excess media. Islets were pre-incubated in 1 ml of 
Krebs–Ringer bicarbonate buffer (KRBB- 115 mmol/l NaCl, 4.7 mmol/l KCl, 1.2 
mmol/l MgSO4, 1.28 mmol/l CaCl2, 1.2 mmol/l KH2PO4, 25 mmol/l HEPES and 8.4% 
NaHCO3, containing 0.5% (w/v) BSA, pH 7.4) supplemented with 1.1 mmol/l glucose 
for 1 h at 37 oC. The pre-incubation buffer was decanted after centrifugation at 2000 
rpm for 1 minute. Test incubations were then carried out for 1 h at 1.4 mmol/l glucose 
with test peptides (10-6 mol/l) alone or in combination with GIP (10-6 mol/l). After 
incubation, tubes were centrifuged at 2000 rpm for 1 minute and 950 µl supernatant 
from each tube was collected. Duplicate aliquots of 200 µl were stored at -20 oC for 
measurement of glucagon secretion using a glucagon chemiluminescent ELISA kit 
(Section 2.12.1). For total islet glucagon content, acid ethanol extraction was carried 
out. Briefly, after retrieval of test supernatant above, 500 µl of ice-cold acid ethanol 





containing islets and incubated overnight at 4 oC. Supernatant was collected after 
centrifugation and stored at -20 oC until glucagon chemiluminescent ELISA (Section 
2.12.1).  
 
2.11 INSULIN RADIOIMMUNOASSAY 
2.11.1 Preparation of iodinated bovine insulin for RIA 
Iodinated bovine insulin was prepared as per the established protocol within the 
Diabetes Research Group. Iodogen solution (100 μg/ml; 1,3,4,6-tetrachloro-3α,6α-
diphenylglycoluril) was prepared in dichloromethane, with 100 μl of iodogen solution 
aliquoted into a series of Eppendorf’s. Following overnight solvent evaporation in a 
fume hood, a uniform coating of iodogen was attained at the bottom of each Eppendorf 
tube. This uniform coating acted as a catalyst during the iodination process of bovine 
insulin. 1 mg of bovine insulin was dissolved in 1 ml of 10 mmol/l HCL, and diluted 
to 125 μg/ml (1:8 dilution) in 500 mmol/l phosphate buffer (pH 7.4). Bovine insulin 
(20 μl) along with sodium iodide (5 μl; Na125I 100 mCi/ml stock, Perkin Elmer, 
Cambridge, UK) were added to the iodogen-coated tube. This reaction was placed on 
ice for 15 minutes, with gentle agitation every 3-4 minutes, with the reaction being 
stopped by transferring the reaction mixture into a clean Eppendorf tube. The reaction 
tube was then washed with 500 μl of 50 mmol/l sodium phosphate buffer, with this 
being combined with the reaction mixture in the fresh Eppendorf tube.  
 
Using RP-HPLC, the iodinate mixture was separated using a Vydac C-8 (250 x 4.6 
mm) analytical column at flow rate of 1.0 ml/minute with 0.12% (v/v) TFA/water. The 
concentration of acetonitrile in eluting solution was increased from 0% to 56% over 





a fraction collector (Frac-100, LKB) during the 67-minute HPLC run. Each collected 
fraction (5 μl) was aliquoted into LP3 tubes and counts measured on a gamma counter 
(Perkin Elmer Wallac Wizard 1470 Automatic Gamma Counter). Fractions with 
highest counts were selected and double diluted with 1 ml of 40 mmol/l sodium 
phosphate buffer (pH 7.4) containing 1 g/100 ml BSA and 0.02 g/100 ml thimerosal. 
Binding capacities of selected fractions were tested with different antibody dilutions 
(1:25,000-1: 45,000). Fractions having similar binding affinities were pooled together 
and kept at 4ºC until use in RIA. 
 
2.11.2 Modified dextran-coated charcoal RIA 
Using guinea pig anti-porcine antibody, rat insulin standard and 125I-labelled bovine 
insulin, the amount of insulin release was measured using a modified dextran-coated 
charcoal radioimmunoassay, as described by Flatt and Bailey (1982). Stock RIA 
buffer was prepared by adjusting the pH of a basic solution of 40 mmol/l disodium 
hydrogen orthophosphate (containing 0.3% (w/v) sodium chloride and 0.02% (w/v) 
thimerosal) to 7.4 with an acidic solution of 40 mmol/l sodium dihydrogen 
orthophosphate. Stock RIA buffer was kept at 4°C until required. On the first day of 
RIA, working RIA buffer was prepared by dissolving 0.5% (w/v) BSA in 40 mmol/l 
sodium phosphate buffer (pH 7.4). Unknown samples were aliquoted in duplicate (200 
μl) into LP3 tubes as outlined previously in Section 2.6.1. Insulin standards (0.039 to 
20 ng/ml) were prepared through serial dilution of frozen stock rat insulin standard 40 
ng/tube (100 μl) with working RIA buffer. To obtain 40% binding, guinea pig anti-
porcine antibody was diluted (1:25000 to 1:45000) from frozen stock in working RIA 
buffer. 100 µl of diluted antibody was then added to 200 µl of standards (in triplicates) 





binding tube (only assay buffer) and a control tube (antibody plus assay buffer) were 
also set up in triplicates. 125I-labeled tracer was added to working RIA buffer to achieve 
10,000 counts/100 µl of solution. 100 µl of tracer was then added to each LP3 tube 
and incubated for 48 h at 4oC. To separate bound and unbound 125I-labelled insulin, 
activated charcoal was added following the 48 h incubation. Charcoal solution (5%) 
coated with dextran T-70 was diluted with stock RIA buffer (1:5 dilution) and 1.0 ml 
added to each tube (except the total tubes) and incubated at 4oC for 20 minutes. 
Following centrifugation at 2500 rpm for 20 minutes at 4ºC in a Sorvall centrifuge, 
supernatant was poured off and radioactivity of the unbound (free) 125I-labelled insulin 
remaining absorbed to black charcoal pellets was determined using a gamma counter 
(Perkin Elmer Wallac Wizard 1470 Automatic Gamma Counter). Counts bound to 
antibody (total counts minus counts bound to charcoal) were inversely proportional to 
the amount of insulin present in standards or unknown samples. 
 
2.12 GLUCAGON CHEMILUMINESCENT ELISA 
2.12.1: Measurement of glucagon secretion 
A glucagon ELISA kit was used to quantitatively determine intact glucagon in cell 
culture supernatants following acute peptide administration. This assay is based on a 
sandwich ELISA for the capture of glucagon molecules measured by a 
chemiluminescent substrate. The enzymatic activity was measured by relative light 
units (RLU) which was proportional to amount of captured glucagon in the unknown 
sample. For sample preparation, 150 µl of cell supernatant was added to 225 µl of 
acetonitrile, vortexed and incubated at room temperature for 10-30 minutes. Samples 
were then centrifuged at 13,000 rpm for 5 minutes using a Beckman microcentrifuge 





concentrated to dryness using an AES1000 Speed-Vac concentrator (Life Sciences 
International, Runcorn, UK) and stored at 4 oC. 
 
All contents of the kit were allowed to reach room temperature prior to use and the 
assay was performed as outlined by the manufacturer’s protocol. A glucagon standard 
curve ranging from 0 – 2 ng/ml was prepared by dilution of the 2 ng/ml stock. Quality 
controls 1 and 2 were reconstituted in distilled water. All unknown samples were 
rehydrated with 60 µl assay buffer and the 96 well assay plate was washed with 300 
µl diluted wash buffer. Assay buffer was added to blank wells (30 µl) and 20 µl to all 
other wells. Glucagon standards and quality controls (10 µl) were added in duplicate 
and unknown samples (10 µl) were added in triplicate to corresponding wells. 
Antibody mixture solution (20 µl) was then added to each well and incubated for 44-
48 h at 4 oC and 500 rpm. Following incubation period, solutions were decanted and 
each well was washed thrice with diluted wash buffer (300 µl). Enzyme solution (100 
µl) was added to each well and incubated for 30 minutes at room temperature. The 96 
well assay plate was washed six times with 300 µl diluted wash buffer. Substrate 
solution (100 µl) was added to each well, and RLU was measured at 425 nm within 5 
minutes of adding substrate. The amount of glucagon in the sample was estimated 
using reference curve of known glucagon standards (ranging from 0 ng/ml – 2 ng/ml). 
 
2.13 ANIMAL MODELS 
In vivo studies in this thesis were carried out using several animal models of obesity, 
diabetes and insulin resistance. Animal experiments were carried out in accordance 
with UK Animals (Scientific Procedures) Act 1986 and approved by the University of 





individually in temperature-controlled rooms (22 ± 2 °C) with a 12 h light:12 h dark 
cycle, at Ulster University’s Behavioural and Biomedical Research Unit (BBRU). No 
adverse effects were observed after drug treatment. When conducting studies, all 
animals had free access to food and drinking water, unless stated.  
 
2.13.1 NIH Swiss mice 
NIH Swiss mice (male, 10-12 weeks, n=8) were obtained from Envigo, Huntingdon, 
UK. All animals were age matched, had free access to drinking water and standard 
laboratory chow (10% fat, 30% protein, 60% carbohydrate; percentage of total energy 
12.99 KJ/g; Trouw Nutrition, Cheshire, UK). Groups of mice were used to conduct 
acute animal studies and used as model of normal glycaemia in chronic studies.  
 
2.13.2 High fat fed NIH Swiss mice 
This is a robust model for early T2DM, and is widely used in studies relating to testing 
new therapeutic methods [Winzell and Ahrén, 2004]. In chapter 3, this model was used 
for sub-chronic animal studies, with all mice maintained on a high-fat diet (45% fat, 
35% carbohydrate and 20% protein; percentage of total energy 26.15 kJ/g; Special 
Diet Services, UK) for 3 months prior to commencement of treatment. The high fat 
fed mice resulted in progressive body weight gain (45.8 ± 0.9 vs. 35.0 ± 1.2 g; 
P<0.001), hyperglycaemia (14.6 ± 1.8 vs. 8.2 ± 0.2 mmol/l; P<0.05) and 
hyperinsulinemia compared with aged matched controls fed on normal laboratory 
chow. Prior to commencement of the long term treatment regimen, mice were grouped 







2.13.3 Streptozotocin treated high fat fed C57BL/6 mice 
This animal model of T2DM induces insulin resistance and beta cell dysfunction 
through combination of high fat diet and low dose streptozotocin (STZ) [Zhang et al. 
2008; Gilbert et al. 2011]. Moreover, it is an animal model of T2DM that resembles 
the human disease [Vatandoust et al. 2018]. In chapter 5, before commencing studies, 
male C57BL/6 mice were given free access to high fat diet. Following two weeks of 
high fat feeding, mice received a low dose STZ injection (50 mg/kg bw, i.p., in sodium 
citrate buffer, pH 4.5), followed by another low dose STZ injection (75 mg/kg bw,) 
one week later. Mice were fasted for 18 h before each STZ injection, with fresh STZ-
sodium citrate buffer solution prepared each time. In this study, blood glucose was 
monitored at regular intervals and animals displayed progressive hyperglycaemia (8.7 
± 0.3 vs. 16.8 ± 2.3 mmol/l; P<0.01) compared with age-matched controls on normal 
laboratory chow. Mice exhibiting blood glucose concentrations ≥ 11.1 mmol/l at the 
end of the 4-week period were then recruited into the study. 
 
In chapter 6, male C57BL/6 mice were given access to high fat diet. Following two 
weeks of high fat feeding, mice received one low dose STZ injection (50 mg/kg), 
followed by two low dose STZ injection (75 mg/kg) on weeks 3 and 4. Mice were 
fasted for 18h before each STZ injection. Mice exhibiting blood glucose 
concentrations ≥ 11.1 mmol/l at the end of 5-week period were recruited into the study. 
 
2.14 ACUTE ANIMAL STUDIES 
2.14.1 Acute food intake studies 
Acute cumulative food intake studies were carried out in 18 h fasted male Swiss mice. 





injection of saline vehicle (0.9% (w/v) NaCl) or test peptides (25 or 250 nmol/kg bw). 
Cumulative food intake (g) was measured at 0, 30, 60, 90, 120, 150 and 180 minutes 
after peptide administration. 
 
2.14.2 Acute effects of peptides on glucose tolerance 
Glucose and insulin concentrations were measured in 18 h fasted male Swiss mice 
before and after i.p. injection of glucose alone (18 mmol/kg bw) or in combination 
with test peptides (25 nmol/kg bw), as well as test peptides together with GIP (25 
nmol/kg bw). Blood samples were collected at various time points (0, 15, 30, 60 and 
105 minutes) and glucose and insulin levels measured as stated in Section 2.15. 
 
2.14.3 Persistent effects of peptides on glucose tolerance 
In order to assess the duration of peptide action, delayed glucose tolerance tests were 
performed on 4 h fasted Swiss mice. Mice were i.p. injected with saline vehicle or test 
peptides (25 nmol/kg bw) at 2, 4, 8 or 12 h prior to administration of a i.p. glucose 
challenge (18 mmol/kg bw). Glucose was monitored at various time points (0, 15, 30, 
60 and 105 minutes) as described in Section 2.15. 
 
2.15 BIOCHEMICAL ANALYSIS 
Blood samples were collected from the cut tip of the tail vein of conscious mice into 
chilled fluoride/heparin glucose micro-centrifuge tubes (Sarstedt, Numbrecht, 
Germany). Blood samples were immediately centrifuged using Beckman centrifuge at 
13,000 rpm for 3 minutes. Plasma was carefully aliquoted into fresh Eppendorf tubes 
and stored at -20 oC for further biochemical analysis. Blood glucose was measured 





pancreatic insulin were assayed using RIA [Flatt and Bailey, 1982]. For measurement 
of plasma insulin, 20 µl of test sample was diluted with 180 µl of working RIA buffer 
(1:10 dilution) and measured in duplicates by RIA, as outlined previously in Section 
2.11.2. For measurement of pancreatic insulin content, 5 µl of test sample was diluted 
with 195 µl of working RIA buffer (1:40 dilution).  
 
2.16 LONG TERM ANIMAL STUDIES 
Two different models were used in sub-chronic assessment of peptides – HFF mice 
and HFF/STZ mice. Mice were grouped and maintained as detailed in Section 2.13.  
 
2.16.1 Monitoring the effects of long term peptide administration 
In chapter 3, groups of HFF mice (n=12) received twice daily (09:00 and 17:00 h) i.p. 
injections of saline vehicle or test peptides alone or in combination (each at 25 
nmol/kg) for duration of test period. Additionally, in Chapter 3, following a 28-day 
treatment period, a sub-group (n=6) of HFF mice received further twice daily 
injections of saline alone for 14 days to determine effect of treatment withdrawal, with 
assessment of the same parameters as documented above. 
 
In chapter 5, respective treatments were commenced on day 0 as follows in HFF 
mice; HFF mice (n = 8) received oral sitagliptin phosphate monohydrate once daily 
(50 mg/kg bw), intraperitoneal (i.p.) Ψ-xenin-6 twice daily (25 nmol/kg bw) or a 
combination of both compounds using the same dosing regimen for 18 days. All twice 
daily treatments were administered at 09:30 and 17:00 h, with once daily treatments 
delivered at 09:30 h. Saline vehicle (i.p. or oral) was administered as control at each 





xenin-6 were chosen based on previous published studies in mice [Gault et al. 2015b; 
Craig et al. 2019]. We also employed a gold standard lean control group (n = 8) on 
normal chow diet without STZ injections. These control mice were also administered 
saline vehicle twice daily (orally at 09:30 and i.p at 17:00 h) throughout the study.  
 
In chapter 6, on day 0, HFF mice (n = 10) received oral sitagliptin once daily 
(25 mg/kg bw), intraperitoneal (i.p.) TNP-470 once daily (1 mg/kg bw) or a 
combination of both compounds using the same dosing regimen for 18 days. All once 
daily treatments were administered at 11:00 h. Saline vehicle (i.p. or oral) was 
administered as control at 11:00 h either po or ip. Sub-optimal therapeutic doses of 
sitagliptin and TNP-470 were chosen [Lijnen et al. 2010; Joharapurkar et al. 2014], to 
facilitate extrapolation of more obvious benefits of combined treatment regimen. 
 
Before the start of the treatment regimens above, all animals were given twice daily 
injections / oral gavage, where appropriate, of saline alone at 09:00 and 17:00 h for 5 
days to acclimatise mice to handling and injection stress. Cumulative energy intake, 
water intake, body weight, non-fasting blood glucose and plasma insulin 
concentrations were monitored at regular intervals. Whole blood was taken for 
measurement of HbA1c concentrations as appropriate. Glucose and insulin 
concentrations were measured as described in Section 2.15.  
 
2.16.2 Parameters assessed following long term studies 
2.16.2.1 Glucose tolerance test  
Fasted (18 h) mice received i.p. injections of glucose alone (18 mmol/kg bw). Blood 





& 6) or 0, 15, 30, 60, 105 and 120 minutes (Chapter 3)). Glucose and insulin 
concentrations were measured as described in Section 2.15.  
 
2.16.2.2 Metabolic responses to acute administration of treatment regimens 
In chapter 3, fasted (18 h) mice received i.p. injections of glucose (18 mmol/kg bw) in 
combination with respective treatment regimens (25 nmol/kg bw). Blood samples 
were collected at various time points (0, 15, 30, 60, 105 and 120 minutes). Glucose 
and insulin concentrations were measured as described in Section 2.15.  
 
2.16.2.3 Pyruvate Tolerance Test 
In chapters 5 and 6, fasted (18 h) mice received i.p. injections of sodium pyruvate (2 
g/kg bw). Blood glucose was measured prior to (t=0) and 5, 15, 30 and 60 minutes 
after i.p. administration. 
 
2.16.2.4 Insulin sensitivity test 
Insulin sensitivity was performed in non-fasted mice. Blood glucose was measured 
prior to (t=0) and then 30 and 60 minutes after i.p. administration of bovine insulin 
(25 U/kg bw). To evaluate insulin resistance, HOMA-IR was calculated [Matthews et 
al. 1985]. HOMA-IR = fasting plasma glucose X fasting plasma insulin / 22.5. Fasting 
glucose and insulin were measured in mmol/l and mU/l, respectively. 
 
2.16.3 Bone mineral density and body composition determination by dual energy 
X-ray absorption (DEXA) 
In chapter 3, lean mass and total fat percentage was measured using the Piximus 





instrument was calibrated using a manufacturer supplied protocol. Once quality 
control was passed, mice were culled by cervical dislocation and positioned on 
specimen tray following manufacturer’s instructions.  
 
2.16.4 Measurement of indirect calorimetry, energy expenditure and locomotor 
activity 
The Comprehensive Laboratory Animal Monitoring System (CLAMS) with Oxymax 
system (Columbus Instruments, OH, USA) was used to assess standard parameters of 
energy expenditure, indirect calorimetry, locomotor activity and feeding patterns as 
described previously by Gault et al. (2011b). At the end of treatment period, mice 
(n=5) were placed into airtight metabolic chambers for 24 h. Mice were allowed to 
acclimatise to the new environment for 3 h prior to 21 h monitoring time period. 
Carbon dioxide and oxygen metabolism was monitored for 30 seconds at 15 min 
intervals for a total of 21 h. Respiratory exchange ratio was calculated by dividing 
volume of CO2 produced by volume of O2 consumed. Energy expenditure (EE) was 
calculated using RER with the following equation:  
EE (Kcal/h) = (3.815 + 1.232 x RER) x VO2 
 
Feeding patterns were recorded using spring loaded feeding hoppers attached to a 
weigh balance. Locomotor activity was recorded using dual infrared (IR) beams- 
primary (X-axis) and secondary (Z-axis) IR beam. Animal motion leading to 
interruption of either infrared beam was represented as ‘one count’. Counts in each 
axis were measured every minute for each mouse over 24 h time period. General 





or ambulatory X-beam counts. Exploration activity of mice was expressed in terms of 
total Z-beam counts.  
 
2.16.5 HbA1c measurement 
Prior to and at the end of respective chronic study in chapter 3, HbA1c values were 
measured in whole blood using A1cNow+ kits (PTS diagnostics, IN, USA) as per 
standard manufacturer’s instructions. 
 
2.16.6 Measurement of pancreatic insulin content 
Following chronic studies, pancreatic tissue was excised and divided longitudinally. 
Half of the tissue was kept for histological analysis (Section 2.16.7) and half 
immediately snap frozen for subsequent protein extraction. Pancreata were weighed 
and homogenized, using a VWR VDI 12 handheld homogenizer (VWR, UK), in ice-
cold acid ethanol (1.5% HCl, 75% ethanol and 23.5% distilled H2O). Samples were 
centrifuged at 3,000 rpm for 20 minutes at 4 oC. Supernatant was transferred to a 15 
ml centrifuge tube, 10 ml TRIS buffer (pH 7.4) added and then concentrated to dryness 
using AES1000 Speed-Vac concentrator. Samples were re-suspended in 200 µl of 
acetonitrile and 1.8 ml TRIS buffer and stored at -20 oC until further analysis. For 
measurement of insulin content of extracts, 20 µl of test sample was diluted with 180 
µl of working RIA buffer (1:10 dilution) and measured using RIA (Section 2.11.2). 
Total protein content was measured by Bradford assay. Briefly, tissue extract (5 µl; in 
duplicate) was aliquoted into a 96-well plate and 250 µl of Bradford reagent (Sigma 
Aldrich, Poole, Dorset, UK) added. The plate was incubated at room temperature for 
15 minutes. Absorbance was read at 595 nm using a microplate reader (Molecular 





linear range of the generated reference curve of BSA standards (concentration ranging 
from 0. – 2 mg/ml). 
 
2.16.7 Immunohistochemistry 
Pancreatic tissue was excised, divided longitudinally and processed for 
immunohistochemical examination. Pancreatic tissues were fixed in 4% 
paraformaldehyde at 4 oC for 48 h, to preserve cellular architecture. Pancreata were 
then embedded in paraffin wax and processed using an automated tissue processor 
(Leica TP1020, Leica Microsystems, Nussloch, Germany). Concisely, this involved 
dehydrating tissues in increasing concentrations of ethanol (70 – 100%), before 
immersion in xylene to remove alcohol and allow for embedding in paraffin wax. Once 
processed, tissues were cut at 7 μm thickness using a microtome (Shandon finesse 325, 
Thermo scientific, UK) and sections selected at an interval of 10 sections. 
Immunoreactive staining for insulin and glucagon was assessed by firstly, 
deparaffinising tissue sections by immersing in xylene (20 minutes; Sigma Aldrich, 
Dorset, UK). Sections were then rehydrated through a series of decreasing ethanol 
concentrations (100%, 95%, 85%, 70% and 50%). After antigen retrieval at 94 oC for 
20 minutes using sodium citrate buffer (10 mmol/l Sodium Citrate, 0.05% Tween 20, 
pH 6.0), slides were allowed to cool (20 minutes) before being blocked using 3% BSA 
for 1 h at room temperature. Sections were then incubated overnight at 4 oC with 
primary antibodies: mouse anti-insulin antibody (1:500; Abcam, ab6995) and guinea-
pig anti-glucagon antibody (PCA2/4, 1:400; raised in-house). Following overnight 
incubation, excess antibody was removed by washing with PBS three times. Slides 
were then incubated with appropriate secondary antibody; Alexa Fluor 488 goat anti-





minutes at 37 oC. Slides were again rinsed with PBS and stained with nuclear stain- 
DAPI (4, 6-diamidino-2-phenylindole; 300 nmol/l in PSB) for 15 minutes at 37 oC. 
Finally, slides were washed with PBS before mounting slides using aqueous mounting 
medium (Glycerol: PBS – 1:1) and coverslips. Stained slides were viewed under a 
FITC (488 nm), TRITC filter (594 nm) or DAPI filter using a fluorescent microscope 
(Olympus system microscope, model BX51) and photographed using a linked DP70 
camera adapter system on CellF software. Islet parameters were analysed using CellF 
image analysis software (Olympus Soft Imaging Solutions, GmbH) as outlined in 
section 2.17.  
 
For Ki67 staining, tissue sections were deparaffinised, rehydrated and probed with 
primary antibodies: mouse anti-insulin antibody (1:400; Abcam, ab6995), guinea-pig 
anti-glucagon pig anti-glucagon antibody (PCA2/4, 1:400; raised in-house), or rabbit 
anti-Ki67 (1:400; Abcam ab16667), as appropriate. Sections were then incubated with 
secondary antibody, Alexa Fluor 488 goat anti-mouse IgG (1:200), Alexa Fluor 488 
goat anti-guinea-pig IgG (1:200; Abcam ab150185) or Alexa Fluor 594 goat anti-
rabbit IgG (1:200) respectively. The slides were viewed under a FITC (488 nm) or 
TRITC filter (594 nm) and analysed as detailed above.  
 
2.16.8 Measurement of plasma and pancreatic GIP and GLP-1 content 
Total GLP-1 and GIP content in plasma were determined using specific ELISA 
following manufacturer’s instructions (GLP-1 Total ELISA, EZGLP-1T-36K, 
Millipore; rat/mouse GIP (Total) ELISA, EZRMGIP-55K, Millipore). The amount of 





standards (8.2 pg/ml–2000 pg/ml). The amount of total GLP-1 was estimated using a 
reference curve of known GLP-1 standards (4.9 pM–1200 pM). 
 
2.16.9 Measurement of plasma and intestinal xenin content 
Xenin content in plasma and intestinal tissue extracts was determined using xenin 
chemiluminescent assay (FEK-046-74, Phoenix Pharmaceuticals), following 
manufacturer’s instructions. The amount of xenin in the sample was estimated using 
a reference curve of known xenin standards (1 pg/ml–1,000,000 pg/ml). 
 
2.1.10 DPP-4 Activity 
DPP‐4 activity of terminal plasma, as well as sitagliptin and Ψ-xenin-6 alone and in 
combination in vitro (both at 10-6 mol/l), was determined using a fluorometric assay 
that measures free 7‐amino‐4‐methyl‐coumarin (AMC) liberated from Gly‐Pro‐AMC 
substrate [Lindsay et al. 2005; Harnedy and Fitzgerald, 2013]. Briefly, 10 μl of plasma 
(n=8) or peptide (n=4) sample, where appropriate, was incubated with 30 μl 0.02 mol/l 
Tris– HCl buffer, pH8.0 containing 0.10 mol/l NaCl and 1 mmol/l EDTA, and 50 μl, 
200 μM H-Gly-Pro-AMC. Following 5 min incubation at 37 °C the reaction with the 
peptide samples were initiated by addition of 10 μl DPP-4 (8 mU mL−1). The change 
in fluorescence was monitored over a 30 min period using a plate reader at excitation 
and emission wavelengths of 360 and 460 nm, respectively.  
 
2.16.11 mRNA extraction and conversion to cDNA 
mRNA was extracted from excised liver tissue. Briefly, liver tissues were 
homogenised in 1 ml TRIZOL reagent per 100 mg of tissue using a power 





were vortexed vigorously for 15 seconds and incubated at room temperature for 3 
minutes. Samples were centrifuged at 12,000 x g for 15 minutes at 4oC. Following 
centrifugation, the mixture separated into a lower red, phenolchloroform phase, an 
interphase, and a colourless upper aqueous phase, with RNA remaining exclusively in 
the aqueous phase. This upper aqueous layer was transferred into a fresh tube, with 
500 µl of isopropanol per 1 ml of TRIZOL reagent added. Samples were incubated at 
room temperature for 10 minutes and centrifuged at 12,000 x g for 20 minutes at 4oC, 
with the RNA precipitate forming a gel-like pellet at the bottom of the tube. 
Supernatant was removed and the pellet washed with 75% ethanol (1 ml of ethanol 
per 1 ml of TRIZOL reagent used) and centrifuged at 12,000 x g for 5 minutes at 4oC. 
The above wash was repeated three times, with the RNA pellet allowed to air dry for 
10 minutes. Pellet was re-suspended in 20 µl nuclease free water, and incubated at 60-
70oC for 5 minutes and then placed on ice. Concentration and purity of extracted 
mRNA was determined using nanophotometer. Each RNA sample (3 μg) was 
converted to cDNA at 42°C for 50 min in the presence of 0.5 μg oligo dT(12–18) 
primer, 10 mmol/l dNTP and 200 U Superscript II reverse transcriptase (Invitrogen, 
Paisley, UK) in a final volume of 20 μl using a GeneStorm GS1 Thermal Cycler (Gene 
Technologies Ltd, Essex, UK). Concentration of cDNA was determined using the 
nanophotometer and cDNA was stored at -20oC. 
 
2.16.12 Real-time reverse transcription polymerase chain reaction (RT-PCR) 
The reaction mix consisted of 4.5 μl of SYBR green, 1 μl of each of the primers 
(forward and reverse), 3 μl RNA free water and 1 μl of respective cDNA. β‐actin 
(ACTB) was used as an internal control for normalisation. Reactions took place in 





cDNA amplification for 45 cycles with 95 °C denaturation for 10 s, 60 °C annealing 
for 30 s and 72 °C elongation for 1 s, followed by 30 s cooling at 40 °C. Relative 
quantification using the 2−ΔΔCT (two delta, delta comparative test) method was used to 
calculate differences in gene expression between samples. mRNA levels of all genes 
were normalised to positive control for PCR (β‐actin – reference gene). (See table 2.2) 
 
2.17 IMAGE ANALYSIS 
Images were analysed using CellF image analysis software (Olympus Soft Imaging 
Solutions, GmbH) to assess: islet area, beta cell area and alpha cell area (expressed as 
μm2). For islet size distribution, islets were defined as small, medium or large (<10,000 
μm2, 10,000-25,000 μm2 or >25,000 μm2 respectively). Proliferation frequency 
analysis in beta cells was quantified using Ki-67 co-stained with insulin. Beta cell 
apoptosis was quantified by counting the number of TUNEL positive cells and 
expressed as a percentage of cells analysed. 
 
2.18 STATISTICAL ANALYSIS 
GraphPad PRISM (Version 5) was used to carry out statistical analysis. Groups of data 
were considered to be significantly different if P<0.05. Results are expressed as mean 
± SEM and data compared using one-way repeated measures ANOVA followed by the 
Student-Newman-Keuls post-hoc test. The unpaired student t-test was used where 
appropriate. Area under curve (AUC) and area above curve (AAC) analyses were 





Table 2.1 Structure of peptides used in Chapter 3, 4 and 5 
Name Purity Sequence 
(DAla2)GIP/Xenin-8-Gln >95% Y[DA]EGTFISDYSIAMHPQQPWIL-OH 
Xenin-6 >95% H-KRPWIL-OH 
Xenin-6-NH2 >95% H- KRPWIL-NH2 
Xenin-6-Gln >95% H-QQPWIL-OH 
Xenin-6-Gln-NH2 >95% H-QQPWIL-NH2 





Table 2.2: Primers used for qPCR.  
 




Forward 5’ – 3’ 
TTGAACTGACAGACTCGCCC 
Reverse 5’ – 3’  
GGCACTTGATGAACTCCCCA 
G6Pase 
Forward 5’ – 3’ 
GGACCTCCTGTGGACTTTGG 
Reverse 5’ – 3’  
TGCTGAGTTCTCCCTTGCAG 
IRS-1 
Forward 5’ – 3’ 
AGGACCTCACGTCTTCCTCTT 
Reverse 5’ – 3’ 
TTCCGGTGTCACAGTGCTTTC 
FGF21 
Forward 5’ – 3’ 
AGATGGGCTCTCTATGGATCG 
Reverse 5’ – 3’ 
GGGCTTCAGACTGGTACACAT 
AKT1 
Forward 5’ – 3’ 
GCCGCCTGATCAAGTTCTCC 
Reverse 5’ – 3’ 
CAGCGCATCCGAGAAACAAAAC 
β-actin 
Forward 5’ – 3’ 
CCTCACTGTCCACCTTCCAG 














Chapter 3  
 
Persistent antidiabetic benefits of GIP/xenin hybrid in 
combination with exendin-4 on glucose tolerance and islet 














Antidiabetic therapeutics that focus on targeting multiple signalling pathways have 
gained more interest in the treatment of T2DM. In this present chapter, we created a 
treatment paradigm of three key gastrointestinal hormones, integrating the antidiabetic 
benefits of GIP, xenin and GLP-1 signalling pathways. The current study has 
determined the ability of exendin-4 to augment the antidiabetic benefits of the recently 
characterised GIP/xenin hybrid, (DAla2)GIP/xenin-8-Gln, in high fat fed (HFF) mice, 
as well as examining persistence of beneficial metabolic effects in HFF mice. Twice-
daily injection of (DAla2)GIP/xenin-8-Gln for 28 days in HFF mice significantly 
reduced energy intake (P<0.05), body weight (P<0.001), circulating glucose (P<0.05) 
and HbA1c (P<0.05 - P<0.01) levels. Glucose tolerance and insulin sensitivity was 
also significantly (P<0.05 - P<0.01) improved by day 28. Overall pancreatic islet, beta- 
and alpha-cell areas were reduced (P<0.001), with concurrent reduction (P<0.001) in 
alpha- and beta-cell proliferation that was more apparent in combined treatment group 
(P<0.05). Addition of exendin-4 to (DAla2)GIP/xenin-8-Gln therapy did not 
significantly improve metabolic control. Remarkably, beneficial effects were still 
evident 14 days following complete cessation of peptide administration. Thus, 
circulating glucose and insulin, HbA1c concentrations and glucose tolerance were 
still significantly improved when compared to control HFF mice on day 42, with 
minimal changes to islet architecture. These studies highlight the clear and persistent 
metabolic advantages of sustained activation of GLP-1 receptors, together with 









The focus of new therapeutic interventions for T2DM is moving towards a 
combinational targeting approach, in a bid to develop drugs capable of simultaneously 
correcting the multiple dysregulated metabolic pathways associated with the disorder 
[Irwin et al. 2015; Mansur et al. 2016; Tschöp et al. 2017; Hasib et al. 2018a, 2018b]. 
One of the major instigating factors behind this initiative correlates with knowledge 
that, in many patients, the rapid remission of T2DM following certain types of bariatric 
surgeries is linked to changes in the secretion and action of numerous intestinal-
derived peptide hormones [Cummings. 2009; Dimitriadis et al. 2017; Meek et al. 
2016; Su et al. 2016]. Thus, combined administration of therapeutically viable gut 
peptide entities improves metabolic control beyond that observed with a single peptide 
hormone [Bhat et al. 2013]. Hybrid gut peptides, designed as single molecules capable 
of modulating multiple hormone receptors, have shown particular promise [Gault et 
al. 2013; Bhat et al. 2013; Irwin et al. 2015; Tschöp et al. 2016; Hasib et al. 2018a, 
2018b]. Indeed, a dual GIP and GLP-1 receptor agonist hybrid has been shown to 
display good initial efficacy for T2DM in early clinical trials [Frias et al. 2017]. This 
observation indicates that the impaired insulinotropic activity of GIP reported in 
humans with T2DM [Nauck et al. 1993] can be reversed. It follows that approaches to 
enhance GIP action could lead to even greater beneficial therapeutic effects for T2DM. 
 
In this regard, xenin, a peptide hormone co-secreted from the same enteroendocrine 
K-cell as GIP, has been shown to potentiate the insulin releasing actions of GIP [Wice 
et al. 2010; Taylor et al. 2010; Wice et al. 2012; Martin et al. 2014; Gault et al. 2015; 
Parthsarathy et al. 2016]. Additional studies have also highlighted independent 





survival [Leckstrom et al. 2009; Gault et al. 2015; Craig et al. 2018]. Recent studies 
have additionally characterised dual- and triple-acting hybrid peptides, with a GLP-1 
backbone, that also contain a xenin component [Hasib et al. 2017; 2018a; 2018b]. 
However, since xenin is known to potentiate the action of GIP [Craig et al. 2018], 
combining the bioactive regions of GIP and xenin into a single fusion hybrid peptide 
would seem more appealing. Indeed, our laboratory has already documented the 
antidiabetic benefits of a GIP/xenin hybrid peptide, namely (DAla2)GIP/xenin-8-Gln 
[Hasib et al. 2017], that integrates enzymatically stable forms of the N-terminally 
biologically active domain of GIP [Hinke et al. 2001] with the C-terminal bioactive 
region of xenin [Silvestre et al. 2003; Martin et al. 2014]. (DAla2)GIP/xenin-8-Gln 
was shown to restore GIP sensitivity, enhance beta cell function and improve glucose 
homeostasis following sustained treatment in HFF mice [Hasib et al. 2017]. Although 
GIP/xenin induced notable positive effects in HFF mice, many metabolic parameters 
were still abnormal in these rodents, suggesting potential for further improvements. 
 
In the present study we have employed combined treatment of (DAla2)GIP/xenin-8-
Gln, with the clinically approved long-acting GLP-1 mimetic exendin-4, to create a 
treatment paradigm that integrates the established antidiabetic benefits of GIP, xenin 
and GLP-1 signalling [Irwin and Flatt 2015; Craig et al. 2018]. Exendin-4 was 
chosen based on knowledge of the positive biological interactions between GLP-1 
with both GIP and xenin [Irwin et al. 2009; Hasib et al. 2018a]. Given the structure 
of (DAla2)GIP/xenin-8-Gln, and the site of the main bioactive regions within GIP, 
xenin and GLP-1 [Hinke et al. 2001; Martin et al. 2016], it was not possible to create 
a triple-acting GIP/xenin/GLP-1 hybrid molecule. As such, antidiabetic effects of 28 





4 were examined in an environmentally induced mouse model of type 2 diabetes, 
namely HFF mice. This model mimics many of the major pathophysiologies of 
human type 2 diabetes including obesity, hyperinsulinemia, and pancreatic beta cell 
demise [King and Austin, 2017]. In addition, to assess the potential for more 
persistent beneficial effects of the treatment paradigms, the consequence of cessation 
of all treatments for a further 14 days was also studied. The results emphasise that 
prolonged modulation of GIP, xenin and GLP-1 signalling pathways represents a 
novel and exciting treatment option for type 2 diabetes, with enduring positive 
metabolic effects.  
  
3.3 MATERIALS AND METHODS 
3.3.1 Peptides   
All peptides were obtained as described (Section 2.2). Peptides were confirmed pure 
by HPLC (Section 2.3.1) and characterised using MALDI-TOF MS (Section 2.3.2). 
 
3.3.2 Animals 
Sub chronic studies were performed using male Swiss mice (10-12 weeks). All 
animals were maintained as described previously in Sections 2.13 and 2.13.2. 
 
3.3.3 Sub chronic in vivo studies 
Over a 28-day period, HFF mice received twice daily (09:30 and 17:00 h) injections 
of saline vehicle, (DAla2)GIP/xenin-8-Gln (25 nmol/kg bw; i.p.), exendin-4 
(25 nmol/kg bw; i.p.), or a combination of both peptides, as described in section 
2.16.1. Energy intake, body weight, blood glucose and plasma insulin concentrations 





appropriate (Section 2.16.5). At the end of the treatment period glucose tolerance and 
insulin sensitivity tests were performed. In addition, metabolic response to acute 
administration of respective treatment regimens was examined (see Sections 2.16.2.1, 
2.16.2.2 and 2.16.2.4). Terminal analyses included measurement of total fat mass by 
DEXA scanning (Section 2.16.3) and extraction of pancreatic tissue with appropriate 
processing for measurement of hormone content following acid/ethanol extraction or 
islet architecture (Section 2.16.6). For proliferation studies, insulin or glucagon stained 
slides were co-incubated at 37 °C with rabbit anti-Ki-67 primary antibody (Section 
2.16.7). Finally, on day 28 observations were continued in a sub-group (n=6) of mice 
following cessation of treatment regimens for a further 14 days, with assessment of 
the same parameters as documented above.  
 
3.3.4 Biochemical analysis 
Blood samples were collected (Section 2.15), and glucose and insulin assayed 
(Sections 2.11.2 and 2.15). HbA1c was measured as described in Section 2.16.5. 
 
3.3.5 Statistical analysis  
Statistical analysis was completed using GraphPad PRISM (Section 2.18). 
  
3.4 RESULTS 
3.4.1 Effect of 28-day peptide administration, as well as 14-day cessation of 
treatment, on energy intake, body weight, HbA1c, circulating glucose and 
insulin in HFF mice.  
On day 28, body weight change was significantly (P<0.001) reduced in all HFF 





following 14-days cessation of treatment, effects on body weight were reversed 
(Figure 3.1A). There was no change in body fat masses during or after the treatment 
interventions (Figure 3.1B). Interestingly, (DAla2)GIP/xenin-8-Gln and exendin-4, 
but not combined treatment, significantly (P<0.05) reduced cumulative energy 
intake over the 28 day period, with this effect fading by day 42 (Figure 3.1C). HbA1c 
was reduced (P<0.05 - P<0.01) in all treatment groups on days 28 and 42 (Figure 
3.1D). In keeping with this, non-fasting glucose levels were also significantly 
(P<0.05) lower in (DAla2)GIP/xenin-8-Gln and exendin-4 treatment groups on day 
15 (Figure 3.2A), and in all HFF treatment groups (P<0.05 - P<0.01) on days 28 and 
42 (Figure 3.2A). Corresponding insulin levels were decreased (P<0.05) in 
(DAla2)GIP/xenin-8-Gln and exendin-4 treated mice on day 28, and in all HFF 
treatment groups (P<0.001) on day 42 (Figure 3.2B).  
 
3.4.2 Effect of 28-day peptide administration, as well as 14 day cessation of 
treatment, on glucose tolerance, acute metabolic response to respective peptide 
treatment, insulin sensitivity and pancreatic insulin content in HFF mice.  
Twice-daily treatment with exendin-4 in HFF mice resulted in a reduction (P<0.05) 
in glucose levels at 105 min following an i.p. glucose load on day 28 (Figure 3.3A). 
The other treatment interventions, namely (DAla2)GIP/xenin-8-Gln alone and in 
combination with exendin-4, had a tendency to decrease time-dependent glucose 
levels following glucose challenge, but this failed to reach significance (Figure 
3.3A). However, overall 0-120 min glucose AUC values were significantly (P<0.05 
- P<0.01) decreased in all treatment groups when compared to saline controls (Figure 
3.3A). Similarly, corresponding AUC insulin secretory responses were reduced 





challenge on day 42, following 14-days treatment cessation, was associated with 
decreased (P<0.05) individual and AUC glucose values in treatment groups when 
compared to saline controls (Figure 3.3C), with no obvious changes in glucose-
induced insulin secretion (Figure 3.3D). In terms of the acute metabolic effects of 
the same peptide treatment in each respective group on day 28, (DAla2)GIP/xenin-
8-Gln had no impact on glucose disposal or insulin secretion when compared to 
saline controls (Figure 3.4A,B). In contrast, exendin-4 alone, and in combination 
with (DAla2)GIP/xenin-8-Gln, retained impressive (P<0.001) glucose-lowering 
effects in their respective treatment groups (Figure 3.4A). The beneficial glucose 
homeostatic actions of combination treatment were associated with reduced (P<0.01) 
insulin levels (Figure 3.4B). Strikingly similar acute metabolic effects of each of the 
peptide treatments were noted on day 42, following 14-days treatment cessation 
(Figure 3.4C,D).  
 
Further to this, following administration of exogenous insulin on days 28 and 42, 
individual glucose levels were non-significantly decreased in all HFF treatment 
groups when compared to saline controls (Figure 3.5A,B). Furthermore, 28 days 
treatment with exendin-4 alone and in combination with (DAla2)GIP/xenin-8-Gln 
significantly (P<0.01) augmented the overall hypoglycaemic action over the 60 min 
observation period (Figure 3.5A). A similar effect (P<0.05) was also noted on day 
42 in mice previously treated with exendin-4 for 28 days mice (Figure 3.5B). 
Analysis of pancreatic insulin on days 28 and 42 revealed elevations (P<0.05 - 






3.4.3 Effect of 28-day peptide administration, as well as 14-day cessation of 
treatment, on pancreatic islet histology in HFF mice.  
Visual inspection of immunofluorescently stained pancreatic islets on day 28 
revealed no obvious abnormalities in saline or peptide treated HFF mice (Figure 
3.6A-D). Interestingly, twice daily treatment with (DAla2)GIP/xenin-8-Gln, 
exendin-4 and a combination of both peptides significantly (P<0.01 - P<0.001) 
decreased overall islet and alpha cell areas when compared to saline control HFF 
mice (Figure 3.6E,F). Beta cell area was also reduced (P<0.001 and P<0.05, 
respectively) in HFF mice treated with exendin-4 alone, or in combination with 
(DAla2)GIP/xenin-8-Gln, but was increased in (DAla2)GIP/xenin-8-Gln treated mice 
when compared to exendin-4 alone treated mice (Figure 3.6G). These islet 
architectural changes were related to reductions (P<0.001) in both alpha- and beta 
cell proliferation in all treatment groups of mice (Figure 3.6H,I), with decreased 
alpha cell proliferation most apparent in HFF mice treated with a combination of 
(DAla2)GIP/xenin-8-Gln and exendin-4. Beta to alpha cell ratio was significantly 
(P<0.05 - P<0.001) increased by all treatments when compared to HFF controls, but 
reduced (P<0.05 - P<0.01) in the combined treatment group when compared to 
(DAla2)GIP/xenin-8-Gln alone (Figure 3.6J). Essentially similar observations as day 
28 were noted following 14-days cessation of treatment, with some small exceptions 
(Figure 3.7A-D). As such, HFF mice treated with (DAla2)GIP/xenin-8-Gln and 
exendin-4 no longer presented with increased beta to alpha cell area (Figure 3.7J). 
 
3.5 DISCUSSION 
In agreement with previous reports [Hasib et al. 2017], sustained administration of 





metabolic parameters. This included substantially reduced hyperglycaemia and 
glycated haemoglobin concentrations, improved glucose tolerance and enhanced beta 
cell function. Assessment of metabolic rate in these mice would have also been useful 
to understand underlying mechanisms. For example, exendin-4 therapy alone 
appeared to be the most effective intervention in terms of reducing body weight, 
despite no obvious changes in energy intake between groups of HFF mice. However, 
similar, although less striking, antidiabetic effects were previously observed in db/db 
mice [Craig et al. 2019], indicating that the positive effects of (DAla2)GIP/xenin-8-
Gln are transferable across diverse aetiologies of T2DM [King and Austin, 2017]. This 
is important given the complex nature of T2DM in humans [Prasad and Groop, 2015], 
and consistent with the positive outcomes of combined activation of GIP and xenin 
cell signalling pathways in diabetes [Hasib et al. 2017]. 
 
In an attempt to augment these advantageous effects, combination therapy of 
(DAla2)GIP/xenin-8-Gln with the clinically approved GLP-1 mimetic, exendin-4, was 
employed. In HFF mice, exendin-4 exhibited a slight tendency to enhance the efficacy 
of (DAla2)GIP/xenin-8-Gln, but this failed to reach significance for any of the 
parameters examined. Although circulating glucose was consistently reduced by all 
treatment interventions, an overnight fast resulted in similar glycaemic status in all 
HFF mice. Thus, the good efficacy of (DAla2)GIP/xenin-8-Gln alone [Hasib et al. 
2017], the relatively mild form of T2DM presented in HFF mice [King and Austin, 
2017] and the fact that (DAla2)GIP/xenin-8-Gln and exendin-4 may function through 
similar or complementary mechanisms [Irwin and Flatt, 2015; Craig et al. 2018], may 
preclude additive effects. More interestingly however, the beneficial effects of 





consistently associated with decreased insulin levels. Thus, despite the normal insulin 
secretagogue action of GIP, xenin and exendin-4 [Feurle et al. 1992; Green et al. 2003; 
Irwin et al. 2006b], beta cell function was suppressed but normal glycaemia 
maintained, as a direct result of amelioration of peripheral insulin resistance, as 
observed following a bolus insulin injection. Consistent with this view, islet and beta 
cell areas were reduced in these mice, most likely due to decreased insulin demand. 
Interestingly, both alpha- and beta cell proliferation were concomitantly decreased by 
all treatment regimens in HFF mice, with similar observations noted following 
cessation of treatment. Combined therapy was associated with the greatest reductions 
in alpha cell proliferation on days 28 and 42, which could partly explain the changes 
in beta:alpha cell ratio noted in this group of mice. However, earlier observations of 
important insulin-independent glucose lowering actions of GIP, xenin and GLP-1 
receptor activation are also likely to be significant in the improved metabolic status of 
all treatment groups of mice [Irwin and Flatt, 2015; Craig et al. 2018]. Additional 
studies to directly assess glucose uptake and disposal in metabolically active tissues 
such as adipocytes, hepatocytes and myocytes would be required to confirm this.  
 
Nonetheless, on day 28 the advantageous glucose-lowering effects of acute injection 
of (DAla2)GIP/xenin-8-Gln together with exendin-4 were confirmed in the combined 
treatment group, and associated with a substantially reduced insulin secretory 
response. This observation also rules out any potential issues around receptor 
desensitisation in the combination treatment, which has been suggested for GIP-based 
therapeutics in T2DM [Pathak et al. 2014]. However, assessment of GIP and GLP-1 
receptor gene and protein expression in beta cells would also be interesting to assess 





of (DAla2)GIP/xenin-8-Gln were somewhat less impressive than anticipated in HFF 
mice previously treated with this peptide for 28 days.  
 
Given the progressive nature of T2DM [Fonseca, 2009], an extremely important 
observation from the current study was the endurance of beneficial metabolic effects 
following 14 days discontinuation of treatments in HFF mice. Thus, it is remarkable 
that circulating glucose concentrations and glucose tolerance remained substantially 
improved in all HFF treatment groups when compared to saline controls on day 42, 
and particularly so in the combination treatment group. This occurred despite no 
elevations in associated insulin concentrations and a progressive increase in body 
weight. It would imply favourable metabolic reprogramming in these mice, 
independent of energy balance that persists despite treatment withdrawal. Such 
positive effects have previously been shown with other gut hormone based therapies 
[Irwin et al. 2013a; Lynch et al. 2014]. Moreover, long lasting metabolic advantages 
are also a notable therapeutic advantage of the thiazolidinedione antidiabetic class of 
drugs [Gegick and Altheimer, 2004], and could represent a key benefit of combined 
(DAla2)GIP/xenin-8-Gln and exendin-4 therapy. The lack of major changes in 
pancreatic islet architecture and insulin sensitivity following discontinuation of 
treatments is also indicative of preservation of improved metabolic state. Accordingly, 
the robust glucose homeostatic action of combined (DAla2)GIP/xenin-8-Gln and 
exendin-4 therapy was associated with a significantly reduced insulin secretory 
response on day 42, similar to observations on day 28, highlighting sustainable 






In conclusion, the present study confirms the antidiabetic attributes of 
(DAla2)GIP/xenin-8-Gln in a HFF model of T2DM, with favourable effects 
augmented by combined therapy with exendin-4. Prominently, metabolic advantages 
of (DAla2)GIP/xenin-8-Gln and exendin-4 therapy were remarkably persistent in 
nature in HFF mice, suggesting enduring positive antidiabetic effects. Taken together, 
it is clear that novel therapies including a GIP, xenin and GLP-1 component may have 
clinically exploitable benefits for human T2DM that merit further investigation. 
Accordingly, shorter xenin analogues may yet hold further therapeutic promise for 
T2DM, with smaller peptides potentially enabling non-injectable drug delivery and 











Figure 3.1. Effects of (DAla2)GIP/xenin-8-Gln, exendin-4 and a combination of both peptides on (A) body weight change, (B) body fat mass (C) 

















































































































































Parameters were measured at regular intervals 28 days during, and 14 days following cessation, of twice daily treatment with (DAla2)GIP/xenin-8-Gln 
(25 nmol/kg bw), exendin-4 (25 nmol/kg bw) or a combination of both peptides, as appropriate. All values are mean ± SEM for twelve (28 days treatment) 
or six (14 days cessation of treatment) mice. *P<0.05, **P<0.01 and ***P<0.001 compared with HFF saline controls. △△△P<0.001 compared with exendin-





Figure 3.2. Effects of (DAla2)GIP/xenin-8-Gln, exendin-4 and a combination of both peptides on (A) non fasting glucose and (B) insulin in 




Parameters were measured at regular intervals 28 days during, and 14 days following cessation, of twice daily treatment with (DAla2)GIP/xenin-
8-Gln (25 nmol/kg bw), exendin-4 (25 nmol/kg bw) or a combination of both peptides, as appropriate. The n = 6 mice randomly selected to 
progress to cessation of treatment for 14 days are depicted by the red symbols. All values are mean ± SEM for twelve (28 days treatment) or six 











Figure 3.3. Effects of (DAla2)GIP/xenin-8-Gln, exendin-4 and a combination of 
both peptides on glucose tolerance in HFF mice.  




















































































































































































































(A,B) Parameters were measured after 28 days twice daily treatment with 
(DAla2)GIP/xenin-8-Gln (25 nmol/kg bw), exendin-4 (25 nmol/kg bw) or a 
combination of both peptides, or (C,D) 14 days following cessation of all treatments. 
(A-D) Glucose (18 mmol/kg bw) was administered i.p. at t = 0 min in overnight fasted 
mice. Glucose and insulin AUC values for 0–120 min post injection are also shown. 
Black squares and white bars, saline control; black triangles and black vertical line 
bars, exendin-4; white diamonds and diagonal line bars, (DAla2)GIP/xenin-8-Gln; 
black/white circles and black bars, (DAla2)GIP/xenin-8-Gln + exendin-4. All values 










Figure 3.4. Effects of (DAla2)GIP/xenin-8-Gln, exendin-4 and a combination of 
both peptides on acute metabolic response to respective peptide treatments in 
HFF mice.  




















































































































































































































































(A,B) Parameters were measured after 28 days twice daily treatment with 
(DAla2)GIP/xenin-8-Gln (25 nmol/kg bw), exendin-4 (25 nmol/kg bw) or a 
combination of both peptides, or (C,D) 14 days following cessation of all treatments. 
(A-D) Glucose (18 mmol/kg bw) in combination with acute i.p. injection of the same 
respective treatment intervention (saline, (DAla2)GIP/xenin-8-Gln (25 nmol/kg bw), 
exendin-4 (25 nmol/kg bw) or a combination of both peptides was administered at t = 
0 min in overnight fasted mice. Glucose and insulin AUC values for 0–120 min post 
injection are also shown. Black squares and white bars, saline control; black triangles 
and black vertical line bars, exendin-4; white diamonds and diagonal line bars, 
(DAla2)GIP/xenin-8-Gln; black/white circles and black bars, (DAla2)GIP/xenin-8-Gln 
+ exendin-4. Values are mean ± SEM for six mice. *P<0.05, **P<0.01 and 
***P<0.001 compared with HFF saline controls. △P<0.05, △△P<0.01 and △△△P<0.001 











Figure 3.5. Effects of (DAla2)GIP/xenin-8-Gln, exendin-4 and a combination of 
both peptides on insulin sensitivity and pancreatic insulin content in HFF mice. 




























































































































































































(A) Parameters were measured after 28 days twice daily treatment with 
(DAla2)GIP/xenin-8-Gln (25 nmol/kg bw), exendin-4 (25 nmol/kg bw) or a 
combination of both peptides, or (B) 14 days following cessation of all treatments. 
(A,B) Insulin (25 U/kg bw) was administered i.p. at t = 0 min in non-fasted mice. 
Glucose AAC values for 0–60 min post injection are also shown. (C) Pancreatic 
insulin content was measured by RIA following acid-ethanol extraction. Values are 
mean ± SEM for six mice. *P<0.05, **P<0.01 and ***P<0.001 compared with HFF 








Figure 3.6. Effects of (DAla2)GIP/xenin-8-Gln, exendin-4 and a combination of both peptides on day 28 on pancreatic islet architecture in 
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(A-H) Parameters were measured after 28 days twice daily treatment with (DAla2)GIP/xenin-8-Gln (25 nmol/kg bw), exendin-4 (25 nmol/kg bw) 
or a combination of both peptides. (A-D) Representative images (20X) of islets showing insulin (red) and glucagon (green) immunoreactivity from 
each treatment group. (E) Islet (F) alpha and (G) beta cell areas, as well as (H) insulin and (I) glucagon positive Ki-67 cells and (J) beta:alpha area 
cell area ratio, were measured using CellF image analysis software. White bars, saline control; black vertical line bars, exendin-4; diagonal line 
bars, (DAla2)GIP/xenin-8-Gln; black bars, (DAla2)GIP/xenin-8-Gln + exendin-4. Scale bar, 200 μm. All values are mean ± SEM for six mice. 
*P<0.05 and ***P<0.001 compared with HFF saline controls. △P<0.05 compared with exendin-4 alone. ΩP<0.05 compared with 
(DAla2)GIP/xenin-8-Gln alone. 





Figure 3.7. Effects of (DAla2)GIP/xenin-8-Gln, exendin-4 and a combination of both peptides 14 days following cessation of all treatment 
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(A-H) Parameters were measured 14 days following cessation of all treatments. (A-D) Representative images (20X) of islets showing insulin (red) 
and glucagon (green) immunoreactivity from each treatment group. (E) Islet (F) alpha and (G) beta cell areas, as well as (H) insulin and (I) glucagon 
positive Ki-67 cells and (J) beta:alpha area cell area ratio, were measured using CellF image analysis software. White bars, saline control; black 
vertical line bars, exendin-4; diagonal line bars, (DAla2)GIP/xenin-8-Gln; black bars, (DAla2)GIP/xenin-8-Gln + exendin-4. Scale bar, 200 μm. 
All values are mean ± SEM for six mice. *P<0.05, **P<0.01 and ***P<0.001 compared with HFF saline controls. △P<0.05, △△P<0.01 and 
△△△P<0.001 compared with exendin-4 alone. ΩΩP<0.01 compared with (DAla2)GIP/xenin-8-Gln alone. 












Assessing the acute biological actions and antidiabetic 
activity of novel xenin-25 C-terminal hexapeptides on 














The K-cell derived peptide hormone, xenin-25, is known to undergo rapid metabolism 
following secretion into the bloodstream. Early studies revealed bioactivity of a C-
terminal hexapeptide fragment peptide of xenin-25, namely xenin-6, which were 
enhanced through introduction of a reduced peptide bond between the first two N-
terminal residues, to yield Ψ-xenin-6. The present study was undertaken to further 
assess biological actions and antidiabetic properties of Ψ-xenin-6, as well as 
characterisation of four additional novel xenin hexapeptides with Gln substitutions. 
Introduction of a reduced peptide bond in Ψ-xenin-6, unlike in the other four 
hexapeptides, resulted in completely resistant peptide to murine enzyme degradation 
in vitro. In BRIN-BD11 and INS-1 cells, as well as isolated murine islets, insulin-
releasing actions of Ψ-xenin-6 were superior to xenin-6 and all other modified 
hexapeptides. Ψ-xenin-6 also prominently enhanced (P<0.001) the insulinotropic 
actions of GIP, with equal or increased potency compared to xenin-25. In α-TC1.9 
cells, all hexapeptides had no impact on glucagon secretion, although, xenin-6 and 
xenin-6-NH2, but not xenin-6-Gln, xenin-6-Gln-NH2 or Ψ-xenin-6, partially reversed 
(P<0.001) the glucagonotropic action of GIP. However, in isolated murine islets, only 
Ψ-xenin-6 significantly (P<0.05) increased glucagon secretion, and further enhanced 
(P<0.001) the glucagonotropic actions of GIP, when compared to respective glucose 
control. Further in vitro investigations revealed that, similar to GLP-1, Ψ-xenin-6 
significantly augmented proliferation of human and rodent clonal beta cells, whilst 
fully protecting against cytokine-induced beta-cell cytotoxicity. Xenin-6-Gln and 
xenin-6-Gln-NH2 also augmented (P<0.001) proliferation of rodent clonal beta cells, 
with xenin-6-Gln having a significant (P<0.05) effect in 1.1B4 cells at the same 





beta cell cytotoxicity. When administered to mice in combination with glucose, all test 
peptides, barring xenin-6-Gln and xenin-6-NH2, significantly (P<0.05 - P<0.01) 
reduced glucose levels. Ψ-xenin-6 had a duration of biological action beyond 8 hours. 
Ψ-xenin-6 also significantly augmented the glucose-lowering action of GIP in vivo. In 
overnight fasted mice, only Ψ-xenin-6 exhibited satiety actions at both 25 and 250 
nmol/kg. Overall, this data demonstrates that Ψ-xenin-6 is a metabolically stable C-
terminal fragment analogue of xenin-25, with an action profile that merits further study 
as a potential antidiabetic compound. 
 
4.2 INTRODUCTION 
Xenin-25, a 25 amino acid gut hormone, co-secreted from enteroendocrine K-cells 
along with GIP, has previously been shown to decrease gastrointestinal motility and 
modulate energy balance [Cline et al. 2007; Leckstrom et al. 2009; Kerbel et al. 2018]. 
Further studies also suggest that xenin-25 plays a role in regulating islet function and 
survival [Silvestre et al. 2003; Taylor et al. 2010; Martin et al. 2012; 2014; Gault et 
al. 2015; Parthsarathy et al. 2016; Khan et al. 2017a]. In this regard, others have also 
suggested therapeutic potential of xenin-25 for diabetes [Craig et al. 2018], as xenin-
25 has also been shown to potentiate the insulinotropic actions of GIP [Wice et al. 
2010, 2012; Martin et al. 2012; Gault et al. 2015]. Notwithstanding this, the evident 
physiological importance of xenin-25 has been somewhat overlooked to date 
[Maryanovich et al. 2018; Craig et al. 2019]. In a similar fashion, the consequence of 
xenin-25 enzymatic degradation, and biological relevance of related circulating xenin 
metabolites, is not fully understood. Thus, numerous regulatory gut-derived peptides 





in the circulation [Deacon 2004; Mayorov et al. 2008; Lafferty et al. 2018; Craig et 
al. 2019]. 
 
A number of C-terminally truncated metabolites of xenin-25 have already been 
characterised including, xenin 9-25, xenin 11-25, xenin 14-25 and xenin 18-25 [Martin 
et al. 2014]. However, the biological significance of xenin 9-25, xenin 11-25 and xenin 
14-25 is largely unknown [Martin et al. 2014]. Interestingly, xenin 18-25, also referred 
to as xenin-8, has been shown to recapitulate the effects of the parent peptide at the 
level of the endocrine pancreas [Silvestre et al. 2003; Martin et al. 2014; 2016; Craig 
et al. 2018] and duodenum [Kaji et al. 2017], as well as potentiating the biological 
actions of GIP [Martin et al. 2014; 2016]. This is particularly encouraging in terms of 
prospective therapeutic application of xenin, since smaller peptide size will lead to 
reduced production costs, promote simpler drug formulation, which together will 
dramatically increase overall commercial attractiveness. Following on from this, two 
very early studies in the xenin field had demonstrated bioactivity of a C-terminal 
hexapeptide of xenin-25, xenin-20-25 or also known as xenin-6 [Feurle et al. 1996, 
2003]. However, full investigations into the potential of xenin-6 are lacking. 
Encouragingly, enzymatic stability and biological efficacy of this xenin hexapeptide 
was shown to be substantially enhanced through introduction of a reduced 
pseudopeptide bond (CH2NH) between Lys
20 and Arg21 amino acid residues, to yield 
a Psi (Ψ) pseudopeptide analogue named Ψ-xenin-6 [Feurle et al. 2003]. However, 
further application of these initial exciting observations with Ψ-xenin-6 have been 






In chapter 3, the persistent antidiabetic effects of xenin-8-Gln were characterised as 
part of a hybrid peptide in combination with an already established antidiabetic drug 
type, exendin-4. However, shorter analogues may be more therapeutically attractive, 
due to cheaper and easier synthesis, and may also enable a non-injectable peptide drug 
delivery [Novakovic et al. 2013; Park et al. 2015], which would improve patient 
compliance when moving towards the clinic. Therefore, the present study aimed to 
further characterise Ψ-xenin-6, along with novel Gln- substituted xenin hexapeptides, 
with a view to potential therapeutic application in the field of diabetes. The peptides 
assessed in this chapter were xenin-6, xenin-6-NH2, xenin-6-Gln, xenin-6-Gln-NH2 
and Ψ-xenin-6. Initially susceptibility to plasma degradation was assessed, followed 
by in vitro and ex vivo assessment on insulin and glucagon secretion from BRIN-
BD11, INS-1 and α-TC1.9 cells as well as isolated mouse islets, as appropriate, for all 
novel hexapeptides. In addition, effects on rodent and human beta cell proliferation 
and protection against cytokine-induced apoptosis were also assessed in BRIN-BD11 
and 1.1B4 cell lines. Finally, impact of each peptide on glucose homeostasis, insulin 
secretion and satiety were examined in mice. The results revealed that Ψ-xenin-6 was 
the most potent hexapeptide investigated. Therefore, taken together, the results 
support further investigation of the potential therapeutic promise of Ψ-xenin-6 for 
diabetes.  
 
4.3 MATERIALS AND METHODS 
4.3.1 Peptides   
All peptides were obtained as previously described in Section 2.2. Peptides were 
confirmed pure by HPLC (Section 2.3.1) and subsequently characterised using 





4.3.2 Assessment of plasma degradation of peptides  
Effect of murine plasma on peptide stability was assessed as described previously in 
Section 2.4.1. 
 
4.3.3 In vitro and ex vivo insulin secretion  
In vitro insulin secretory studies were performed using BRIN-BD11 and INS-1 cells 
as described previously in Section 2.6.1. In a separate set of experiments, BRIN-BD11 
cells were incubated at 5.6 mmol/l glucose with test peptides in the presence of GIP 
(10-6 mol/l) for 20 minutes, as outlined in Section 2.6.1, and insulin measured by RIA 
as described in Section 2.11.2. In a final set of experiments, BRIN-BD11 cells were 
cultured at 22.2 mmol/l glucose and insulinotropic effects of GIP, xenin-6 and Ψ-
xenin-6 determined, as described in Section 2.6.1. Effects of xenin hexapeptides on ex 
vivo insulin secretion were examined using isolated mouse islets (Section 2.10.2). 
 
4.3.4 Assessment of toxicity of peptides 
Toxicity of test peptides (10-6 mol/l, 20 minutes) was determined by assessing levels 
of LDH release in BRIN-BD11 cells, as described in Section 2.7.1. 
 
4.3.5 In vitro and ex vivo glucagon secretion 
In vitro glucagon secretory studies were performed using α-TC1.9 cells (Section 
2.8.1). Ex vivo glucagon secretory effects were examined using isolated mouse islets 
as described in Section 2.10.3. Glucagon concentrations were measured by 







4.3.6 In vitro beta cell proliferation and apoptosis 
In vitro effects of peptides on proliferation and apoptosis were performed using BRIN-
BD11 and 1.1B4 cells as described previously in Section 2.9.1. 
 
4.3.7 Animals 
Acute and persistent dose dependent studies were carried out in lean mice. All animals 
were maintained as described previously in Section 2.13.1. 
 
4.3.8 Acute in vivo effects of peptides on glucose-lowering, insulinotropic activity 
and food intake in lean mice  
For food intake, studies were carried out as described in Section 2.14.1. Effects on 
glucose homeostasis and insulin secretory activity of test peptides alone or in 
combination with GIP were carried out as described in Section 2.14.2. Persistent 
peptide effects were assessed as outlined in Section 2.14.3. 
 
4.3.9 Biochemical analysis  
Blood samples were collected as previously described in Section 2.15 at the time 
points indicated in the Figures. Blood glucose and plasma insulin were assayed as 
described in Sections 2.11.2 and 2.15.  
 
4.3.10 Statistical analysis  
Statistical analysis was completed using GraphPad PRISM (Version 5) as described 








4.4.1 Xenin hexapeptide characterisation and plasma enzymatic stability  
In-house characterisation confirmed successful synthesis of test peptides using HPLC 
and MALDI-TOF MS (Table 4.1). Experimental and theoretical mass of each peptide 
was closely related, confirming successful synthesis of peptides (Table 4.1). In 
addition, Ψ-xenin-6 was completely resistant to plasma degradation for up to 6 h, 
whereas native xenin-6, xenin-6-NH2, xenin-6-Gln and xenin-6-Gln-NH2 had an 
estimated in vitro half-life of less than 2 h (Table 4.2). 
 
4.4.2 Insulin secretory actions of novel xenin hexapeptides 
In BRIN-BD11 cells at 1.1 mmol/l glucose, only xenin-6-Gln elicited significant 
(P<0.05 - P<0.001) augmentations of insulin secretion when compared to glucose 
control, with xenin-6-Gln-NH2 displaying significant (P<0.05) insulinotropic effects 
at 10-6 mol/l concentrations (Figure 4.1A). All xenin hexapeptides displayed 
significant (P<0.05 - P<0.001) dose-dependent insulin secretory actions at 5.6 mmol/l 
glucose when compared to respective glucose controls (Figure 4.1B). Interestingly, at 
5.6 mmol/l glucose, xenin 6-Gln and Ψ-xenin-6 exhibited superior (P<0.05 - P<0.001) 
insulinotropic effects than native xenin-6 at 10-12, 10-10 and 10-6 mol/l peptide 
concentrations, with xenin-6-Gln-NH2 exhibiting significant (P<0.01 - P<0.001) 
effects at 10-12 and 10-10 mol/l (Figure 4.1B). At 16.7 mmol/l glucose, Ψ-xenin-6 
displayed significant (P<0.01 - P<0.001) insulinotropic effects when compared to 
respective glucose controls at 10-8 and 10-6 mol/l concentrations, with superior 
(P<0.05) effects compared to xenin-6 at 10-6 mol/l concentrations. All other peptides 
failed to elicit any significant insulinotropic increase (Figure. 4.1C). When xenin 





xenin-6-NH2, significantly (P<0.05 - P<0.001) augmented the insulinotropic actions 
of GIP at 10-8 and 10-6 mol/l concentrations (Figure 4.2). In this regard, Ψ-xenin-6 
exhibited superior (P<0.01 - P<0.001) GIP-potentiating efficacy than all xenin-6 
peptides at all concentrations examined (Figure 4.2). The potent insulin-releasing 
actions of Ψ-xenin-6, were again superior over all other peptides tested, as confirmed 
in isolated murine islets (Figure 4.3).  
 
None of the xenin peptides compromised BRIN-BD11 cell plasma membrane 
integrity, as displayed by lack of effects on LDH levels (Figure 4.4A). Under 
glucotoxic culture conditions, the insulin secretory responses of GIP, xenin-6 and Ψ-
xenin-6 were significantly (P<0.05 - P<0.01) impaired (Figure 4.4B) Interestingly, 
when xenin-6 was co-incubated with GIP, the insulinotropic response was not 
significantly different in BRIN BD11 cells cultured under normal or glucotoxic culture 
conditions (Figure 4.4B). In contrast, although co-incubation with Ψ-xenin-6 and GIP 
under glucotoxic conditions augmented insulin secretion to a higher degree than co-
incubation with xenin-6 and GIP, insulin secretion was reduced (P<0.01) when 
compared to control cultures. In INS-1 cells, only Ψ-xenin-6 exhibited significant 
(P<0.001) insulinotropic effects at 10-8 and 10-6 mol/l, with xenin-6, xenin-6-NH2 and 
xenin-6-Gln-NH2 eliciting significant (P<0.01 - P<0.001) insulin secretory effects at 
10-6 mol/l (Figure 4.5). Ψ-xenin-6 also exhibited superior insulinotropic effects 
compared to xenin-6 at 10-12, 10-10 and 10-8 mol/l (Figure 4.5). 
 
4.4.3 Glucagon secretory actions of novel xenin hexapeptides 
As expected, arginine and GIP augmented (P<0.001) glucagon secretion from α-TC1.9 





(Figure 4.6A). However, xenin-6 and xenin-6-NH2 partially reversed the 
glucagonotropic actions of GIP, whereas xenin-6-Gln, xenin-6-Gln-NH2 and Ψ-xenin-
6 did not (Figure 4.6A). Ψ-xenin-6 significantly (P<0.01) augmented the 
glucagonotropic actions of GIP (Figure 4.6A). The observations on glucagon secretion 
following incubation of arginine, GIP, xenin-6, xenin-6-NH2, xenin-6-Gln, xenin-6-
Gln-NH2 and Ψ-xenin-6 in α-TC1.9 cells were similar in isolated murine islets (Figure 
4.6B). All peptides except Ψ-xenin-6 partially reversed the glucagonotropic actions of 
GIP. In addition, whilst the ability of xenin-6 to reverse GIP-induced elevations of 
glucagon secretion was again apparent, this failed to reach significance in mouse islets 
(Figure 4.6B). 
 
4.4.4 Effects of novel xenin hexapeptides on beta cell proliferation and protection 
against apoptosis 
Similar to GLP-1, Ψ-xenin-6 significantly (P<0.001) augmented BRIN-BD11 and 
1.1B4 beta cell proliferation at both 10-8 and 10-6 mol/l (Figure 4.7A,B). Xenin-6-Gln 
enhanced BRIN-BD11 and 1.1B4 beta cell proliferation at 10-6 mol/l, with xenin-25 
and xenin-6-Gln-NH2 only displaying beta cell proliferative effects in BRIN-BD11 
cells at 10-6 mol/l (Figure 4.7A). Xenin-6 and xenin-6-NH2 displayed no proliferative 
actions in BRIN-BD11 or 1.1B4 beta cells (Figure 4.7A,B). In relation to protection 
against cytokine-induced apoptosis, all test peptides reversed detrimental DNA 
damaging effects of co-incubation with cytokines in BRIN-BD11 cells, but only at the 
highest concentration employed (Figure 4.7C). In 1.1B4 beta cells, Ψ-xenin-6 offered 
full protection against cytokine-induced apoptosis at both 10-8 and 10-6 mol/l, with 
benefits of GLP-1, xenin-25, xenin-6, xenin-6-NH2, xenin-6-Gln and xenin-6-Gln-
NH2 only observed at 10





6 (10-6 M) reduced (P<0.05) cytokine-induced elevations of TUNEL staining to below 
control levels (Figure 4.7D).  
 
4.4.5 Acute effects of novel xenin hexapeptides on in vivo food intake  
At a dose of 25 nmol/kg, only xenin-25 and Ψ-xenin-6 induced a significant (P<0.01 
and P<0.05) reduction in food intake compared to saline controls (Figure 4.9A). All 
other treatments had no effect on re-feeding at a dose of 25 nmol/kg (Figure 4.9A). 
Interestingly, at a supraphysiological dose (250 nmol/kg), only Ψ-xenin-6 exhibited 
appetite suppressive actions (P<0.05), evident at both 30 and 180 min post-injection 
(Figure 4.9B), with xenin-6-Gln-NH2 displaying suppressive effects 30 min post 
injection (P<0.05; Figure 4.9B). All other xenin hexapeptides, including native xenin-
6, did not exhibit any significant appetite suppressive effects at either of the doses 
employed (Figure 4.9A,B). When in combination with exendin-4, all hexapeptides 
assessed significantly reduced food intake compared to saline (Figure 4.10). 
 
4.4.6 Acute glucose lowering and insulin releasing effects of novel xenin 
hexapeptides in lean mice 
Administration of xenin-6, xenin-6-Gln-NH2 and Ψ-xenin-6, concomitantly with 
glucose resulted in significantly (P<0.05 - P<0.01) decreased overall 0-105 min AUC 
glucose when compared to glucose alone (Figure 4.11B). Treatment with GIP, xenin-
6, xenin-6-Gln-NH2 and Ψ-xenin-6 elevated (P<0.05 - P<0.001) corresponding 0-105 
min AUC insulin concentrations (Figure 4.11D). When administered in combination 
with GIP, there was a significant (P<0.01 - P<0.001) reduction in glucose levels at 30 
and 60 min post-injection when compared to glucose alone (Figure 4.12A). 





when GIP was combined with Ψ-xenin-6 (P<0.05), but not with the other xenin-6 
peptides assessed (Figure 4.12B). All treatments, barring xenin-6-Gln, elevated 
(P<0.05 - P<0.001) corresponding 0-105 min AUC insulin concentrations, when 
compared to glucose control (Figure 4.12D). Overall AUC insulin levels demonstrated 
that xenin-6 and Ψ-xenin-6 augmented the insulinotropic actions of GIP (Figure 
4.12D). 
 
4.4.7 Persistent glucose lowering and insulin releasing effects of novel xenin 
hexapeptides in lean mice 
Administration of xenin-6, xenin-6-Gln-NH2 or Ψ-xenin-6 2 h prior to glucose load, 
resulted in significantly reduced individual (P<0.05 - P<0.01) and AUC overall 
(P<0.05 - P<0.01) glucose levels when compared to saline controls (Figure 4.13A,B). 
All other xenin hexapeptides were devoid of beneficial glucose-lowering effects at this 
time point (Figure 4.13A,B). Similar observations were made when xenin-6, xenin-6-
Gln-NH2 or Ψ-xenin-6 were injected 4 h before the glucose challenge (Figure 
4.13C,D). When administered 8 h prior to the glucose load, xenin-6 reduced (P<0.05) 
individual glucose levels at 15 min post-injection, with Ψ-xenin-6 reducing (P<0.05) 
individual glucose levels at 30 min post-injection (Figure 4.13F). Both xenin-6 and Ψ-
xenin-6 significantly (P<0.05) decreased overall AUC glucose values (Figure 4.13F). 
Xenin-6-Gln-NH2 exhibited no beneficial effects when administered 8 h prior to 
glucose challenge. Both xenin-6 and Ψ-xenin-6 failed to elicit any significant glucose-









Previous studies have established the antidiabetic potential of truncated metabolites of 
xenin-25 [Martin et al. 2014]. In chapter 3, the antidiabetic abilities of the truncated 
modified xenin-8 peptide, xenin-8-Gln, as a hybrid agent were explored. In this 
chapter, the aim was to further characterise truncated forms of xenin-25, namely 
xenin-6. Earlier reports established that chemical manipulation of the C-terminal 
hexapeptide of xenin-25, namely xenin-6, through introduction of a reduced 
pseudopeptide bond between Lys20 and Arg21, yields an enzymatically stabilised 
peptide with enhanced biological activity [Feurle et al. 2003]. Similar improved 
metabolic stability and bioactivity has been observed in neurotensin, a peptide closely 
related to xenin [Feurle et al. 2002], following introduction of a reduced 
pseudopeptide bond [Lugrin et al. 1991]. These studies are in complete harmony with 
previous work from our laboratory, demonstrating enhanced stability and biological 
activity of an octapeptide C-terminal fragment of xenin-25 following rationally 
introduced amino-acid modifications [Irwin et al. 2012; Martin et al. 2016; 
Parthsarathy et al. 2016].  
 
Consistent with this knowledge, in the present study xenin-25, xenin-6, xenin-6-NH2, 
xenin-6-Gln, xenin-6-Gln-NH2 and particularly Ψ-xenin-6 evoked clear increases of 
insulin secretion from BRIN-BD11 cells [Feurle et al. 1992; Taylor et al. 2010]. 
Indeed, all xenin hexapeptides had similar, or even enhanced efficacy when compared 
to the parent peptide, xenin-25. Notably, Ψ-xenin-6 and xenin-6-Gln were 
significantly more efficacious at 10-6 mol/l than xenin-6 and xenin-25 at 5.6 mmol/l 
glucose, which is interesting and may require further study. The insulinotropic potency 





in BRIN-BD11 cells, and this may be due to difficulties in assessing additive peptide 
effects in the face of increased insulin output by elevated glucose. Nevertheless, these 
observations corroborate that C-terminal hexapeptides of xenin-25 are capable of 
activating xenin related beta cell signalling pathways. Indeed, insulin secretory studies 
using functional isolated mouse islets fully confirmed this concept. At the beta cell 
level, notable GIP-potentiating actions of xenin-25 are recognised [Wice et al. 2010; 
2012; Martin et al. 2012; Parthsarathy et al. 2016], which were reproduced in this 
study by all hexapeptides examined and to a significantly greater magnitude by Ψ-
xenin-6. The effects of xenin-6 and Ψ-xenin-6 were further assessed in BRIN-
BD11 cells cultured under glucotoxic conditions to mimic beta cell stress encountered 
in diabetes [Pathak et al. 2014].  
 
As would be expected, there was an impairment of the insulin-releasing action of GIP 
and xenin-6 peptides. GIP-augmenting actions of the truncated xenin peptides were 
still observed under glucotoxic culture, especially in the case of xenin-6. Nonetheless, 
the most effective of the compounds assessed in terms of GIP-potentiation was Ψ-
xenin-6, albeit with notably less efficacy than in normal beta cells. In addition, Ψ-
xenin-6 was the only peptide examined that significantly enhanced the glucose-
lowering action of GIP in mice. Thus, whilst the exact mechanism of xenin-induced 
GIP potentiation remains to be elucidated [Wice et al. 2010; Clemens et al. 1997; 
Mazella et al. 2012], these observations substantiate the idea that Ψ-xenin-6 possesses 
enhanced biological potency over xenin-6 and the other hexapeptides considered 
[Feurle et al. 2003]. It is also encouraging to note that the amino-acid modifications 
and the reduced pseudopeptide bond present within these novel hexapeptides had no 





Based on previous observations of glucagonotropic actions of a C-terminal 
octapeptide fragment of xenin-25 [Silvestre et al. 2003], and evidence that GIP 
induces glucagon secretion under fasting glycaemic levels [Christensen et al. 2011], 
the aim was to further examine this concept with our modified xenin hexapeptides. 
Unlike GIP, all hexapeptides examined were devoid of glucagonotropic actions in α-
TC1.9 cells and isolated rodent islets. This does slightly contrast with previous 
findings in rodent islets using xenin-8, although in situ perfusion as opposed to static 
incubations were employed for this earlier study [Silvestre et al. 2003]. In addition, 
the most prominent secretory effect of xenin-8 was noted to be potentiation of 
arginine- and carbachol-induced glucagon elevations [Silvestre et al. 2003]. Given 
this, and the notable interactions between the gut hormones xenin and GIP [Wice et 
al. 2012; Martin et al. 2012; Chowdhury et al. 2013; Irwin and Flatt, 2015; Hasib et 
al. 2017], the impact of co-incubation with the xenin-6 fragment peptides and GIP was 
considered. Interestingly, xenin-6 and xenin-6-NH2, but not xenin-6-Gln, xenin-6-
Gln-NH2 and Ψ-xenin-6, had a strong tendency to reverse GIP-mediated increases in 
glucagon release. This is interesting, considering both augmentation and blockade of 
glucagon receptor signalling has been advocated as being beneficial in 
diabetes [Pathak et al. 2015; McShane et al. 2016]. The difference in biological 
activity between these C-terminal hexapeptides examined is intriguing and 
presumably not related to the enhanced stability of Ψ-xenin-6 noted here and 
elsewhere [Feurle et al. 2002; Craig et al. 2019]. However, it could also relate to 
structure/function complexities between the numerous peptides, which would require 
further in-depth study. In humans, GIP infusion has been shown to prevent insulin-
induced hypoglycaemia, therefore the overall impact of xenin on GIP-induced 





this may represent an important homeostatic metabolic mechanism of GIP 
[Christensen et al. 2011], where xenin may also play a key role, and could have 
particular relevance in a diabetic setting.  
 
Further to this, previous studies with xenin-25 have clearly highlighted potential 
benefits at the level of the beta cell. As well as enhancing insulin release and 
potentiating GIP-induced insulin release [Taylor et al. 2010; Wice et al. 2010; Martin 
et al. 2012, 2014], the parent xenin peptide has been shown to promote beta cell 
growth and survival [Khan et al. 2017a]. Xenin-6-Gln-NH2 exhibited similar or 
enhanced beta cell proliferative properties in BRIN-BD11 cells, with xenin-6-Gln 
displaying enhanced proliferative properties in both BRIN-BD11 and 1.1B4 beta cells. 
Promisingly, Ψ-xenin-6 had similar, or even enhanced, beta cell proliferative and 
survival beneficial effects in both rodent BRIN-BD11 and human 1.1B4 beta cells. 
This is encouraging given that T2DM is a disease characterised by beta cell loss 
[Halban et al. 2014], although the exact mechanisms involved in these xenin-induced 
beneficial effects still need to be clarified. Similar to previous reports [Mohan et al. 
2018, 2019], baseline apoptosis rates were somewhat elevated in both beta cell lines, 
representing a particularly challenging environment. As such, it may have been 
interesting to assess the benefits of xenin hexapeptides on beta cell survival under less 
severe beta cell insults. Indeed, the aforementioned positive effects of Ψ-xenin-6 on 
glucose homeostasis, insulin release and GIP potentiation, coupled with an in vivo 
duration of approximately 8 hours in mice, further promote its potential therapeutic 
value for diabetes. The observation of enhanced glucose homeostatic actions of 
combined GIP and Ψ-xenin-6 administration in mice, despite no obvious 





extrapancreatic glucose-lowering effects of GIP and xenin [Irwin and Flatt, 
2015; Craig et al. 2018].  
 
Furthermore, xenin has been suggested to supress food intake [Craig et al. 2018] and 
delay gastric emptying rate [Kim and Mizuno 2010], which would also be 
complementary in the T2DM setting [Al-Goblan et al. 2014]. In our system, Ψ-xenin-
6 induced small, but significant, appetite suppressive effects in mice at doses of 25 
and 250 nmol/kg, whereas all other xenin-6 peptides assessed were ineffective. 
Notably, physiological circulating concentrations of xenin are not well defined, and 
local tissue production of xenin has been documented outside of the gut [Khan et al. 
2017a]. In addition, previous studies demonstrating prominent efficacy of xenin 
peptides to inhibit feeding have largely employed intracerebroventricular 
administration [Alexiou et al. 1998; Leckstrom et al. 2009; Cooke et al. 2009; Bhavya 
et al. 2017; Kerbel et al. 2018], as opposed to peripheral application in the present 
study. This may suggest that efficient passage through the blood-brain barrier is 
critical for xenin-based peptides to positively modulate energy balance.  
 
In conclusion, these data substantiate the notion that Ψ-xenin-6 is a stable, long-acting 
xenin analogue that retains the full biological action profile of the parent peptide. 
Benefits of Ψ-xenin-6 on islet cell function and survival, appetite suppression and 
GIP-potentiation, coupled with a prolonged half-life, emphasise prospective 
therapeutic potential of this peptide for diabetes, above all other hexapeptides 
examined. Future studies should therefore evaluate the preclinical utility of Ψ-xenin-
6 in appropriate models of diabetes, both alone and in combination with established 





Table 4.1 Amino acid sequence, HPLC retention times, MALDI-TOF MS and murine plasma stability of xenin peptides 






























Lys & Arg deletion 
(Lys20, Arg21) and 
substitution with Gln 





Lys & Arg deletion 
(Lys20, Arg21) and 
substitution with Gln 
+ C-terminal 
Amidation 





bond (between the 
Lys20 and Arg21 
amino acid residues) 
798.1 798.5 16.6 97.0 > 6 h 
Peptides were confirmed pure using HPLC and retention times recorded using ChromQuest software. Molecular masses of peptides were confirmed 


















Peptide stability was assessed following 0, 2, 4 and 6 hr incubation with plasma. Degradation products were separated using HPLC and percentage 
degradation calculated from peak area. 
 
 
Percentage Degradation (%) 
Peptide 0h 2h 4h 6h 
Xenin-6 0 53.2 85.8 88.2 
Xenin-6-NH2 0 43.4 64.9 70.3 
Xenin-6-Gln 0 54.7 65.5 66.6 
Xenin-6-Gln-NH2 0 45.9 57.4 64.3 















1.1 mmol/l Glucose + Xenin 25 [10
-6
M]
1.1 mmol/l Glucose + Xenin 6
1.1 mmol/l Glucose + Xenin 6-NH2
1.1 mmol/l Glucose + Xenin 6-Gln
1.1 mmol/l Glucose + Xenin 6-Gln-NH 2







































5.6 mmol/l Glucose + Xenin-25 [10
-6
 M]
5.6 mmol/l Glucose + Xenin 6-NH 2
5.6 mmol/l Glucose + Xenin 6-Gln
5.6 mmol/l Glucose + Xenin 6-Gln-NH 2
5.6 mmol/l Glucose + -Xenin 6
5.6 mmol/l Glucose + Xenin 6





























































16.7 mmol/l  Glucose + Xenin 25 [10
-6
M]
16.7 mmol/l  Glucose + Xenin 6
16.7 mmol/l  Glucose + Xenin 6-NH 2
16.7 mmol/l  Glucose + Xenin 6-Gln
16.7 mmol/l  Glucose + Xenin 6-Gln-NH 2


































BRIN-BD11 cells were incubated (20 min) with a range of concentrations (10-12 to 10-6 mol/l) of test peptides in the presence of (A) 1.1, (B) 5.6 
and (C) 16.7 mmol/l glucose, and insulin measured using RIA. Values represent means ± SEM (n=8). *P<0.05, **P<0.01 and ***P<0.001 






Figure 4.2 Acute effects of xenin hexapeptides in combination with GIP on insulin 
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5.6 mmol/l Glucose + GIP [10
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5.6 mmol/l Glucose + GIP [10
-6
M] + Xenin 6-Gln-NH2
5.6 mmol/l Glucose + GIP [10
-6








































BRIN-BD11 were incubated (20 min) with a range of concentrations (10-12 to 10-6 
mol/l) of test peptides in combination with GIP. Insulin was measured using RIA. 
Values represent means ± SEM (n=8). *P<0.05, **P<0.01 and ***P<0.001 compared 
to respective glucose control. ΩΩΩP<0.001 compared to xenin-6. ΦΦP<0.01, 











Figure 4.3 Acute effects of xenin hexapeptides on insulin release from isolated 







16.7 mmol/l Glucose + Xenin 25 [10
-6
M]
16.7 mmol/l Glucose + Xenin 6
16.7 mmol/l Glucose + Xenin 6-NH2
16.7 mmol/l Glucose + Xenin 6-Gln
16.7 mmol/l Glucose + Xenin 6-Gln-NH2







































Insulin release was measured in isolated mouse islets incubated (60 min) with test 
peptides (10-8 and 10-6 M) at 16.7 mmol/l glucose. Insulin was measured using RIA. 
Values represent means ± SEM (n=8). *P<0.05 and ***P<0.001 compared to 
respective glucose controls. ∆∆∆P<0.001 compared to respective xenin-25 control. 









Figure 4.4 Effects of xenin hexapeptides on LDH accumulation in BRIN-BD11 cells, as well as effects of xenin 6 and Ψ-xenin-6 on insulin 
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LDH accumulation was assessed in BRIN-BD11 cells following a 20 min incubation with 10-6 mol/l test peptides. BRIN-BD11 cells were cultured 
under glucotoxic (22.2 mmol/l glucose) culture conditions for 48 h and then incubated (20 min) with (10−6 mol/l) GIP, xenin-6 and Ψ-xenin-6 alone 
or in combination, as appropriate, in the presence of 5.6 mmol/l glucose. Insulin was measured using RIA. Values represent means ± SEM (A n=8; 
B n=4). *P<0.05, **P<0.01 and ***P<0.001 compared to respective glucose control. ΔP< 0.05 and ΔΔP< 0.01 compared to same concentration of 
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INS-1 cells were incubated (20 min) with a range of concentrations (10-12 to 10-6 mol/l) 
of test peptides in the presence of 5.6 mmol/l glucose, with insulin release measured 
using RIA. Values represent means ± SEM (n=8). *P<0.05, **P<0.01 and ***P<0.001 
compared to respective glucose controls. ∆P< 0.05 compared to xenin-25. ΩP< 0.05, 















































































































































































































































































                          
Effects of test peptides alone (10−6 mol/l) or in combination with GIP (10−6 mol/l) on glucagon secretion from (A) α-TC1.9 cells (120 min 
incubation) and (B) isolated mouse islets (60 min incubation) at 1.4 mmol/l glucose. Glucagon was measured using ELISA. Values represent 






Figure 4.7 Effect xenin hexapeptides on proliferation and protection 



















































































































































































































































































































































































































































































































(A) BRIN-BD11 and (B) 1.1B4 beta-cells were incubated overnight (18 
hours) with GLP-1, xenin-25, xenin-6, xenin-6-NH2, xenin-6-Gln, xenin-6-
Gln-NH2 or Ψ-xenin-6 (each at 10
-8 and 10-6 mol/l). Proliferation was 
measured using Ki-67 immunocytochemistry. (C,D) TUNEL positive 
apoptotic cells were assessed following 2 h exposure to a cytokine cocktail 
(IL-1β 100 U/mL, IFN-γ 20 U/mL, TNF-α 200 U/mL) with or without co-
culture in the presence of GLP-1, xenin-25, xenin-6, xenin-6-NH2, xenin-6-
Gln, xenin-6-Gln-NH2 or Ψ-xenin-6 (each at 10
-8 and 10-6 mol/l) in (C) BRIN-
BD11 and (D) 1.1B4 beta-cells. Values represent means ± SEM (n=4). For 
proliferation; *P<0.05, **P<0.01 and ***P<0.001 compared to respective 
media control. ΔΔP<0.01 and ∆∆∆P<0.001 compared to xenin-6. For apoptosis; 
*P<0.05, **P<0.01 and ***P<0.001 compared to respective media control. 








Figure 4.9 Effects of xenin hexapeptides on cumulative food intake in 18 













































































Cumulative food intake was measured in 18 h fasted mice at 30, 60, 90, 120, 
150, and 180 min after i.p. injection of saline vehicle (0.9% w/v NaCl), xenin-
25, xenin-6, xenin-6-NH2, xenin-6-Gln, xenin-6-Gln-NH2 or Ψ-xenin-6 at (A) 
25 and (B) 250 nmol/kg bw. Values represent means ± SEM (n=8). *P<0.05 
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Cumulative food intake was measured in 18 h fasted mice at 30, 60, 90, 120, 150, and 180 min after i.p. injection of saline vehicle (0.9% w/v 
NaCl), xenin-25, xenin-6, xenin-6-NH2, xenin-6-Gln, xenin-6-Gln-NH2 or Ψ-xenin-6 in combination with exendin-4 (both at 25 nmol/kg bw). 






Fig. 4.11 Effects of xenin hexapeptides on glucose and insulin concentrations in 
lean mice.  
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(A) Blood glucose and (C) plasma insulin concentrations were measured immediately 
before and 15, 30, 60 and 105 min after i.p. injection of glucose alone (18 mmol/kg 
bw) and test hexapeptides (each at 25 nmol/kg bw) in 4 h fasted mice. (B,D) Glucose 
and insulin AUC values for 0-105 min post injection. Values represent mean ± SEM 
for 6 mice. *P<0.05, **P<0.01 and ***P<0.001 compared to glucose alone. ∆∆P<0.01 









Fig. 4.12 Effects of xenin hexapeptides in combination with GIP on glucose and 
insulin concentrations in lean mice.  
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(A) Blood glucose and (C) plasma insulin concentrations were measured immediately 
before and 15, 30, 60 and 105 min after i.p. injection of glucose alone (18 mmol/kg 
bw) and combined injection of GIP and test peptides (each at 25 nmol/kg bw) in 4 h 
fasted mice. (B, D) Glucose and insulin AUC values for 0-105 min post injection. 
Values represent mean ± SEM for 6 mice. *P<0.05, **P<0.01 and ***P<0.001 








Fig. 4.13 Persistent glucose lowering effects of xenin hexapeptides in lean mice.  






















































































































































































































































































































































(A,C,E,G) Blood glucose concentrations were measured immediately before and 15, 30, 60 and 105 min following i.p. glucose load (18 mmol/kg 
bw) in 4 h fasted mice injected with saline vehicle or test peptides (each at 25 nmol/kg bw) 2 (A), 4 (C), 8 (E) or 12 h (G) previously. (B,D,F,H) 
Blood glucose AUC values for 0-105 min post injection. Values represent mean ± SEM for 6 mice. *P<0.05, **P<0.01 and ***P<0.001 compared 















A pseudohexapeptide xenin analogue, Ψ-xenin-6, augments 
the antidiabetic benefits of the DPP-4 inhibitor sitagliptin in 





















The previous chapter characterised the biological properties of an enzymatically 
stable, C-terminal hexapeptide fragment of the gut hormone xenin, namely Ψ-xenin-
6, including ability to potentiate the bioactivity of the incretin hormone GIP. Given 
that the primary therapeutic target of clinically approved DPP-4 inhibitors is 
augmentation of the incretin effect, the present study assessed the capacity of Ψ-xenin-
6 to enhance the antidiabetic efficacy of sitagliptin in high fat fed (HFF) mice. 
Individual administration of either sitagliptin or Ψ-xenin-6 alone to HFF mice for 18 
days resulted in numerous benefits including, reduced body weight gain (P<0.05), 
increased circulating and pancreatic insulin (P<0.001), improved glucose tolerance 
(P<0.01) and returning circulating glucose as well as pancreatic islet architecture 
similar to that observed in lean controls. As expected, sitagliptin therapy was 
associated with elevated circulating GIP and GLP-1 levels, with concurrent Ψ-xenin-
6 not elevating these or enhancing DPP-4 inhibitory activity of the drug. However, 
combined sitagliptin and Ψ-xenin-6 therapy in HFF mice was associated with further 
notable benefits on metabolism, beyond that observed with either treatment alone. As 
such, combination therapy resulted in body weight change similar to lean controls, 
more pronounced and rapid benefits on circulating glucose and insulin as well as 
additional improvements in attenuating gluconeogenesis. Similarly, favourable effects 
on pancreatic islet architecture and peripheral insulin sensitivity were more apparent 
with combined therapy. Furthermore, expression of hepatic genes involved in 
gluconeogenesis and insulin action, such as AKT1, FGF21, G6Pase, IRS-1 and 
PEPCK were partially, or fully restored to normal levels by treatment regimens, with 
beneficial effects being more prominent in combination treatment group. These data 





offers clear antidiabetic advantages, which merit further consideration as a potential 
therapeutic option for T2DM. 
 
5.2 INTRODUCTION 
DPP-4 inhibitors are an orally available class of drugs, clinically approved for the 
treatment of T2DM [Scott, 2017]. The primary therapeutic benefit of DPP-4 
inhibitors in T2DM relates to preventing degradation and subsequent loss of 
bioactivity, of the endogenous intestinal-derived incretin hormones, GLP-1 and GIP 
[Deacon, 2019]. Thus, GLP-1 and GIP stimulate glucose-dependent insulin secretion 
and improve glycaemic status, resulting in reduced glycated haemoglobin 
concentrations [Baggio and Drucker, 2007]. These hormones also exert a number of 
extrapancreatic actions that have beneficial glucose homeostatic effects [Baggio and 
Drucker, 2007; O’Harte et al. 1998].  
 
However, a key pathophysiological aspect of T2DM relates to an impaired incretin 
effect [Holst and Ørskov, 2004]. As such, circulating levels of GLP-1 are believed to 
be reduced in T2DM, while the insulinotropic effects of GIP are severely diminished 
[Knop et al. 2007a]. DPP-4 inhibition will increase circulating concentrations of 
biologically active GLP-1 [Ahrén, 2007], but does not correct GIP insensitivity in 
T2DM. In this regard, a related 25 amino acid gut-derived hormone known as xenin, 
has been shown to augment the biological actions of GIP in vitro and in vivo [Wice et 
al. 2010; Martin et al. 2012; Gault et al. 2015a]. In addition, xenin also independently 
stimulates insulin secretion and supresses appetite [Taylor et al. 2010; Martin et al. 
2012, 2014, 2016; Gault et al. 2015; Craig et al. 2018], which would be further 





[Taylor et al. 2010], and thus DPP-4 inhibitors do not alter circulating xenin levels. 
However, enzymatic degradation fragment peptides of xenin are present in plasma 
[Martin et al. 2012], with some of these shown to retain the parent peptide biological 
action profile [Martin et al. 2014,2016; Parthsarathy et al. 2016; Craig et al. 2019]. In 
this regard, xenin-6 appears to be the shortest xenin form that recapitulates the key 
physiological actions of xenin at the level of the endocrine pancreas [Craig et al. 
2019]. 
 
Recent studies in our laboratory [Craig et al. 2019; Chapter 4] have followed up on 
the initial characterisation of an enzymatically stabilised xenin-6 form, namely Ψ-
xenin-6 [Feurle et al. 2003]. Ψ-xenin-6 is a C-terminal hexapeptide of xenin with a 
reduced pseudopeptide bond (CH2NH) positioned between the first two N-terminal 
amino acid residues that possesses a significantly extended pharmacokinetic profile 
[Feurle et al. 2003]. Chapter 4 demonstrated that Ψ-xenin-6 stimulated insulin 
secretion from in vitro and ex vivo systems, promoted beta cell proliferation and 
survival, augmented glucose homeostasis, insulin secretion and satiety in rodents as 
well as amplifying the insulinotropic actions of GIP [Craig et al. 2019; Chapter 4]. 
Thus, combination therapy with a DPP-4 inhibitor and Ψ-xenin-6 represents an 
exciting potential therapeutic option for T2DM. Recent positive advances in the field 
of peptide hormone therapeutics and T2DM relate to the targeting of multiple receptor 
signalling pathways [Bhat et al. 2013; Irwin et al. 2015; Khajavi et al. 2017; Coskun 
et al. 2018; Frias et al. 2018]. Such strategies linked to observations of rapid remission 
of T2DM subsequent to certain types of bariatric surgeries, being directly associated 
with distinct changes in the secretion and action of numerous gut-derived peptide 





In a distinct progression from previous work reported in this thesis (Chapter 4), in the 
present chapter a novel and targeted combinational therapeutic approach, employing 
Ψ-xenin-6 administration alongside the established DPP-4 inhibitor sitagliptin has 
been created. It is hypothesised that the complementary biological actions of both 
compounds would significantly improve diabetic status beyond that observed with 
either treatment alone. Thus, the major benefit of sitagliptin in diabetes therapy 
relates specifically to GLP-1 induced effects [Bennettt, 2018], whereas Ψ-xenin-6 
will promote additional antidiabetic actions of the increased GIP levels encouraged by 
sitagliptin. As such, the primary objective was to examine therapeutic efficacy of 
18-day combined administration of Ψ-xenin-6 and sitagliptin in HFF mice. Effects 
on body weight, energy intake, circulating glucose, insulin, GIP and GLP-1 as well as 
glucose and pyruvate tolerance, peripheral insulin sensitivity, expression of key genes 
involved in liver glucose metabolism and insulin action, as well as DPP-4 activity and 
pancreatic islet morphology were assessed.  
 
5.3 MATERIALS AND METHODS 
5.3.1 Animals 
Sub chronic studies were performed using male C57BL/6 mice (10-12 weeks old). 
All animals were maintained as described previously in Sections 2.13 and 2.13.3. 
 
5.3.2 Experimental design  
Prior to commencement of sub-chronic study, a combination of high fat diet and low 
dose STZ injections were used to develop a diet-induced type 2 diabetes mellitus 
animal model with increased loss of pancreatic beta cells, as described in Section 





regimens were conducted as described in Section 2.16.1. Cumulative energy intake, 
body weight, non-fasting circulating glucose and insulin concentrations were assessed 
at regular intervals during the study. At the end of the treatment period, glucose 
tolerance (18 mmol/kg bw; i.p.; 18 h-fasted mice), insulin sensitivity (25 U/kg bovine 
insulin; i.p.; non-fasted mice) and pyruvate tolerance (2 g/kg sodium pyruvate; i.p.; 18 
h-fasted mice) were assessed. HOMA-IR, fasting glucose (mmol/L) x fasting insulin 
(mU/L) / 22.5, was also calculated as a surrogate marker of insulin resistance (for more 
detail see sections 2.16.2.1, 2.16.2.3 and 2.16.2.4). Terminal analyses included 
extraction of pancreatic tissue for determination of pancreatic insulin content (sections 
2.16.6 and 2.16.7). In addition, liver tissue was processed for hepatic gene expression 
by qPCR after total RNA extraction as described previously in sections 2.16.11 and 
2.16.12). Real-time ready qPCR target-specific primers (Roche Diagnostics, West 
Sussex, UK) included: PEPCK, G6pase, IRS-1, FGF21 and AKT1. β-actin was used 
as internal control for normalisation.  
 
5.3.3 Biochemical analysis  
Blood samples were collected as described (Section 2.15). Glucose and insulin were 
assayed as described in Sections 2.11.2 and 2.15. Total GLP-1 and GIP plasma 
concentrations were determined using specific ELISAs as described in Sections 
2.16.8. DPP‐4 activity of terminal plasma, as well as sitagliptin and Ψ-xenin-6 alone 
and in combination in vitro (both at 10-6 mol/l), was determined using a fluorometric 
assay that measures free 7‐amino‐4‐methyl‐coumarin (AMC) (Section 2.16.10).  
 
5.3.4 Statistical analysis  






5.4.1 Effects of 18-day treatment of Ψ-xenin-6, sitagliptin or a combination of 
both compounds on body weight, fluid intake, energy intake, glucose and insulin 
concentrations in HFF mice  
Increases of body weight were significantly (P<0.01 - P<0.001) reduced in HFF mice 
treated with Ψ-xenin-6, sitagliptin or a combination of both drugs by day 18, when 
compared to HFF saline controls (Figure 5.2A). Notably, in the combination 
treatment group, but not with monotherapy, percentage body weight increase was 
not significantly different from lean controls (Figure 5.2A). Water intake was 
significantly (P<0.05) reduced in all HFF treated groups on days 4, 18 and 18, when 
compared to HFF controls (Figure 5.2B). Energy intake was elevated (P<0.01 - 
P<0.001) in all HFF mice compared to lean controls, but not significantly different 
between HFF groups (Figure 5.2C). Non-fasting glucose levels were reduced to lean 
controls in a time-dependent manner by all treatments, but this was more prominent 
in combined treatment group with benefits evident from day 12 (Figure 5.3A). In 
addition, all HFF treatment groups exhibited progressive increases in insulin 
concentrations, with levels significantly (P<0.05 - P<0.001) elevated compared to 
HFF saline controls from day 7 onwards (Figure 5.3B). Moreover, in HFF mice treated 
with Ψ-xenin-6 in combination with sitagliptin, circulating insulin was not 
significantly different to lean control mice by day 18 (Figure 5.3B) and were 







5.4.2 Effects of 18-day treatment of Ψ-xenin-6, sitagliptin or a combination of 
both compounds on glucose and pyruvate tolerance, insulin sensitivity as well as 
pancreatic insulin content in HFF mice 
Treatment of HFF mice with Ψ-xenin-6, sitagliptin or a combination of both drugs for 
18 days resulted in reductions (P<0.05 - P<0.01) of individual and overall glucose 
levels when compared to saline controls following i.p. glucose load (Figure 5.4A,B). 
However, glucose disposal was still impaired in all HFF mice when compared to 
lean controls (Figure 5.4A,B). Interestingly, corresponding glucose-induced insulin 
levels were not significantly different between all groups of mice at each of the 
observed time points (Figure 5.4C). However, overall AUC insulin concentrations 
were elevated (P<0.01) in saline treated HFF mice when compared to all other 
groups (Figure 5.4D). When challenged with a pyruvate load on day 18, only 
combined treatment with Ψ-xenin-6 and sitagliptin resulted in significant decrease 
(P<0.05 - P<0.001) in glucose levels when compared to HFF controls (Figure 5.5A). 
Overall blood glucose AUC values were reduced (P<0.05 - P<0.001) by all treatment 
interventions, but still elevated (P<0.01 - P<0.001) when compared to lean control 
mice (Figure 5.5B). However, combination treatment was significantly reduced 
(P<0.05) when compared to sitagliptin monotherapy (Figure 5.5B). Peripheral 
insulin sensitivity was improved (P<0.05 - P<0.001) by all treatment interventions 
(Figure 5.6A,B), although administration of sitagliptin alone, or in combination with 
Ψ-xenin-6, resulted in similar glucose-lowering effects of exogenous insulin as 
observed in lean mice (Figure 5.6A,B). HOMA-IR was also significantly (P<0.05 - 
P<0.01) improved in all HFF treatment groups, and not different from lean control 





HFF treatment groups, and significantly elevated (P<0.001) when compared to saline 
treated HFF mice (Figure 5.6D). 
 
5.4.3 Effects of 18-day treatment of Ψ-xenin-6, sitagliptin or a combination of 
both compounds on pancreatic islet histology in HFF mice  
Images of pancreatic islets stained for insulin and glucagon from all groups of mice 
are shown in Figure 5.7A-E. Visual inspection of these images illustrates marked 
reduced insulin staining in HFF saline treated mice when compared to lean controls 
(Figure 5.7A,B). Following appropriate quantification, it was revealed that HFF saline 
mice had significantly reduced overall islet (P<0.05) and beta cell (P<0.01) areas when 
compared to lean controls (Figure 5.8A,B). All treatment interventions returned islet 
and beta cell area to normal levels (Figure 5.8A,B). Alpha cell area was increased in 
HFF saline (P<0.001) and sitagliptin (P<0.05) treated mice, but similar to lean 
controls in HFF mice treated with Ψ-xenin-6 alone, or in combination with sitagliptin 
(Figure 5.8C).  
 
Beta to alpha cell ratios were significantly (P<0.001) increased by all treatments 
when compared to HFF controls, and by Ψ-xenin-6 alone or in combination with 
sitagliptin, when compared to sitagliptin alone (P<0.001), but still reduced (P<0.001) 
when compared to lean control mice (Figure 5.8D). Islet size distribution was 
comparatively similar in all groups of mice, but all HFF mice administered treatment 
did have reduced (P<0.05 - P<0.01) numbers of smaller sized islets when compared 






5.4.4 Effects of 18-day treatment of Ψ-xenin-6, sitagliptin or a combination of 
both compounds on expression of hepatic genes involved in gluconeogenesis and 
insulin action in HFF mice  
As expected, high fat feeding increased (P<0.01 and P<0.05, respectively) hepatic 
expression of PEPCK and G6pase (Figure 5.9A,B). All treatment interventions 
significantly (P<0.05) reduced pEpCK mRNA levels (Figure 5.9A), but only 
combined Ψ-xenin-6 and sitagliptin therapy reduced (P<0.05) G6pase expression, 
and returned expression of both genes to lean control levels (Figure 5.9A,B). In 
addition, IRS-1 hepatic expression levels were increased (P<0.01) in all HFF 
treatment groups when compared to saline controls (Figure 5.9C). Interestingly, only 
combination therapy increased (P<0.001) FGF21, and decreased (P<0.01) AKT1, 
hepatic mRNA levels compared to HFF control mice (Figure 5.9D,E). Indeed, 
expression levels of both genes were similar to lean control mice in the combined 
Ψ-xenin-6 and sitagliptin treatment group (Figure 5.9D,E).  
 
5.4.5 Effects of 18-day treatment of Ψ-xenin-6, sitagliptin or a combination of 
both compounds on GLP‐1 and GIP concentrations as well as DPP-4 activity in 
HFF mice 
Following the 18-day treatment regimen, all sitagliptin treated mice had significantly 
(P<0.01 and P<0. 001) increased circulating total GIP concentrations (Figure 5.10B). 
Interestingly, Ψ-xenin-6 therapy also increased (P<0.01) GIP levels, but did not affect 
GLP-1 concentrations (Figure 5.10A,B). However, the combination treatment group 
did not present with GIP levels greater than with those with sitagliptin therapy alone 
(Figure 5.10B). High fat feeding reduced (P<0.001) circulating GLP-1, but this was 





Plasma DPP-4 activity was significantly (P<0.05) reduced in all HFF mice treated 
with sitagliptin when compared to HFF controls (Figure 5.10C). DPP-4 activity in Ψ-
xenin-6 treatment group was not significantly altered when compared to lean or high 
fat control mice (Figure 5.10C). To confirm in vivo observations, DPP-4 activity of 
sitagliptin, Ψ-xenin-6 and a combination of both compounds was evaluated in the in 
vitro setting (Figure 5.10D). In harmony with data from our mouse study, Ψ-xenin-
6 (10-6 mol/l) had no effect on DPP-4 activity and did not augment sitagliptin-induced 
reductions of DPP-4 activity (Figure 5.10D).  
 
5.5 DISCUSSION 
Although DPP-4 inhibitors have undoubted therapeutic benefits in T2DM [Elrishi et 
al. 2007], their overall efficacy is perhaps less striking than other clinically approved 
drugs [Rosenstock et al. 2010]. Taking into consideration that the primary 
pharmacological benefit of DPP-4 inhibition is enhancement of the incretin effect 
[Gallwitz, 2013], known to be severely perturbed in T2DM [Nauck et al. 1993], this 
is perhaps not overly surprising. In the current chapter, we sought to address this 
problem through concurrent administration of the DPP-4 inhibitor, sitagliptin, with 
the enzymatically stable xenin form, Ψ-xenin-6 [Feurle et al. 2003]. Ψ-xenin-6 
represents a compound known to correct the underlying incretin defect in T2DM, 
specifically GIP insensitivity [Craig et al. 2019], as outlined in chapter 4. 
 
As would be expected, sitagliptin and Ψ-xenin-6 therapy induced a number of 
benefits on metabolism in HFF mice. This is interesting, given that Ψ-xenin-6 was 
administered at a reduced molar concentration when compared to sitagliptin, and 





intervention. Such benefits included reduced glucose levels as well as improved 
glucose tolerance and insulin sensitivity, with notable improvements in pancreatic 
islet architecture. Indeed, assessment of peripheral insulin sensitivity would have 
been even more positive, but for normal adaptive responses in these mice to prevent 
glucose concentrations falling towards life threatening hypoglycaemia levels, 
following exogenous insulin injection. As expected, positive effects of sitagliptin 
were linked to elevated circulating GIP and GLP-1 concentrations [Deacon et al. 
1998]. Interestingly, Ψ-xenin-6 also increased GIP levels, which may be somewhat 
unexpected. As such, the secretory dynamics of intestinal K-cells are well established 
[Gribble and Reimann, 2019], although whether xenin exerts a positive autocrine 
effect on GIP secretion from K-cells is currently unknown. More importantly, elevated 
GIP and GLP-1 concentrations of the combined treatment group were not greater than 
with sitagliptin alone, confirming that benefits of combination therapy are not linked 
to increased incretin hormone levels. 
 
Despite administration of the specific beta cell toxin STZ, each of the treatments, 
namely sitagliptin, Ψ-xenin-6 or a combination of both compounds, returned overall 
islet and beta cell areas, as well as pancreatic insulin content, to normal levels. It is 
intriguing to note that in a related HFF mouse model with STZ-induced defects of 
insulin secretion, similar benefits of pancreatic islet architecture were noted 
following sustained administration of an analogue of sitagliptin, namely des-fluoro-
sitagliptin [Mu et al. 2006]. Notably, in this study by Mu and co-workers, des-fluoro-
sitagliptin was administered for 11 weeks in the diet, as opposed to 18 days oral 
gavage in the current study. Thus, the oral gavage route ensures consistent dosing, 





supplemented animal diets. Whether augmented pancreatic insulin content in the 
current study was due to increases in beta-cell proliferation, reductions of beta cell 
apoptosis or increased insulin production within beta cells still needs to be 
determined. However, the beneficial impact of such pancreatic changes was clearly 
apparent on circulating insulin concentrations, with steady augmentations being 
evident in the combined treatment group. In keeping with this, GIP, GLP-1 and xenin 
have been shown to independently stimulate insulin secretion [Schmidt et al. 1985; 
Taylor et al. 2010], as well as promote pancreatic beta cell growth and survival 
[Vilsbøll and Holst, 2004; Drucker, 2006; Khan et al. 2017a]. In addition to this, 
intra-islet synthesis and secretion of GLP-1 has previously been shown to play a 
fundamental role in appropriate pancreatic islet adaptations to various diabetes-like 
disease states [Vasu et al. 2014b; Moffett et al. 2014]. As such, it would have been 
interesting to assess pancreatic islet levels of both GLP-1 and GIP in the current 
study. Nonetheless, dual treatment with sitagliptin and Ψ-xenin-6 evoked rapid 
improvements in glycaemic status, beyond that observed with either treatment alone. 
Such benefits were more apparent in the fed, as opposed to fasted state, as evidenced 
during glucose tolerance testing that revealed no differences between the treatment 
regimens. This could simply be a consequence of the primary metabolic benefits of 
GIP, GLP-1 and xenin being more associated with the postprandial setting 
[Chowdhury et al. 2013; Irwin and Flatt, 2015].  
 
Although benefits on circulating insulin and pancreatic morphology were evident, 
none of the treatments increased the insulin response to exogenous glucose on day 18. 
Furthermore, there was a significant improvement in peripheral insulin sensitivity in 





solely a result of pancreatic-related benefits, and could be related to the weight loss 
induced by each treatment. Indeed, hepatic expression of IRS-1 was augmented to a 
similar level by all treatment interventions. Moreover, combined sitagliptin and Ψ-
xenin-6 therapy also increased FGF21 expression in the liver and returned mRNA 
levels of hepatic AKT1 to that of lean controls, both of which would improve insulin 
action [Kim et al. 2000; Emanuelli et al. 2014]. However, whether these positive 
changes in gene expression are independent of body weight loss still needs to be 
determined. In keeping with insulin action, hepatic gluconeogenesis was decreased in 
all treatment groups, but particularly by combined therapy, as established through 
assessment of pyruvate tolerance. In this respect, hyperinsulinaemic clamp studies 
may have given a more consistent readout of hepatic glucose production, but are 
beyond the scope of the current study. Nonetheless, irregular carbohydrate metabolism 
and inappropriate pyruvate flux are well known to be associated with diabetes and 
obesity [Gao et al. 2009; Singla et al. 2010]. To further support the notion that 
sitagliptin and Ψ-xenin-6 diminish hepatic gluconeogenesis, we determined 
expression of PEPCK and G6pase in liver tissue, key signalling molecules in the 
gluconeogenesis pathway [Lochhead et al. 2000]. As such, PEPCK and G6Pase are 
fundamental in the initial and final steps, respectively, of the gluconeogenic pathway 
[Hers and Hue, 1983]. Only combined sitagliptin and Ψ-xenin-6 treatment 
significantly reduced expression of both genes, and although some obvious restraint 
is required in interpretation especially since individual treatments also evoked 
reductions in the expression of these genes, this does suggest that the expression and 
subsequent biological function of these proteins could be a major factor in the 
improvement of gluconeogenesis. In addition, it would also have been interesting to 





flux. Moreover, assessment of related protein expression would be required to confirm 
overall relevance of the observed changes in gene expression. 
 
Despite knowledge of the weight neutral effects of DPP-4 inhibitors [Foley and 
Jordan, 2010], as well as lack of effect of prolonged administration of enzymatically 
stable versions of xenin on body weight in diabetic mice [Gault et al. 2015a; Martin 
et al. 2016; Parthsarathy et al. 2016], both sitagliptin and Ψ-xenin-6 reduced body 
weight gain in the current setting. Moreover, combined treatment in HFF mice resulted 
in body weight change that was not different to lean controls, despite similar energy 
intake in all groups of HFF mice. In keeping with this, lack of effect of sitagliptin and 
xenin peptides on feeding has previously been observed in rodents using the same 
dosing regimens employed here [Taylor et al. 2010; Gault et al. 2015b; Hasib et al. 
2017]. In view of the role of obesity in the development of T2DM [Al-Goblan et al. 
2014], and the comparable increasing prevalence of both conditions [Agha and Agha, 
2017], this more pronounced body weight lowering effect could represent an attractive 
therapeutic effect of combined therapy. As such, it is well recognised that the central 
pathways controlling energy balance display notable plasticity [Irwin and Flatt, 2015], 
thus concurrent positive modulation of signal transduction proteins linked to both 
compounds may be essential to yield such appreciable benefits. A reduction of body 
weight could also be a contributing factor to improved metabolic effects of the 
combination treatment [Wilding, 2014], although further assessment of body 
composition, locomotor activity and metabolic rate, including energy expenditure, 






Taken together, data presented within the current study supports the view that the 
antidiabetic benefits of DPP-4 inhibitors can be augmented. Importantly, assessment 
of DPP-4 activity on day 18, together with in vitro observations, demonstrated that Ψ-
xenin-6 does not augment DPP-4 inhibitory activity of sitagliptin. Given that incretin 
hormone levels were also not increased by dual administration of Ψ-xenin-6 and 
sitagliptin, it suggests that the likely benefit of combined therapy is linked to the 
augmentation of GIP bioactivity by Ψ-xenin-6, as has been previously established 
[Craig et al. 2019]. Observations of improved effects of combined Ψ-xenin-6 and 
sitagliptin treatment on body weight, circulating glucose and insulin, attenuation of 
gluconeogenesis, as well as improvements in pancreatic islet morphology are 
encouraging, especially over a relatively short treatment period of 18 days. Clinical 
studies already confirm some enhanced antidiabetic efficacy when using 
combinational therapies that incorporate DPP-4 inhibitor drugs [Goldstein et al. 
2007; Barnett et al. 2015], in line with NICE treatment guidelines, corroborating 
proof-of-concept. Taking into account that Ψ-xenin-6 positively regulates the primary 
therapeutic target of DPP-4 inhibitors, unlike other available antidiabetic medications; 
the current therapeutic regimen represents an attractive novel option for T2DM that 















Streptozotocin (STZ) treatment: Two low dose STZ injections (50 mg/kg bw & 75 mg/kg bw, i.p, in sodium citrate buffer, pH 4.5) at one week 
intervals 
Treatments started on Day 0 (n=8); 
Group 1 (Lean control) – Lean control mice on normal diet received saline vehicle (0.9% w/v NaCl, i.p.) for 18 days  
Group 2 (HFF control) – HFF saline vehicle (0.9% w/v NaCl, i.p.) for 18 days  
Group 3 (Sitagliptin) – HFF Sitagliptin (50 mg/kg bw, p.o, once daily) for 18 days  
Group 4 (Ψ-xenin-6) – HFF Ψ-xenin-6 (25 nmol/kg bw, i.p., twice daily) for 18 days  
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Treatment regimen stopped and 
terminal analysis commenced  
Metabolic parameters assessed 





Figure 5.2 Effects of 18-day treatment with Ψ-xenin-6, sitagliptin or a combination of both compounds on (A) body weight, (B) water 



































































































































Parameters were measured during 18-days treatment with sitagliptin (50 mg/kg bw, p.o., once daily), Ψ-xenin-6 (25 nmol/kg bw. i.p., twice daily) 
or a combination of both compounds using the same dosing regimens. Values are mean ± SEM for eight mice. *P<0.05, **P<0.01 and ***P<0.001 


























Figure 5.3 Effects of 18-day treatment with Ψ-xenin-6, sitagliptin or a combination of both compounds on (A) glucose and (B) insulin 
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Parameters were measured during 18-day treatment with sitagliptin (50 mg/kg bw, p.o., once daily), Ψ-xenin-6 (25 nmol/kg bw. i.p. twice daily) 
or a combination of both compounds using the same dosing regimens. Values are mean ± SEM for eight mice. *P<0.05, **P<0.01 and ***P<0.001 
compared to lean controls. ∆P<0.05, ∆∆P<0.01 and ∆∆∆P<0.001 compared to HFF saline controls. ΩP<0.05 compared to sitagliptin alone. ϕP<0.05 







Figure 5.4 Effects of 18-day treatment with Ψ-xenin-6, sitagliptin or a 
combination of both compounds on glucose tolerance and insulin secretion in 
HFF mice. 
 
















































































































































Parameters were assessed following 18 days treatment with sitagliptin (50 mg/kg bw, 
p.o., once daily), Ψ-xenin-6 (25 nmol/kg bw. i.p. twice daily) or a combination of both 
compounds using the same dosing regimens. Glucose (18 mmol/kg bw) was 
administered by i.p. injection at t=0 min in 18 hour fasted mice. Glucose and insulin 
AUC values for 0–60 min post injection are also shown. Values are mean ± SEM for 
eight mice. *P<0.05, **P<0.01 and ***P<0.001 compared to lean controls. ∆P<0.05 





Figure 5.5 Effects of 18-day treatment with Ψ-xenin-6, sitagliptin or combination 
of both compounds on pyruvate tolerance in HFF mice. 





















































































Parameters were assessed following 18-days treatment with sitagliptin (50 mg/kg bw, 
p.o., once daily), Ψ-xenin-6 (25 nmol/kg bw. i.p. twice daily) or a combination of both 
compounds using the same dosing regimens. (A) Pyruvate (2 g/kg bw sodium 
pyruvate) was administered by i.p. injection at t=0 min in 18 hour fasted mice. (B) 
Blood glucose AUC values for 0–120 min post injection are shown. Values are mean 
± SEM for eight mice. *P<0.05, **P<0.01 and ***P<0.001 compared to lean controls. 
∆P<0.05, ∆∆P<0.01 and ∆∆∆P<0.001 compared to HFF saline controls. ΩP<0.05 





Figure 5.6 Effects of 18-day treatment with Ψ-xenin-6, sitagliptin or a 
combination of both compounds on insulin sensitivity and pancreatic insulin 
content in HFF mice.  






































































































































































Parameters were assessed following 18-days treatment with sitagliptin (50 mg/kg bw, 
p.o., once daily), Ψ-xenin-6 (25 nmol/kg bw. i.p. twice daily) or a combination of both 
compounds using the same dosing regimens. (A) Insulin (25 U/kg bw) was 
administered by i.p. injection at t=0 min in non-fasted mice. (B) Blood glucose AAC 
values for 0–60 min post injection. (C) HOMA-IR was calculated by the following 
equation: fasting glucose (mmol/L) x fasting insulin (mU/L) / 22.5. (D) Pancreatic 
insulin content was measured by RIA following acid-ethanol extraction. Values are 
mean ± SEM for eight mice. *P<0.05 and ***P<0.001 compared to lean saline 
controls. ∆P<0.05 and ∆∆∆P<0.001 compared to HFF saline controls. ϕϕP<0.01 












Images (20X) were captured following 18-days treatment with sitagliptin (50 mg/kg bw, p.o., once daily), Ψ-xenin-6 (25 nmol/kg bw. i.p., twice 
daily) or a combination of both compounds using the same dosing regimens. Pancreatic islet images show insulin (red) and glucagon (green) 
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Medium islets (10,000 m2- 25,000 m2)



































Parameters were assessed following 18-days treatment with sitagliptin (50 mg/kg bw, p.o., once daily), Ψ-xenin-6 (25 nmol/kg bw. i.p. twice daily) 
or a combination of both compounds using the same dosing regimens. (A) Islet, (B) beta- and (C) alpha-cell areas, as well as (D) beta:alpha area 
cell area ratio and (E) islet size distribution were measured using CellF image analysis software. Values are mean ± SEM for eight mice. *P<0.05, 
**P<0.01 and ***P<0.001 compared to lean controls. ∆P<0.05, ∆∆P<0.01 and ∆∆∆P<0.001 compared to HFF saline controls. ΩΩΩP<0.001 compared 




























































































































































































































Expression was assessed following 18-days treatment with sitagliptin (50 mg/kg bw, p.o., once daily), Ψ-xenin-6 (25 nmol/kg bw. i.p., twice daily) 
or a combination of both compounds using the same dosing regimens. mRNA expression of (A) phosphoenolpyruvate carboxykinase (PEPCK), 
(B) glucose 6-phosphatase (G6pase), (C) insulin receptor substrate-1 (IRS-1), (D) fibroblast growth factor 21 (FGF21) and (E) serine-threonine 
protein kinase (AKT1) were determined relative to control gene expression (β‐actin). Values are mean ± SEM for eight mice. *P<0.05, **P<0.01 
and ***P<0.001 compared with lean controls. ∆P<0.05, ∆∆P<0.01 and ∆∆∆P<0.001 compared to HFF saline controls. ΩΩP<0.01 compared to 





Figure. 5.10 Effects of Ψ-xenin-6, sitagliptin or a combination of both compounds 
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(A-C) Parameters were assessed following 18 days treatment with sitagliptin (50 
mg/kg bw, p.o., once daily), Ψ-xenin-6 (25 nmol/kg bw. i.p., twice daily) or a 
combination of both compounds using the same dosing regimens. Total plasma (A) 
GLP‐1 and (B) GIP concentrations in plasma were determined using commercially 
available ELISA kits. (C) DPP‐4 activity was measured in plasma using established 
procedures (Lindsay et al. 2005). (D) DPP-4 activity of all test compounds (10-6 mol/l) 
was also determined in the in vitro setting. Values are mean ± SEM for (A-C) eight 
mice or (D) four experimental replicates. *P<0.05, **P<0.01 and ***P<0.001 
compared with lean or vehicle controls, as appropriate. ∆P<0.05, ∆∆P<0.01 and 
∆∆∆P<0.001 compared to HFF saline controls. ΩP<0.05 and ΩΩΩP<0.001 compared to 

















Combined modulation of TNP-470 with sitagliptin results in 
rapid restoration of normoglycaemia and enhances 















The therapeutic mechanism of methionine aminopeptidase 2 (MetAP2) inhibitors for 
obesity-diabetes has not yet been fully defined. Xenin, a K-cell derived peptide 
hormone, possesses an N-terminal Met amino acid residue and sub-chronic parenteral 
administration of long-acting xenin analogues improves obesity-diabetes. Thus, 
elevated xenin levels could represent a potential pharmacological mechanism of 
MetAP2 inhibitors. The present study examined the ability of the MetAP2 inhibitor, 
TNP-470, to augment the antidiabetic utility of the DDP-4 inhibitor, sitagliptin, in high 
fat fed (HFF) mice. TNP-470 (1 mg/kg) and sitagliptin (25 mg/kg) were administered 
once-daily alone, or in combination, to HFF mice for 18 days. Individual therapy with 
TNP-470 or sitagliptin resulted in numerous metabolic benefits including reduced 
(P<0.05 - P<0.001) glucose, increased (P<0.01 - P<0.001) circulating and pancreatic 
insulin and improved (P<0.05 - P<0.001) glucose tolerance, insulin sensitivity, 
pyruvate tolerance and pancreatic islet architecture. Further assessment of metabolic 
rate revealed that all treatments reduced (P<0.01) RER and increased (P<0.05 - 
P<0.01) locomotor activity, with energy expenditure increased (P<0.05 - P<0.01) in 
all mice receiving sitagliptin therapy. In addition, treatment with TNP-470 alone, or 
in combination with sitagliptin, reduced (P<0.05 - P<0.01) food intake and body 
weight, as well as elevating (P<0.01) plasma and intestinal xenin. Importantly, 
combined sitagliptin and TNP-470 therapy was associated with further significant 
(P<0.05) benefits beyond that observed by either treatment alone. This included more 
rapid restoration of normoglycaemia, superior glucose tolerance, increased circulating 
GIP concentrations and enhanced beta:alpha cell ratio. These data demonstrate that 
TNP-470 increases plasma and intestinal xenin levels, and augments the antidiabetic 






Chapter 5 demonstrated that the therapeutic efficacy of sitagliptin can be augmented 
through combination therapy with ψ-xenin-6. Sitagliptin, the first clinically approved 
DPP-4 inhibitor, is a highly selective and potent, orally available drug for the 
management of T2DM [Scott, 2017]. The primary pharmacological mechanism of 
sitagliptin concerns blocking DPP-4 mediated degradation, and subsequent loss of 
bioactivity, of the two incretin hormones, namely GLP-1 and GIP [Drucker, 2007b]. 
As such, a reduced postprandial insulinotropic incretin effect is a recognised 
significant physiopathological aspect of T2DM [Holst et al. 2011b]. Suggestions for 
this diminished incretin effect include reduced circulating GLP-1 levels, as well as 
blunted insulinotropic effects of GIP [Knop et al. 2007b]. DPP-4 inhibitors increase 
circulating levels of GLP-1 [Omar and Ahrén, 2014], with subsequent stimulation of 
insulin secretion and inhibition of glucagon secretion, as well as enhancing glucose 
utilisation and reducing hepatic glucose production [Omar and Ahrén, 2014]. 
However, this class of drug fails to correct the insensitivity of GIP in T2DM. Thus, it 
would be favourable if the biological actions of GIP were potentiated in DPP-4 related 
therapies, especially since recent observations reveal significant complimentary 
beneficial antidiabetic actions of these two hormones [Portron et al. 2017; Frias et al. 
2018; Bastin and Andreelli, 2019].  
 
In this respect, xenin, a peptide hormone secreted postprandially from the same 
intestinal K-cells as GIP, has been shown to augment GIP-mediated insulinotropic 
responses [Wice et al. 2010; Taylor et al. 2010; Martin et al. 2012, 2014; Parthsarathy 
et al. 2016; Craig et al. 2019]. As with GIP and GLP-1, a major problem with clinical 





degradation [Martin et al. 2014]. However, there is a relative dearth of information 
regarding the enzyme(s) responsible for degradation of xenin [Taylor et al. 2010; 
Martin et al. 2014]. With this in mind, methionine aminopeptidase 2 (MetAP2) is a 
cytosolic metalloenzyme that catalyses hydrolytic removal of N-terminal methionine 
(Met) residues from nascent proteins [Varland et al. 2015]. As such, xenin is a peptide 
hormone that possess an N-terminal Met amino acid residue [Martin et al. 2016]. More 
interestingly, orally available MetAP2 inhibitors have already been generated, such as 
TNP-470 [Kusaka et al. 1991; Kruger and Figg, 2000], with demonstrated therapeutic 
efficacy for obesity and T2DM [Sin et al. 1997; Bråkenhielm et al. 2004; White et al. 
2012; Joharapurkar et al. 2014]. Intriguingly, this accords well with the established 
metabolic advantages of sustained xenin administration in animal models of T2DM 
[Gault et al. 2015a; Martin et al. 2016; Craig et al. 2019], implying that benefits of 
MetAP2 inhibition in diabetes could partly be due to enhanced xenin bioactivity. As 
such, combinational therapy with a DPP-4 inhibitor, such as sitagliptin, and a MetAP2 
inhibitor like TNP-470, could represent a highly effective therapeutic strategy for 
T2DM. DPP-4 inhibition will augment circulating GIP and GLP-1 levels, whilst 
MetAP2 inhibition should help to re-establish the biological actions of GIP through 
increasing circulating xenin concentrations. Although peptidic, long-acting, 
enzymatically resistant forms of GIP, GLP-1 and xenin have been characterised 
[Gupta, 2013; Tatarkiewicz et al. 2014; Gault et al. 2015a; Craig et al. 2019], these 
require parenteral administration, whereas enzyme inhibitors are orally available 
which should enhance patient compliance.  
 
Therefore, in the current study a novel treatment paradigm, through co-





hypothesised that the biological efficacy of combined administration should 
outweigh the benefits of either treatment alone. Effects on body weight, food and 
water intake, circulating glucose and insulin, glucose and pyruvate tolerance, insulin 
sensitivity were investigated following 18-days treatment in HFF mice. Impact of 
the treatment regimens on plasma GIP, GLP-1 and xenin as well as intestinal xenin 
levels, locomotor activity and metabolic rate were also examined. 
 
6.3 MATERIALS AND METHODS 
6.3.1 Animals 
Sub chronic studies were performed using male C57BL/6 mice (10-12 weeks old). 
All animals were maintained as described previously in Sections 2.13 and 2.13.3. 
 
6.3.2 Experimental design  
Figure 6.1 shows experimental timeline for this study. Animal model was derived as 
described in section 2.13.3. Treatment regimens were conducted as described in 
section 2.16.1. At regular intervals during the study, cumulative food and water intake, 
body weight, circulating glucose and insulin levels were assessed (Section 2.16.1). In 
addition, on day 18, locomotor activity and metabolic rate were assessed as described 
in Section 2.16.4. At the end of the treatment period, glucose tolerance (18 mmol/kg 
bw; i.p.; 18 h-fasted mice), insulin sensitivity (25 U/kg bovine insulin; i.p.; non-fasted 
mice) and pyruvate tolerance (2 g/kg sodium pyruvate; i.p.; 18 h-fasted mice) were 
assessed (Sections 2.16.2.1, 2.16.2.3 & 2.16.2.4). HOMA-IR was calculated as a 
surrogate marker of insulin resistance (Section 2.16.2.4). Terminal analyses included 





extraction of intestinal tissue for determination of xenin concentrations (Section 
2.16.6, 2.16.7 & 2.16.9). 
 
6.3.3 Biochemical analysis  
Blood samples were collected as described in Section 2.15. Glucose and insulin were 
assayed as described in Sections 2.11.2 and 2.15. Assessment of GIP, GLP-1 and xenin 
concentrations were carried out as described in Sections 2.16.8 & 2.16.9.  
 
6.3.4 Statistical analysis  
Statistical analysis was completed using GraphPad PRISM (Version 5) as described 
in Section 2.18.  
 
6.4 RESULTS 
6.4.1 Effects of TNP-470, sitagliptin or a combination of both compounds on body 
weight, energy and fluid intake, glucose and insulin concentrations in HFF mice  
Treatment for 18 days with TNP-470 alone, or in combination with sitagliptin, 
significantly reduced percentage body weight gain (P<0.001) and cumulative energy 
intake (P<0.05 - P<0.001) in HFF, when compared to both saline controls and 
sitagliptin treated mice (Figure 6.2A, B). Only TNP-470 treatment alone affected 
fluid intake, with significant (P<0.01 - P<0.001) reductions from day 14 onwards 
compared to HFF controls (Figure 6.2C). Non-fasting glucose concentrations were 
reduced (P<0.05 - P<0.01) in a time-dependent manner by all treatment regimens, 
although significant (P<0.05) benefits on day 4 were only evident in the combined 





circulating insulin concentrations, being significantly (P<0.05 - P<0.001) elevated 
compared to HFF saline controls from day 11 onwards (Figure 6.3B) 
 
6.4.2 Effects of TNP-470, sitagliptin or a combination of both compounds on 
glucose and pyruvate tolerance, insulin sensitivity as well as pancreatic insulin 
content in HFF mice 
Following a glucose load, all HFF mice treated with TNP-470, sitagliptin or a 
combination of both drugs displayed reductions (P<0.05 - P<0.001) in individual 
and overall glucose concentrations (Figure 6.4A, B). Notably, overall AUC glucose 
in the combined treatment group were significantly (P<0.05) reduced compared to 
either treatment alone (Figure 6.4B). Corresponding glucose-induced insulin 
concentrations were significantly (P<0.05 - P<0.01) reduced by all treatment groups 
at 30 and 60 min post-injection compared to HFF controls (Figure 6.4C). Overall 
insulin AUC values were accordingly decreased by TNP-470 alone (P<0.05), and to 
a significantly greater degree (P<0.05) in the combined treatment group (Figure 
6.4D). Following a pyruvate load, TNP-470 monotherapy resulted in significant 
(P<0.05 - P<0.001) decreases in glucose levels compared to HFF saline controls (15 
and 30 min), with combined group displaying significant (P<0.05) reductions at 15 
min post-injection (Figure 6.5A). Overall AUC glucose values were reduced (P<0.01 
- P<0.001) by all treatment groups, with TNP-470 and combined treatment 
interventions also inducing reductions (P<0.001 and P< 0.05, respectively) when 
compared to sitagliptin alone (Figure 6.5B). Sitagliptin therapy alone, and in 
combination with TNP-470, significantly improved (P<0.01) peripheral insulin 
sensitivity following a bolus insulin injection (Figure 6.6A). Interestingly, HOMA-





compared to controls (Figure 6.6B), whereas pancreatic insulin content was 
significantly (P<0.01 - P<0.001) elevated (Figure 6.6C). 
 
6.4.3 Effects of TNP-470, sitagliptin or a combination of both compounds on total 
GIP, total GLP-1 and xenin levels in HFF mice 
Following 18-day treatment regimen, only the combined treatment approach resulted 
in significantly (P<0.05) elevated total plasma GIP concentrations (Figure 6.7A). 
However, all sitagliptin treated mice had significantly (P<0.05) increased total GLP-
1 plasma levels on day 18 (Figure 6.7B). Plasma xenin levels were significantly 
(P<0.05 - P<0. 01) increased in all HFF groups of mice treated with TNP-470 (Figure 
6.7C). Similar to this, only TNP-470 treatment augmented (P<0. 01) intestinal xenin 
concentrations (Figure 6.7D).   
 
6.4.4 Effects of TNP-470, sitagliptin or a combination of both compounds on islet 
histology in HFF mice  
Images of pancreatic islets stained for insulin and glucagon from all groups of mice 
are shown in Figure 6.8 A-D, with visible increases of islet area in all treatment groups. 
Indeed, following appropriate quantification, it was confirmed that all treatment 
groups had significantly (P<0.05 and P<0. 01) increased overall islet and beta cell 
areas when compared to HFF controls (Figure 6.8E,F). Alpha cell area was decreased 
(P<0.001) by all treatment regimens (Figure 6.8G). Consequently, beta to alpha cell 
ratios were significantly (P<0.001) increased by all treatment interventions (Figure 
6.8H), with combined treatment inducing further significant (P<0.05) increase in 






6.4.5 Effects of TNP-470, sitagliptin or a combination of both compounds on O2 
consumption, CO2 production, respiratory exchange ratio (RER), energy 
expenditure (EE), cumulative food intake and locomotor activity in high fat fed 
mice 
Following 18-days treatment with TNP-470, sitagliptin or TNP-470 in combination 
with sitagliptin, mice (n=6) were placed in CLAMS metabolic chambers, with effects 
on metabolic rates and locomotor activity recorded for 21 h. None of the treatment 
groups displayed any significant effects on O2 consumption or CO2 production on day 
18 (Figure 6.9 & 6.10). In addition, there were no differences between the groups of 
HFF mice in terms of RER during the light phase (Figure 6.11A). However, all 
treatments significantly (P<0.01) reduced RER during the dark phase (Figure 6.11B). 
Energy expenditure was significantly (P<0.01) increased by sitagliptin during the light 
phase, and by sitagliptin alone (P<0.01), and when combined with TNP-470 (P<0.05), 
during the dark phase (Figure 6.12A,B). During this 21 h CLAMS analysis, 
cumulative food intake was significantly reduced by TNP-470 alone and the combined 
treatment group (Figure 6.13A,B). There were no changes in ambulatory locomotor 
activity, as assessed by X-beam breaks, between groups of mice during the light phase 
(Figure 6.14A). However, ambulatory activity was significantly (P<0.05 and P<0. 01) 
increased in all treatment groups during dark phase (Figure 6.14B). Rearing events, as 
assessed by Z-beam breaks, were similar in both treatment and control HFF groups of 
mice during light phase (Figure 6.14C). Treatment with TNP-470 alone, or in 
combination with sitagliptin, significantly (P<0.05 - P<0.01) reduced Z-beam breaks 








The primary mechanism of action of DPP-4 inhibitors is augmentation of the incretin 
effect, known to be severely compromised in patients with T2DM [Knop et al. 2007b]. 
Whilst elevation of circulating GLP-1 concentrations by DPP-4 inhibitors has 
established benefits in T2DM [Gallwitz, 2007], there is a well-characterised 
insensitivity to the biological actions of GIP in this disease [Vilsbøll et al. 2002]. Thus, 
incorporating strategies to enhance GIP bioactivity when administering DPP-4 
inhibitors could represent an extremely attractive therapeutic strategy. Such an 
approach holds even more merit given observations of significant complimentary 
beneficial antidiabetic actions of GIP and GLP-1 in T2DM patients [Portron et al. 
2017; Frias et al. 2017, 2018]. Based on this premise, and the promising results 
displayed in chapter 5, the present study has integrated DPP-4 and MetAP2 inhibition, 
utilising established knowledge that xenin can potentiate the biological actions of GIP 
[Wice et al. 2010, 2012; Taylor et al. 2010; Chowdhury et al. 2014; Martin et al. 
2014], together with the likelihood that part of the antidiabetic benefits of MetAP2 
inhibitors are linked to inhibition of xenin degradation.  
 
Treatment with sitagliptin or TNP-470 alone induced various metabolic benefits in 
HFF mice. Such improvements included substantially reduced glucose concentrations, 
as well as improved glucose and pyruvate tolerance in addition to increased plasma 
and pancreatic insulin concentrations. These metabolic benefits were associated with 
notable improvements in islet morphology, which is particularly noteworthy given that 
the HFF mice were also administered STZ, a recognised beta cell toxin [Lenzen, 
2008]. Positive effects are even more encouraging considering the somewhat reduced 





Indeed, although expected [Gault et al. 2015b], treatment with sitagliptin alone 
increased circulating GLP-1 levels, surprisingly corresponding plasma GIP levels 
were not significantly elevated in these mice. This could imply that at the 25 mg/kg 
dose of sitagliptin used, antidiabetic benefits are largely linked to augmentation of 
GLP-1 actions. However, investigation of plasma levels of other DPP-4 substrates 
with a potential impact upon metabolism, such as neuropeptide Y or Peptide YY 
[Khan et al. 2017b; Lafferty et al. 2018a; 2019], would also be necessary to confirm 
this, but outside the scope of the current study. Remarkably, even at the relatively 
reduced dose of 1 mg/kg, TNP-470 clearly augmented both plasma and intestinal xenin 
concentrations, whether administered alone or in combination with sitagliptin. Thus, 
metabolic benefits of MetAP2 inhibition do appear to be mediated, at least in part, by 
enhanced xenin activity [Gault et al. 2015a; Martin et al. 2014, 2016; Craig et al. 
2018].    
 
In addition to elevated plasma GLP-1 and xenin concentrations in the combined 
sitagliptin and TNP-470 treatment group, these mice also presented with notably 
increased GIP levels. In this regard, the secretory dynamics of intestinal K-cells has 
previously been explored in depth [Gribble and Reimann, 2019], but whether xenin 
can further augment GIP secretion still needs to be determined. Nonetheless, 
combined upregulation of GIP, GLP-1 and xenin signalling pathways was associated 
with distinct benefits over either treatment option alone. This involved a more rapid 
restoration of normoglycaemia and dramatically improved glucose tolerance. 
Interestingly, benefits on glucose disposal were in conjunction with a significantly 
decreased, as opposed to increased, glucose stimulated insulin secretory profile. This 





xenin [Seino et al. 2010; Craig et al. 2018], and these mice having a much improved 
beta:alpha cell ratio. Hepatic gluconeogenesis was not improved in the combined 
treatment group, as determined through assessment of pyruvate tolerance, implying 
improved glycaemic status is linked to enhanced insulin action in these mice. This was 
indeed manifest during insulin tolerance tests, although it is worthwhile noting that 
such a method of assessment of insulin action is limited by normal adaptive 
responses to prevent glucose concentrations falling towards life threatening 
hypoglycaemic levels. To account for this, we also calculated HOMA-IR [Wallace 
et al. 2004] that again evidenced clear improvements in insulin resistance. Reductions 
in body weight could be one explanation for improved insulin sensitivity in the 
treatment groups [Clamp et al. 2017], but unlikely given that sitagliptin therapy did 
not induce weight loss. 
 
In agreement with previous reports [Rupnick et al. 2002; White et al. 2012], all TNP-
470 treated mice had reduced body weight gain, that was associated with appetite 
suppressive actions. In harmony with this, xenin has previously been documented to 
possess anorectic effects [Taylor et al. 2010]. In addition, in accordance with the 
elevated GIP and GLP-1 levels in the combined treatment group, robust reductions 
of appetite and body weight have been evidenced following sustained upregulation 
of GIP and GLP-1 signalling in rodents [NamKoong et al. 2017] and humans 
[Coskun et al. 2018]. In contrast, whilst GLP-1 infusion has recently been shown to 
lower energy intake in man, simultaneous GIP infusion did not potentiate this effect 
[Bergmann et al. 2019]. Thus, to further investigate potential related mechanisms, 
metabolic rate and locomotor activity were assessed at the end of the treatment cycle. 





[Baggio and Drucker, 2007; Barrera et al. 2011; Craig et al. 2018], all treated mice 
had decreased respiratory exchange ratio, with sitagliptin treatment evoking a further 
increase in energy expenditure. Since TNP-470 induces appetite suppression, and 
the impact of sitagliptin on markers of energy turnover, it is perhaps surprising that 
a more striking benefit on body weight loss was not observed in the combined 
treatment group. However, DPP-4 inhibitors are well recognised to have body 
weight neutral actions [Gallwitz, 2007], and all mice had similar increases of 
locomotor activity. Thus, assessment of tissue thermogenic capacity may be useful 
to uncover related mechanisms. Indeed, GIP, GLP-1 and xenin have all been 
revealed to alter lipid metabolism and adipocyte function [McClean et al. 2007; 
Irwin and Flatt, 2009; Vendrell et al. 2011; Farr et al. 2014; Bhavya et al. 2017]. In 
addition, these observations on body weight control could simply be a reflection of 
the plasticity in signalling pathways linked to overall energy homeostasis [Lenard 
and Berthoud, 2008]. As such, metabolic rate in diabetic mice was unaltered by 
sustained dual activation of GLP-1 and xenin pathways [Hasib et al. 2018a]. 
Moreover, long-acting GLP-1 analogues are believed to modestly reduce locomotor 
activity [Sorensen et al. 2015], whereas related GIP [Gault et al. 2011b] or xenin 
[Gault et al. 2015a] analogues have been shown to increase this parameter.  
 
Clinical application of MetAP2 inhibitors has been limited due to their high toxicity 
profiles [Chang, 2017]. In contrast to this, previous studies using TNP-470 has 
revealed a relatively tolerable toxicity profile [Kruger and Figg, 2000; Bråkenhielm 
et al. 2004]. It should be emphasised that mice treated with TNP-470 did not alter 
animal behaviour. However, a more thorough examination of toxicity at the organ / 






In conclusion, the current study establishes that the antidiabetic efficacy of DPP-4 
inhibition can be augmented by concurrent use of MetAP2 inhibitors, such as TNP-
470. These benefits appear to be, at least in part, linked to an elevation of xenin 
concentrations by TNP-470, and the recognised ability of xenin to potentiate the 
biological actions of GIP [Taylor et al. 2010; Martin et al. 2012, 2014; Gault et al. 
2015a; Parthsarathy et al. 2016]. Taken together, such an approach merits further 













Streptozotocin (STZ) treatment: Three low dose STZ injections (50 mg/kg bw, 75 mg/kg bw & 75 mg/kg bw, i.p.) at 1- week intervals 
Treatments started on Day 0; 
Group 1: HFF control – HFF saline vehicle (0.9% w/v NaCl, i.p. / oral) for 18 days 
Group 2: Sitagliptin – HFF Sitagliptin (25 mg/kg bw, oral) for 18-days  
Group 3: TNP-470 – HFF TNP-470 (1 mg/kg bw, i.p.) for 18-days  






(75 mg/kg bw) 
Day -7 
STZ injection 











Treatment regimen stopped and 
terminal analysis commenced  
Metabolic parameters assessed 
at regular intervals 
Day -21 
STZ injection 








Figure 6.2 Effects of 18-day treatment with TNP-470, sitagliptin or a combination of both compounds on (A) body weight, (B) energy 

















































































































Parameters were measured during 18-day treatment with sitagliptin (25 mg/kg bw, p.o., once daily), TNP-470 (1 mg/kg bw. i.p. once daily) or a 
combination of both compounds. Values are mean ± SEM for ten mice. *P<0.05, **P<0.01 and ***P<0.001 compared to HFF saline controls. 






Figure 6.3 Effects of 18-day treatment with TNP-470, sitagliptin or a combination of both compounds on (A) glucose and (B) insulin 

















































































































































































































































































Parameters were measured during 18-day treatment with sitagliptin (25 mg/kg bw, p.o., once daily), TNP-470 (1 mg/kg bw. i.p. once daily) or a 






Figure 6.4 Effects of 18-day treatment with TNP-470, sitagliptin or a combination 
of both compounds on glucose tolerance and insulin secretion. 





































































































































Parameters were assessed following 18-day treatment with sitagliptin (25 mg/kg bw, 
p.o., once daily), TNP-470 (1 mg/kg bw. i.p. once daily) or a combination of both 
compounds using the same dosing regimens. (A,C) Glucose (18 mmol/kg bw) was 
administered by i.p. injection at t=0 min in 18 hour fasted mice. (B,D) Glucose and 
insulin AUC values for 0–60 min post injection. Values are mean ± SEM for ten mice. 
*P<0.05, **P<0.01 and ***P<0.001 compared to HFF saline controls. ∆P<0.05 






Figure 6.5 Effects of 18-day treatment with TNP-470, sitagliptin or a combination 
of both compounds on pyruvate tolerance in HFF mice. 


































































Pyruvate (2 g/kg bw, i.p.) at t=0 min in 18 hour fasted mice (A). Blood glucose AUC 
values for 0–120 min post injection (B). Values are mean ± SEM for ten mice. 
*P<0.05, **P<0.01 and ***P<0.001 compared to HFF saline controls. ∆P<0.05 and 





Figure 6.6 Effects of 18-day treatment with TNP-470, sitagliptin or a combination of both compounds on insulin sensitivity and pancreatic 
insulin content in HFF mice.  
























































































































































Parameters were assessed following 18-day treatment with sitagliptin (25 mg/kg bw, p.o., once daily), TNP-470 (1 mg/kg bw, i.p., once daily) or 
a combination of both compounds using the same dosing regimens. (A) Insulin (25 U/kg bw) was administered by i.p. injection at t=0 min in non-
fasted mice. Glucose AAC values post injection are shown. (B) HOMA-IR was calculated by the following equation: fasting glucose (mmol/L) x 
fasting insulin (mU/L) / 22.5. (C) Pancreatic insulin content was measured by RIA following acid-ethanol extraction. Values are mean ± SEM for 





Figure 6.7 Effects of 18-day treatment with TNP-470, sitagliptin or a combination of both compounds on total plasma GIP and GLP-1, as 
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Parameters were assessed following 18-day treatment with sitagliptin (25 mg/kg bw, p.o., once daily), TNP-470 (1 mg/kg bw. i.p. once daily) or 
a combination of both compounds using the same dosing regimens. (A) Total plasma GIP, (B) total plasma GLP-1, (C) plasma xenin and (D) 
intestinal xenin concentrations were assessed using ELISAs. Values are mean ± SEM (A,B; n= 10, C,D; n=6) *P<0.05 and **P<0.01 compared to 






Figure 6.8 Effects of 18-day treatment with TNP-470, sitagliptin or a combination of 






































































































Parameters were assessed following 18-day treatment with sitagliptin (25 mg/kg bw, p.o., 
once daily), TNP-470 (1 mg/kg bw, i.p., once daily) or a combination of both compounds. 
(A-D) Representative images (20X) of islets showing insulin (red) and glucagon (green) 
immunoreactivity from each treatment group. (E) Islet, (F) beta- and (G) alpha-cell areas, 
as well as (H) beta:alpha area cell area ratio were measured using CellF image analysis 
software. Values are mean ± SEM for ten mice. *P<0.05, **P<0.01 and ***P<0.001 






Figure 6.9 Effects of 18-day treatment with TNP-470, sitagliptin or a combination 
of both compounds on O2 consumption in HFF mice.  






























































































































O2 consumption was assessed following 18-day treatment with sitagliptin (25 mg/kg 
bw, p.o., once daily), TNP-470 (1 mg/kg bw, i.p., once daily) or a combination of both 
compounds using the same dosing regimens. Mice were placed in CLAMS metabolic 








Figure 6.10 Effects of 18-day treatment with TNP-470, sitagliptin or a 
combination of both compounds on CO2 production in HFF mice.  







































































































































CO2 production was assessed following 18-day treatment with sitagliptin (25 mg/kg 
bw, p.o., once daily), TNP-470 (1 mg/kg bw, i.p., once daily) or a combination of both 
compounds using the same dosing regimens. Mice were placed in CLAMS metabolic 
chambers for 21 h. Values represent mean ± S.E.M. for 6 mice. ΩP<0.05 compared to 







Figure 6.11 Effects of 18-day treatment with TNP-470, sitagliptin or a 
combination of both compounds on respiratory exchange ratio (RER) in HFF 
mice.  











































































































































































RER was assessed following 18-day treatment with sitagliptin (25 mg/kg bw, p.o., 
once daily), TNP-470 (1 mg/kg bw, i.p., once daily) or a combination of both 
compounds using the same dosing regimens. Mice were placed in CLAMS metabolic 
chambers for 21 h and RER during the (A) light and (B) dark phases assessed, with 
RER AUC displayed in the inset. Values represent mean ± S.E.M. for 6 mice. 







Figure 6.12 Effects of 18-day treatment with TNP-470, sitagliptin or a 
combination of both compounds on energy expenditure (EE) in HFF mice. 































































































































































Energy expenditure was assessed following 18-day treatment with sitagliptin (25 
mg/kg bw, p.o., once daily), TNP-470 (1 mg/kg bw, i.p., once daily) or a combination 
of both compounds using the same dosing regimens. Mice were placed in CLAMS 
metabolic chambers for 21 h, with energy expenditure (EE), during the (A) light and 
(B) dark phases, measured. Values represent mean ± S.E.M. for 6 mice. *P<0.05 and 
**P<0.01 compared to HFF saline controls. ∆P<0.05 and ∆∆P<0.01 compared to 







Figure 6.13 Effects of 18-day treatment with TNP-470, sitagliptin or a combination of both compounds on cumulative food intake in HFF 
mice. 































































Cumulative food intake was assessed following 18-day treatment with sitagliptin (25 mg/kg bw, p.o., once daily), TNP-470 (1 mg/kg bw, i.p., 
once daily) or a combination of both compounds using the same dosing regimens. Mice were placed in CLAMS metabolic chambers for 21 h, with 





Figure 6.14 Effects of 18-day treatment with TNP-470, sitagliptin or a 






























































































































































Locomotor activity was assessed following 18-day treatment with sitagliptin (25 
mg/kg bw, p.o., once daily), TNP-470 (1 mg/kg bw, i.p., once daily) or a combination 
of both compounds using the same dosing regimens. Mice were placed in CLAMS 
metabolic chambers for 21 h. Activity counts in the (A, B) X- and (C, D) Z- axes were 
recorded every minute for 21 h. Values represent mean ± S.E.M. for 6 mice. *P<0.05 










































7.1 Type 2 diabetes mellitus – an increasing epidemic 
T2DM, the most common type of diabetes, is now considered a major global health 
problem, due to its rapidly increasing prevalence and economic burden it imposes. 
Characterised by both beta cell dysfunction and insulin resistance, T2DM is a complex 
metabolic disorder that is closely related to increasing prevalence of obesity [Ozcan et 
al. 2004; Malone and Hansen, 2019]. T2DM, caused by the decreased response and 
utilisation of insulin by peripheral tissues, coupled with the insensitivity of beta cells, 
is progressed through the escalation of both insulin insensitivity and deficiency. 
T2DM and its associated micro- and macro-vascular complications [Fowler, 2008], 
contribute to the multi-morbidity and mortality associated with this disease, thereby 
creating a huge economic burden, and therefore necessitating the need for novel, more 
effective treatment paradigms. 
  
7.2 Limitations of current anti-diabetic therapeutics 
First and foremost, life-style changes, including a healthy diet and exercise regime, is 
recommended to achieve normoglycaemia. However, this often fails leading to 
pharmacological intervention being required. There is a plethora of anti-diabetic 
therapies available, with the key aim being the maintenance of normal glucose 
homeostasis and preservation of beta cell function, whilst attenuating associated 
micro- and macro-vascular complications. First line monotherapy routinely fails to 
achieve and maintain normoglycaemia, with long-term patient response rates 
deteriorating over time, necessitating the need for combinational therapy approaches 
to maintain glycaemic control. Nevertheless, these current therapeutics fail to combat 
chronic complications. In addition, due to the complex, multifactorial pathophysiology 





a single glucoregulatory pathway, such as insulin secretion or insulin insensitivity 
[Bailey, 2000], fail to achieve the desired prolonged response. Treatments also are 
inadequate in restoring beta cell mass and impaired beta cell function that accompanies 
T2DM, which ultimately leads to beta cell exhaustion and worsens prognosis [Bailey, 
2000]. Therefore, an efficient T2DM therapy should aim to reverse the major 
pathophysiological abnormalities associated with this disease, including impaired 
insulin secretion, incretin deficiency, enhanced glucagon secretion, hepatic glucose 
production, accelerated lipolysis in adipocytes, increased glucose reabsorption in the 
kidney as well as decreased uptake in muscle [De Fronzo et al. 2014]. Hence, novel 
anti-diabetic agents, which have multiple exploitation capacities, are required to 
sustain improved management and decrease the associated complications. 
 
According to recent ADA/EASD guidelines, metformin monotherapy continues to be 
the first-line recommended therapy for almost all patients with T2DM, however, 20-
30% of patients have suffered metformin-associated adverse effects, including 
gastrointestinal tract discomfort, nausea and vomiting, with approximately 5% of 
patients unable to tolerate metformin at all [Dujic et al. 2015; McCreight et al. 2016]. 
Metformin is followed by addition of second-line glucose-lowering medications, such 
as sulfonylureas, DPP-4 inhibitors or thiazolidinediones, however the efficacy of these 
are unsustainable due to undesirable side effects which promote weight gain and 
increase hypoglycaemic risk [Kerru et al. 2018]. The intensification of treatments 
beyond dual-therapy, which is more often required, increases side-effects as well as 
amplifying the burden and cost of treatment. Therefore, different treatment models 
need to be implemented to achieve optimum cost-effective approaches to both diabetic 






More recent advances in therapies for T2DM has identified incretin mimetics as a 
promising drug class. These mimetics, with increased biological stability, have shown 
promise in the maintenance of glucose homeostasis and beneficial effects on beta cells 
[Drucker, 2006; Irwin and Flatt, 2015]. Incretin mimetics have also been shown to 
omit the risk of hypoglycaemia [Hansen et al. 2010], with other favourable effects on 
both cardio health and protection [Hansen et al. 2010], as well as benefits on cognitive 
function [Porter et al. 2011]. However, incretin mimetics focus on augmenting the 
actions of the incretin GLP-1, with much less attention on promoting the biological 
actions of GIP, which has been designated as the major incretin hormone, accounting 
for 70% of the incretin effect [Gault et al. 2003c; Holst, 2019]. Therefore, the 
potentiation of this incretin is missing in current therapies and therefore novel 
therapeutics with GIP potentiating actions is warranted. 
 
7.3 Therapeutic application of gut derived peptides 
There has been considerable interest in bioactive peptides as a novel drug class, due 
to favourable anti-diabetic, anti-cancerous and anti-microbial properties [Yan et al. 
2019]. For treatment of diabetes, peptide hormones released from the intestine act as 
key regulators in postprandial insulin release and energy regulation [Drucker, 2007; 
Monteiro and Batterham, 2017]. Receptors for these gut hormones are widely 
distributed throughout the body in organs including the pancreas, brain, muscle and 
adipose tissue [Usdin et al. 1993; Holst, 2007; Baggio and Drucker, 2007], and in turn 
play vital roles in glucose and energy homeostasis. The incretin hormones, GLP-1 and 
GIP, are the two most studied gut hormones in diabetes and are primarily involved in 





highlighted beneficial extrapancreatic effects and favourable metabolic profiles, in 
addition to the glucose-lowering incretin mediated effect [Yamada et al. 2016]. 
However, they are rapidly degraded by the enzyme DPP-4. For clinical exploitation, 
stable, long-acting analogues of GIP have been generated [Irwin et al. 2006b; Kerr et 
al. 2009; Tatarkiewicz et al. 2014], displaying anti-diabetic promise, however, have 
not yet been clinically approved. In contrast, several GLP-1 agonists, namely 
liraglutide and exendin-4, have been clinically approved for therapeutic use [Eng et 
al. 1992; Gupta, 2013]. Further to this, other gut-derived hormones, including CCK, 
PYY and xenin, have been the focus of recent research as potential therapeutic targets 
alone or in combination for the treatment of T2DM [Pathak et al. 2018; Lafferty et al. 
2018b; Craig et al. 2018]. For novel therapies aimed at managing diabetes, there has 
been an increase in gut-derived hormone pharmacological strategies, due to 
modification enabling longer-acting analogues, enhanced efficacy through 
combination, as well as the knowledge that the significant benefits following bariatric 
surgery is mainly linked to the altered secretion of various gut hormones [Pournaras 
et al. 2010].  
 
7.4 Potentiating the biological actions of GIP  
There is a misconception that GLP-1 is a superior pharmacological target for 
antidiabetic therapy over GIP [Bastin and Andreelli, 2019], with current therapies 
focusing on augmentation of GLP-1. However, GIP acts to stimulate glucose-
dependent insulin secretion through the incretin effect, whilst also playing other key 
roles [Seino et al. 2010]. These additional roles include promoting beta cell 
proliferation and inhibiting apoptosis, thus resulting in expansion of beta cell mass, 





survival though signalling pathways, which are independent of GLP-1, therefore 
proposing that both incretin hormones may have individual specific roles in T2DM 
therapy and may act to complement each other [Campbell et al. 2016]. GIP also 
modulates postprandial glucagon responses, whilst in addition facilitating fat 
deposition in adipose tissue and stimulating bone formation. Furthermore, GIP has 
been shown to regulate appetite and satiety effects in the brain [Seino et al. 2010]. 
However, in T2DM there is decreased secretion of GLP-1 and defective 
responsiveness to GIP, resulting in a diminished incretin effect, which is a key 
pathophysiological defect in T2DM [Knop et al. 2007b]. Many agents have been 
clinically approved to increase GLP-1 levels, however promising GIP analogues that 
act to augment the biological actions of GIP still await pre-clinical trials. GIP 
desensitisation is thought to be a result of the downregulation of GIP receptors on beta 
cells as a result of hyperglycaemic status in T2DM patients. However, Højberg et al. 
2009 demonstrated that normalisation of blood glucose levels in diabetic subjects 
resulted in an enhanced incretin response to GIP, potentially due to up-regulation of 
GIP receptors on beta cells. This therefore suggests that GIP desensitisation is 
potentially just a consequence of the hyperglycaemic state, and that sensitivity to GIP 
can be restored with improved glycaemic control. Issues regarding receptor 
desensitisation have also been suggested as a problem with GIP based therapies, 
however in vitro glucose tolerance tests performed in chapter 3 may help to exclude 
this problem. Thus, GIP may not be as inconsequential as first thought in T2DM. 
 
Further to this, the gut derived peptide hormone xenin, co-secreted from the same 
intestinal K-cells as GIP, potentiates the diminished biological actions of GIP in 





al. 2018]. Moreover, the independent insulinotropic actions of xenin, combined with 
its GIP augmenting abilities, have been solidified in this thesis. The work contained 
here has developed novel treatment paradigms, based around the gut peptide xenin, 
either alone, in combination or as part of a hybrid peptide to target the impaired GIP 
arm of the incretin axis, improving glycaemic status in various mouse models of 
obesity / diabetes. This represents proof-of-concept for the efficacy of xenin based 
therapies for diabetes. 
 
7.5 A GIP/xenin hybrid in combination with exendin-4 as a persistent therapeutic 
agent  
In T2DM, elevated glucose concentrations lead to desensitisation of GIP receptors, 
which is established as a fundamental determinant of beta-cell insensitivity to GIP 
causing GIP resistance [Xu et al. 2007]. However, this can be reversed and normal 
incretin action restored through improved glycaemic control [Højberg et al. 2009]. 
However, other studies have suggested that additional mechanisms are involved in the 
defective actions of GIP in T2DM, such as genetic defects in GIP signalling [Meier 
and Nauck, 2010], with Pathak et al. [2014] also suggesting that the defective 
insulinotropic actions of GIP are related to mechanisms beyond receptor expression. 
Previous studies within our research group have shown that the palmitate-derivatised 
analogue of xenin improves the biological actions of GIP [Martin et al. 2012, Gault et 
al. 2015a], along with previous studies showing the metabolic benefits of this analogue 
incorporated into a GIP hybrid molecule [Hasib et al. 2016]. Based on previous studies 
which show that combined activation of GIP and GLP-1 receptor pathways may 
provide additive beneficial effects compared to GLP-1 analogues alone, and following 





assess if the already established effects of (DAla2)GIP/xenin-8-Gln could be 
augmented through combination therapy with the clinically approved GLP-1 mimetic, 
exendin-4, and to evaluate persistent efficacy in HFF mice.  
 
The persistent improvements in glycaemic control induced by this hybrid in 
combination with exendin-4 where coupled with favourable changes in body weight, 
but independent of any changes in energy intake. This is intriguing since appetite 
suppressive effects of xenin have been established, mediated through the 
hypothalamus, but independent of hypothalamic ERK1/2 [Kim et al. 2016] or 
melanocortin signalling pathways [Leckstorm et al. 2009]. In terms of body weight, 
treatments that elicit reductions in body weight represent a clear advantage over 
currently available drug classes such as thiazolidinediones or sulfonylureas, which are 
linked with weight gain [Cheng and Kashyap, 2011]. Exendin-4 has established 
weight reducing effects [Kanoski et al. 2016], with other suggestions of the weight 
reducing effects of xenin [Craig et al. 2018]. In this regard, further studies examining 
metabolic rate, locomotor activity and energy expenditure would also be useful.  
 
Indeed, twice-daily administration also significantly improved glucose tolerance in 
HFF mice, with this effect persistent in nature, in all treatment groups, further 
confirming the therapeutic potential of this treatment paradigm in overcoming beta-
cell associated problems in this HFF model. Both exendin-4 and the combination 
group improved insulin sensitivity, however, (DAla2)GIP/xenin-8-Gln alone failed to 
improve insulin sensitivity. These improved persistent benefits on metabolic profile 
could be a result of enhance glycaemic control, or improved incretin hormone actions 





Furthermore, reduction in HbA1c levels was also indicative of sustained glycaemic 
control, which is highly favourable in such a multifactorial disease. Thus, this durable 
effect of this hybrid could be due to enhanced incretin effect through augmentation of 
GIP actions. Future studies to assess gene and protein expression involved in synthesis 
or secretion of insulin as well as genes involved in beta cell proliferation and apoptosis, 
could help explain the persistent beneficial effects shown. Surprisingly, a lack of 
additive effects when combined with exendin-4 was apparent in this study. This could 
be a result of the good efficacy of the GIP/xenin hybrid peptide alone [Hasib et al. 
2017], or the relatively mild form of diabetes in this model.  
 
The combination approach employed resulted in stimulation of GLP-1, GIP and xenin 
signalling pathways. By augmenting all three pathways, this would help to lessen 
progression of disease severity. Progression of T2DM results in reduction of islet beta-
cell mass, beta cell function, or both, therefore due to the favourable effects GIP, GLP-
1 and xenin have on beta cells [Chon and Gautier, 2016; Craig et al. 2018], this 
combinational approach could be very favourable when disease severity progresses. 
As was apparent in this study, the diabetic state was progressing and worsening, 
illustrated by the reduced pancreatic content on day 42 compared to day 28. However, 
as this combined modulation may also work through similar or complementary 
mechanisms, thus it could preclude additive effects. Indeed, a triple-acting hybrid 
peptide consisting of GIP/xenin/exendin-4 may be more patient favourable through 
the stimulation of multiple pathways through one molecule, but unfortunately due to 
the hybrid structure and main bioactive region sites of all three components this is not 






The findings from Chapter 3 further highlight that a GIP/xenin hybrid in combination 
with the GLP-1 analogue, exendin-4, has the capacity to restore the beneficial actions 
of GIP which are diminished in T2DM, as well as GLP-1 related actions. More 
importantly, this treatment paradigm has favourable significant persistent effects, 
which lasted 14-days after cessation of treatment, which is an exciting prospect given 
the progressive nature of T2DM. Thus, this hybrid may be useful as a new drug class 
for the treatment of T2DM.  
 
7.6 Novel modified truncated forms of xenin in obesity-diabetes 
The degradation fragments of native xenin, first discovered in 1992 [Feurle et al. 
1992], have more recently been fully identified [Martin et al. 2014]. Therapeutically, 
xenin has been shown to exert dual beneficial properties, including independent anti-
diabetic effects and GIP additive effects. However, only the fragment peptide, xenin-
8, was shown to elicit the biological actions of the parent peptide [Martin et al. 2014, 
2016]. Truncated peptides hold pharmacological advantages, including ease and cost 
of synthesis and enhanced efficacy. However, these truncated peptides are still prone 
to enzymatic degradation, with Lys and Arg regions within xenin known to be linked 
to enzymatic cleavage sites [Martin et al. 2014]. Thus, amino acid substitution of these 
Lys and Arg residues to Gln within the parent peptide and xenin-8 was shown to 
generate stable, potent peptides [Parthsarathy et al. 2016; Martin et al. 2016]. Studies 
within our laboratory have already characterised the potent actions of xenin-8-Gln 
[Martin et al. 2016], with initial characterisation and assessment of hybrid peptides 
incorporating xenin-8-Gln being performed [Hasib et al. 2018a, 2018b, 2019; Craig et 
al. 2019]. However, full characterisation of the biological activity of xenin-6 has been 





In chapter 4, modified forms of xenin-6 were developed, using C-terminal amidation, 
amino acid substitutions or introduction of a reduced peptide bond to increase stability. 
However, the reduced pseudopeptide bond was the only modification employed within 
xenin-6 that elicited stability, which corresponds to previous research that the 
introduction of a reduced pseudopeptide bond produced an enzymatically stable 
peptide [Feurle et al. 2003]. Xenin has established dual therapeutic application, due to 
its insulinotropic and glucose-lowering actions, along with its ability to augment the 
diminished incretin effect by GIP in T2DM [Wice et al. 2010; Taylor et al. 2010; 
Martin et al. 2012, 2014; Parthsarathy et al. 2016; Craig et al. 2019]. These dual 
actions were also confirmed in truncated xenin-6 peptides. The insulinotropic 
capabilities were established in all modified hexapeptides assessed, in both BRIN-
BD11 cells and isolated islets, but to a greater degree by Ψ-xenin-6. This demonstrated 
that these C-terminal hexapeptides are capable of triggering the insulin-secreting 
signalling pathways involved between xenin and pancreatic beta cells. However, 
further investigations are required to establish how exactly these insulinotropic effects 
of xenin are elicited, as many potential mechanisms have been suggested, including 
acting through neurotensin receptors [Clemens et al. 1997]. Although studies within 
our laboratory and others have demonstrated that these effects are likely to be 
independent of neurotensin receptors [Heuser et al. 2002; Taylor et al. 2010], and thus 
further assessments are required to clarify the mechanism/s of action. The 
hexapeptides assessed also exhibited GIP additive effects. In harmony with the parent 
peptide [Leckstrom et al. 2009], Ψ-xenin-6 was also shown to exhibit appetite 
suppressive actions. This confirms that the reduced pseudopeptide bond does not 
compromise peptide biological activity, but may improve bioactivity. In addition, 





hours, superior over all other xenin hexapeptides examined, indicating enhanced 
duration of biological action through insertion of a pseudopeptide bond. Thus, chapter 
4 highlights the favourable anti-diabetic and anti-obesity effects of novel hexapeptides 
of xenin, in particular the exciting potential of Ψ-xenin-6, and warrants further 
investigation to elucidate further therapeutic benefits in T2DM/ obesity models. 
 
7.7 Augmenting the biological actions of sitagliptin through co-administration 
with xenin 
Chapter 4 highlighted the exciting acute anti-diabetic potential of Ψ-xenin-6 in vitro 
and in vivo. Therefore, the rationale behind chapter 5 was to elucidate sub-chronic 
effects of this stable, long-acting peptide, and its ability to augment the established 
anti-diabetic benefits of the established DPP-4 inhibitor sitagliptin through co-
administration in HFF mice. Ψ-xenin-6 alone did elicit various benefits in HFF mice, 
which is intriguing given the reduced dose employed compared to sitagliptin. These 
observations could be due to the independent insulinotropic benefits of xenin or 
through the augmentation of GIP by Ψ-xenin-6 as established in chapter 4. However, 
further studies are needed to confirm its mechanism of action and signalling pathways 
involved. Surprisingly, favourable effects on energy intake were lacking in both Ψ-
xenin-6 alone and in the combination treated group, which is unexpected given the 
appetite suppressive effects shown by Ψ-xenin-6 in chapter 4, and by xenin in general 
[Alexiou et al. 1998; Cline et al. 2007; Cooke et al. 2009; Taylor et al. 2010]. 
However, favourable weight reductions were apparent, independent of feeding 
patterns, and therefore analysis of energy expenditure would have been helpful in 
understanding this effect. Following 18-day treatment, and consistent with acute 





actions. Chapter 4 also demonstrated benefits of Ψ-xenin-6 on beta cells that was 
confirmed in this chronic study. 
 
As expected, combination therapy did induce numerous metabolic benefits in HFF 
mice, and the benefits of sitagliptin were further augmented through combination 
therapy with this hexapeptide. To explore potential mechanism(s) of these beneficial 
effects a DPP-4 activity assay was conducted. As expected sitagliptin decreased DPP-
4 activity of plasma following 18-days treatment in HFF mice. Importantly, this was 
not altered by concurrent Ψ-xenin-6 treatment, with these observations further 
corroborated using established in vitro methodologies. As such, Ψ-xenin-6 does not 
augment elevations of GIP and GLP-1 induced by sitagliptin, and does not enhance 
the DPP-4 inhibitory action of this drug. Thus, the benefits of the combined sitagliptin 
and Ψ-xenin-6 treatment regimen are most likely related to augmentation of GIP 
bioactivity by Ψ-xenin-6, as has been previously demonstrated. As anticipated, 
sitagliptin significantly increased levels of both incretin hormones, whether 
administered alone or in combination with Ψ-xenin-6. Interestingly, treatment with Ψ-
xenin-6 alone increased plasma GIP levels, but this effect was not additive with 
sitagliptin, whereas high fat feeding decreased circulating GLP-1 concentrations. 
 
Previous studies have omitted xenin based therapeutics as potential antidiabetics due 
to the suggestion that xenin may act to decrease GLP-1 concentrations [Sterl et al. 
2016], however in this study no antagonistic effects on GLP-1 secretion was apparent. 
Also, given the favourable effects of combination therapy on gene expression in the 
liver, linked with reductions in weight gain, additional insight on lipid profiles would 





further assess the effects of therapies examined on expression of genes, RNAseq on 
murine samples could be performed.  
 
In conclusion, chapter 5 demonstrated the clear antidiabetic potential of Ψ-xenin-6 
alone, and highlighted that a combinational treatment approach of Ψ-xenin-6 with 
sitagliptin can further augment the established therapeutic benefits of sitagliptin. This 
demonstrates that targeting both arms of the incretin axis provides clear antidiabetic 
and anti-obesity qualities and thus represents a suitable novel treatment option for 
obesity / diabetes.  
 
7.8 Anti-obesity and anti-diabetic potential of combination therapy of an 
angiogenesis inhibitor and sitagliptin  
Chapter 5 demonstrated that the favourable anti-diabetic benefits of sitagliptin can be 
further augmented through combination therapy. However, a drawback of sitagliptin 
monotherapy is its weight neutral effects. Therefore, in chapter 6 we employed the 
MetAP2 inhibitor TNP-470, which has been shown to exhibit potent weight-reducing 
effects, as well as anti-diabetic capabilities, in combination with the established 
therapeutic sitagliptin. A major advantage of employing combination therapy is the 
possibility of lower dose administration compared to either treatment alone [Irwin and 
Flatt, 2015]. This was apparent in chapter 6, as sub-maximal doses still exhibited 
significant potent beneficial effects, thus reducing patient drug-exposure and limiting 
off-target adverse effects as previously described for the use of GLP-1 based therapies 
[Butler et al. 2013b]. The anti-diabetic benefits shown by TNP-470 treatment, could 
be linked to xenin-related pathways, as a consequence of inhibiting xenin degradation. 





and improvement in diabetic status with augmented GIP concentrations. Thus, 
combination therapy of TNP-470 with sitagliptin targeted both incretin hormones and 
xenin signalling pathways, resulting in favourable insulinotropic and anti-
hyperglycaemic effects, as well as substantial weight reducing effects by TNP-470. 
Further studies using mass spectrometry could be used to confirm the elevated 
concentrations of these hormones in plasma. This treatment paradigm also offers 
exciting anti-obesity therapeutic potential as shown through decreased energy 
expenditure, reduced food intake coupled with substantial weight-reducing properties. 
Indeed, assessment of body fat mass would have been interesting to consider in view 
of the roles GIP and xenin play in lipid metabolism [McIntosh et al. 2009; Bhavya et 
al. 2017]. Further analysis of adipocyte action using in vitro models and ex vivo, 
imaging would be insightful, along with studies examining the effects of xenin on 
adipogenic-specific genes or proteins. 
 
Oral delivery is a big patient benefit over peptide therapies. In this study, i.p. injection 
was utilised to allow for reduced doses, ensure consistent dosing of animals, and 
negate need for specialised vehicle. Essentially, this study was a ‘proof-of-concept’ 
study, which has confirmed that the concept works, thus the next step would be to 
perfect oral delivery methods and doses.  
 
Therapies which target both obesity and diabetes would offer superior metabolic 
benefits for T2DM [Skow et al. 2016], due to the considerable links between obesity 
and diabetes. This chapter confirmed the importance of concurrently targeting both 
incretin hormones within the incretin axis, along with targeting mechanisms involved 





displayed both anti-diabetic and anti-obesity effects, which is highly promising 
considering the parallel escalations in obesity and T2DM, and thus should be explored 
as a novel treatment paradigm. As evident from this thesis, the concept of multi-
functional peptide targeting combinations is exciting and requires further progression 
towards the clinic. 
 
7.9 Future studies 
This thesis has highlighted the potential of modified truncated forms of xenin and 
subsequent elevations in GIP concentrations in alleviation of diabetes and obesity, 
particular through improvement of metabolic control and additive GIP actions. 
Combination therapy with established drug classes also possess vast advantages over 
monotherapy, and allows lower dose administration, which is highly favourable 
moving towards the clinic. Nevertheless, future studies are required to fully elucidate 
the signalling pathways and mechanisms involved in the satiety effects, insulinotropic, 
and GIP-potentiating actions demonstrated by xenin to fully understand the 
therapeutic potential of the therapies investigated. Future studies should aim to 
identify a specific xenin receptor, and clarify the involvement, if any, of neurotensin 
receptors. Indeed, this could involve incubation of test peptides with various receptor 
transfected cell lines, for example, a neurotensin-receptor 1 transfected cell line and 
measurement of insulin secretion. Other mechanistic studies that could be employed 
include the use of antagonists, blocking key pathways or receptors, to help enlighten 
which receptors or pathways are involved in these beneficial effects. Similarly, 
specific receptors in beta cells could be knocked out using CRISPR/Cas 9 technology 
to establish essential receptors for these anti-diabetic effects. The GIP potentiating 





potentiating effects are still present. Finally, following on from the encouraging results 
from this thesis, the next step should be recruitment of Ψ-xenin-6 into clinical trials, 
given its superior stability, strong insulinotropic effects and prominent enhancements 
on metabolic profile both alone and in combination with established anti-diabetic 
therapies. Otherwise, Ψ-xenin-6 could also be incorporated into a hybrid peptide 
agent, as hybrid agents offer a more patient friendly approach through one single 
injection of a multi-targeting peptide rather than multiple administration of mono-
peptides. However, challenges are apparent with translation from animal model to 
human due to risk of off-target effects caused by cross-reactivity with other off-target 
receptors [Skow et al. 2016]. Accordingly, more than one animal model of 
diabetes/obesity should be used due to diversity seen in the human disease, along with 
further receptor affinity studies before conversion to a human setting.  
 
Given the prevalence of both obesity and T2DM, current anti-diabetic therapies fail to 
successfully target the established links between both metabolic diseases. Therefore, 
it would be highly favourable, and a necessity, for a novel treatment to be established 
that could potentially act as an obesity preventative measure or a more potent 
management therapy, along with having antidiabetic efficacy. As such, further 
research into TNP-470 as a preventative measure or as a therapy is warranted in 
various obesity / diabetic mouse models, before progression to the clinic, either alone 









7.10 Concluding remarks 
To summarise, collectively the studies in this thesis demonstrate that truncated forms 
of xenin-25 retain the biological actions of the parent compound, and that elevated 
xenin concentrations exert beneficial metabolic effects through potentiation of GIP. 
Remarkably, (DAla2)GIP/xenin-8-Gln in combination with exendin-4 retained 
persistent beneficial effects following cessation of treatment. Notably, the established 
benefits of sitagliptin can be further enhanced through combination therapy with 
xenin-related peptides, and that TNP-470 in combination with sitagliptin possess 
beneficial anti-hyperglycaemic and anti-obesity effects. This thesis endorses that 
monotherapy in T2DM is no longer an effective treatment option for this multifactorial 
disease, and that combination therapy with either gut hormones or hybrid peptides has 
potential to emerge as a leading therapeutic approach for T2DM. Taken together, the 
promising therapeutic actions displayed within this thesis will hopefully advance the 
therapeutic repertoire and result in the development of a safe, efficient, long-acting 
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